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ABSTRACT 
 
The emergence of antibiotic-resistant bacterial strains is a growing 
concern as antimicrobial drug discovery is not proceeding at the same pace as 
the growth of resistance. Genome sequencing techniques have advanced in the 
last 20 years and have revealed the hidden capacity of microbes to generate 
natural products including antibiotics. Most of these compounds were not 
detected with the traditional techniques due to conditional expression and low 
production. One group of natural products that is much larger than anticipated 
based on the genomes identified is the ribosomally-synthesized and post-
translational modified peptides (RiPPs). Lanthipeptides are a class of RiPPs with 
pharmaceutically valuable properties including antimicrobial activity against 
clinically-relevant bacterial pathogens, even including drug-resistant strains.  
These peptides are characterized by thioether crosslinks making them more 
resistant to degradation under physiological conditions. A detailed understanding 
of the biosynthesis and mode of action could allow engineering of these peptides 
for better pharmacological properties. In this thesis, biosynthesis of several 
lanthipeptides belonging to the cinnamycin group of peptides is described, and 
the biosynthetic enzymes of cinnamycin were studied in detail. In Chapter II, the 
biosynthesis of cinnamycin was investigated by reconstitution of the cinnamycin 
biosynthetic enzyme activities in vitro, and through heterologous expression of 
the cinnamycin biosynthetic genes in E. coli. These two approaches employed to 
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produce cinnamycin have their own advantages. For instance, in vitro 
reconstitution of the lantibiotic synthetase CinM and the tailoring enzyme CinX 
allowed for detailed studies of these enzymes as described in Chapter III. On the 
other hand, through production of cinnamycin in E. coli, the activity of a new 
enzyme called cinorf7 was discovered, which could not be achieved in the in vitro 
experiments. Therefore, Chapter III also contains our attempts to identify the 
catalytically important residues of cinorf7 by mutational studies. These 
experiments on cinnamycin biosynthesis set the stage for the biosynthesis of 
other lanthipeptides in the cinnamycin-group of peptides, which is described in 
Chapter IV. Lanthipeptide synthetases have been shown to have relaxed 
substrate specificity, creating new possibilities in the engineering of these 
molecules for desired functions. Peptide libraries have been commonly used for 
engineering and selection of pharmaceutically valuable molecules. 
Lanthipeptides have great potential for drug development compared to linear 
peptides as they are chemically and metabolically more stable because of the 
thioether crosslinks. Therefore, large molecular libraries of lanthipeptides with 
designed ring structure would be useful. In Chapter V, phage display of the well 
known lanthipeptide nisin is described, which will form a platform for the 
production and selection of lanthipeptide libraries.  
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CHAPTER I: INTRODUCTION TO LANTHIPEPTIDES 
1.1 General view on natural products  
 Natural products produced by living organisms such as animals, plants, 
and microbes often, have valuable biological activities and thus, they have been 
employed in a variety of areas including medicine, cosmetics, and the food 
industry (1). The isolation and discovery of pharmaceutically valuable 
compounds for the use of humans peaked in the period of 1970-1980 (2-3); 
however, the lack of new approaches to isolate new natural products in addition 
to a long and expensive development process has caused pharmaceutical 
companies to retract from this field in recent years (2). However, a new urgency 
for the discovery of new antibiotics that operate with different mechanisms of 
action compared to current antibiotics emerged as antibiotic-resistant infectious 
bacterial strains, such as methicillin-resistant Staphyloccocus aureus (MRSA) 
and vancomycin-resistant Enterococci (VRE), have started to appear in clinical 
settings (3). Many studies have demonstrated a clear relationship between 
exposure time to an antibiotic and the appearance of resistant strains (4). 
Therefore, higher usage of an antibiotic leads to development of resistant 
bacterial strains, requiring the continual discovery of new pharmaceutically 
available antibiotics.  
The advancements in genome sequencing in the last two decades has 
allowed for re-investigation of the strains studied previously, yielding discovery of 
new natural products, which could not be obtained by the older techniques for 
2 
 
several reasons such as low amount of production leading to detection problems 
(5). One class of natural products that is much more abundant in the genomes 
than anticipated is the ribosomally-synthesized and post-translationally modified 
peptides (RiPPs) (6). These peptides contain an immense structural diversity 
compared to linear peptides, and the post-translational modifications provide tight 
target binding surfaces and increased metabolic and chemical stability of the 
molecules.  
1.2 Lanthipeptides and their biosynthesis 
Lanthipeptides are ribosomally-synthesized polycyclic peptides 
characterized by post-translationally introduced thioether rings called 
lanthionines (Lan) and methyllanthionines (Melan) (Figure 1.1A). These rings 
form by activation of specific serine (Ser) or threonine (Thr) residues followed by 
β-elimination to form dehydroalanine (Dha) and dehydrobutyrine (Dhb), 
respectively. Subsequent stereoselective intramolecular Michael-type addition of 
cysteine thiols to the dehydroamino acids completes the ring formation (Figure 
1.2A). In addition to providing bioactivity to the peptide, these cross-links provide 
chemical and thermal stability to the peptide, important features in 
pharmaceutical applications. 
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Figure 1.1 Formation of lanthipeptides. (A) Representation of the mechanism of 
(Me)Lanthionine formation, (B) Representation of processing of lanthipeptides by enzymes to 
yield mature RiPP. 
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When the lanthipeptide precursors are synthesized by the ribosomes, they 
have an N-terminal sequence called the leader peptide that is recognized by 
various enzymes that process the C-terminal core peptide (Figure 1.1B). In 
addition to the enzymes that introduce (Me)Lan modifications, there are proteains 
that catalyze the formation of more than 15 different structural motifs such as 
lysinoalanine, β-hydroxyl-aspartate, D-alanine, 2-oxobutyrate, pyruvate, lactate, 
S-aminovinyl-D-cysteine and S-aminovinyl D-methylcysteine. Moreover recently, 
the first glycosylated labionin-containing lanthipeptide called NAI-112 was 
discovered (7). After the core peptide is processed, the leader peptide needs to 
be removed to afford the mature, biologically active compound. More than sixty 
lanthipeptides have been discovered to date and hundreds of them have been 
identified in genomic databases (Figure 1.2).  
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Figure 1.2 Representation of several different lanthipeptides. Lipid II binding motif of class I 
lantibiotics is circled in green, whereas class II-lipid II binding domain is circled in red. Lan are 
shown in red, MeLan are shown in blue. Several other post-translational modifications are shown 
in different colors.  
 
Nisin-lipid II binding motif 
 
Mersacidin-lipid II 
 binding motif 
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1.2.1 Classes of lanthipeptides  
Lanthipeptides can be classified into four classes based on the type of 
lanthionine synthetase that forms the lanthionine rings (Figure 1.3). In the first 
class, the dehydration and cyclization activities are carried out by individual 
enzymes called LanB and LanC whereas, in classes II, III and IV, both reactions 
are catalyzed by bifunctional lanthionine synthetases. The lanthionine synthetase 
LanM in class II contains a cyclization domain at the C-terminus that shows 
homology with the LanC cyclases of class I. However, the N-terminal dehydration 
domains of class II enzymes do not display sequence homology with other 
enzymes in the databases (Figure 1.3). Both class III and class IV enzymes 
contain a bifunctional enzyme with three domains. The central kinase domain 
and N-terminal phosphoSer/phosphoThr lyase domain of these two classes show 
homology to each other. However, the C-terminal cyclization domain of class III 
enzymes differ from class IV and the other LanC proteins as they lack the zinc 
ion that is used to activate the cysteines in the substrate for nucleophilic attack 
(5). A subset of class III enzymes generates an additional carbon–carbon 
crosslink, putatively by attack of the initially generated enolate onto a second 
dehydroalanine (Figure 1.1A) (8-9). The structure thus formed is called a labionin 
(Lab), which was first detected in the labyrinthopeptins (7, 10). The recently 
discovered Class IV enzymes (LanL) have three different domains, including N-
terminal lyase and kinase domains as in class III, but its C-terminal cyclase 
domain is homologous to LanC (Figure 1.3) (11).  
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Figure 1.3 Representation of the lanthionine forming enzymes that define the classes of 
lanthipeptides.  
 
Some lantibiotics are composed of two components encoded by two 
different structural genes, lanA1 and lanA2, that are subsequently modified by 
two different LanM protein, LanM1 and LanM2. Then, both peptides are exported 
and their leader sequences are removed by a multifunctional protein possessing 
an N-terminal protease domain called LanT as observed in class II 
lanthipeptides. Generally, the α- and β-peptides of two-component lantibiotics 
formed from LanA1 and LanA2, respectively act synergistically to exert their full 
antibacterial activity, and currently this group includes eight lantibiotics including 
haloduracin and lacticin 3147 (12).  
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1.2.2 Role of leader peptides  
The majority of the leader peptides of lanthipeptides do not show 
homology to secretion signals commonly used to direct proteins to the sec and 
twin-arginine translocation (tat) secretion pathways (13).  Their lengths range 
between approximately 20 to 60 amino acids and their sequences vary largely 
(13). Leader peptides have been proposed to have several different functions. 
Firstly, the leader peptide is required for recognition of the precursor peptide by 
several of the processing enzymes (14-18). It is proposed that the leader peptide 
might induce a conformational change in the processing enzymes, causing the 
enzymes to shift from an inactive form to an active form (13, 19). For example, 
studies on nisin biosynthesis demonstrated that the highly conserved residues in 
the leader peptide of NisA between – 18 and – 15 are crucial for lanthionine 
incorporation into the precursor peptide (20). Secondly, the leader peptide acts 
as a secretion signal, directing the peptide to the extracellular space of the 
producing organism (20-24). Finally, in most of the lantibiotics, the leader peptide 
provides immunity to the producing organism as biological activity is not gained 
until the removal of the leader peptide from the core (19-21), which is 
accompanied by export of the mature peptide outside the cell (13, 22, 25-27) .    
The removal of the leader peptide is performed by different sets of 
enzymes in different classes of the lanthipeptides. In class I lanthipeptides, a 
proteolytic enzyme called LanP, which has similarity to subtilisin-like serine 
proteases, removes the core region from the leader (25, 28-31) and a separate 
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enzyme called LanT is responsible for export of the molecule before or after 
function of LanP, depending on where LanP is located. In class II lanthipeptides, 
both proteolysis and secretion are typically performed by the dedicated ATP-
binding cassette (ABC) transporter family proteins, called LanTs, which have a 
protease domain that utilizes Cys, His, and/or Asp residues for catalysis (32). 
The protease domains of LanTs share sequence homology with papain-like 
cysteine proteases. Site-directed mutagenesis of the protease domain of the 
lacticin 481 transporter showed that Cys12 is important for the cleavage reaction, 
whereas His90 affects regio-specificity (27). The prepeptide substrates of LanT 
share a conserved double-glycine type cleavage site (27). 
1.3 Mode of action of lanthipeptides  
Lantibiotics, lanthipeptides with antimicrobial activity, form the majority of 
known lanthipeptides. Among these peptides, a derivative of actagardine is in 
clinical trial for the treatment of Clostridium difficile infections (33-34), whereas 
mutacin 1140 is currently in preclinical development for the treatment of gram-
positive bacterial infections (35). Lantibiotics also possess potent activity against 
many clinically relevant gram-positive bacteria (5), in addition to having potent 
activity against some gram-negative pathogens, such as Neisseria and 
Helicobacter (36). Lanthipeptides with low or no antimicrobial activity can also 
have pharmaceutically important properties. For example, despite possessing 
weak antibacterial activity, NAI-112 and the labyrinthopeptins are effective 
against nociceptive pain (7), and labyrinthopeptin A1 demonstrates broad anti- 
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human immunodeficiency virus (HIV) and anti-herpes simplex virus (HSV) activity 
(37). Moreover, the class II lantibiotic duramycin is in clinical trials for the 
treatment of cystic fibrosis (38-42).  
Lanthipeptides gained interest due to the use of a lantibiotic called nisin as 
a food preservative for more than 50 years without significant development of 
resistant bacteria (43). The reason bacteria could not develop resistance to nisin 
may be due to its unique dual mode of action (44). Nisin kills mainly gram-
positive bacteria through first binding to the pyrophosphate motif of lipid II by its A 
and B thioether rings. This  binding lipid II inhibits cell wall biosynthesis  (Figure 
1.3, Figure 1.4) (45). Lipid II, which is composed of a polyprenyl pyrophosphate, 
N-acetyl-D-muramic acid pentapeptide (MurNAc-pp), and N-acetyl-D-
glucosamine (GlcNAc), is a membrane-anchored cell-wall precursor that is 
essential for bacterial cell-wall biosynthesis (46). Through binding to lipid II, nisin 
uses its flexible hinge region located between residues 20-22 to orient itself (47) 
and form pores by insertion of its C-terminal tail into the cell membrane (48). 
Studies of nisin on the cell membrane suggests that eight nisin molecules form a 
complex together with four lipid II molecules to create pores in the membrane, 
which results in efflux of molecules from the cytoplasm of the gram-positive 
bacteria (49).  
Since the discovery of the mode of action of nisin, many other lantibiotics 
have been shown to target lipid II to prevent the synthesis of peptidoglycan (46). 
For example, the A and B rings of nisin are conserved in other class I 
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lanthipeptides. Therefore, the lanthipeptides microbisporicin (50) and mutacin 
1140 (51) also exert their antimicrobial activity through binding to lipid II. 
The first lanthipeptide known to bind to lipid II among class II 
lanthipeptides was mersacidin. Unlike nisin, mersacidin has a different binding 
motif, conserved in some of the other class II lanthipeptides (Figure 1.3), and it 
inhibits transglycosylation in a Ca2+- dependent manner without forming pores 
(Figure 1.4) (52-53). Recently, lacticin 481 was shown to inhibit PBP1b-catalyzed 
peptidoglycan formation by binding to lipid II and not form pores in the 
membranes of susceptible bacteria (54). For the two-component lantibiotics 
lacticin 3147 and haloduracin, the α-peptide shares the mersacidin-binding motif 
and interacts with lipid II, which then recruits the β-peptide to form pores (55-56). 
Fluorescent labeling of lacticin 481 and haloduracin α showed that they localized 
predominantly at sites of new and old cell division as well as in punctate patterns 
along the long axis of rod-shaped bacilli, similar to the localization of lipid II. On 
the other hand, fluorophore labeled haloduracin β was localized nonspecifically in 
the absence of haloduracin α, but formed specific patterns when coadministered 
with haloduracin α. These data with living cells supports a model in which the α 
component recognizes lipid II and then recruits the β-component (57).  
Molecular targets of a few more lanthipeptides are known, however little is 
known about the mode of action of other lanthipeptides. For example, Pep5 and 
epilancin K7 do not bind to lipid II but form pores on bacteria membrane 
suggesting other targets. In addition, cinnamycin and duramycins were shown to 
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bind to phosphatidylethanolamine (PE) with micromolar affinities, destabilizing 
the membrane without forming pores (38, 58-61). 
 
 
Figure 1.4 Representation of peptidoglycan formation on the cell membrane.  Nisin and well-
known antibiotic vancomycin binding sites are labeled with red on lipid II (blue). Peptidoglycan 
has a dynamic structure provided by transglycosylation (green) and transpeptidation reactions 
(green).  
  
1.4 Engineering of lanthipeptides and their biosynthetic enzymes 
Lanthipeptide engineering methods are divided into two approaches, 
preparation in vitro or in vivo in the producing strain or other bacteria such as E. 
coli. These two techniques have their own advantages and limitations. 
1.4.1 In vitro techniques 
In vitro reconstitution of lantibiotic synthetases and other modifying 
enzymes involved in lanthipeptide biosynthesis has been accomplished for many 
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lanthipeptides. Activity has been reconstituted for the class I LanB and LanC 
enzymes involved in nisin biosynthesis: NisB (62) and NisC (63), and for many 
class II LanM enzymes such as CinM, LctM, HalM1 and HalM2, and ProcM 
which are  involved in the formation of cinnamycin (16), lacticin 481 (64), 
haloduracin (15), and prochlorosins (18), respectively. In addition, activity has 
been reconstituted for class III enzymes LabKC, CurKC, and AciKC involved in 
the biosynthesis of labyrinthopeptin A2 (9), curvopeptin (8), and catenulipeptin 
(65) respectively, and for the class IV enzyme VenL involved in the biosynthesis 
of a lanthipeptide from Streptomyces venezuelae (11, 66).  
In vitro reconstitution of these enzymes allows substrate preparation by 
chemical techniques such as solid phase peptide synthesis (SPPS), native 
chemical ligation, and click chemistry (67-75). The use of these chemical 
synthesis techniques drastically increased the range of chemical modifications 
which have been used to make chemically and biologically more stable and/or 
more effective lanthipeptides. For example, mutants of lacticin 481 containing the 
unnatural amino acids 3-(4-pyridyl)alanine (Pal) and 3-(2-naphthyl)alanine (Nal) 
were prepared via SPPS and were demonstrated to have more potent growth 
inhibition activity compared to authentic lacticin 481 (54, 76).  
Many lanthipeptide producing enzymes have relaxed substrate specificity 
for substrates prepared by site-directed mutagenesis. To illustrate, a series of 
mutants of lacticin 481 was prepared in vitro by incubating mutant precursor 
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peptides prepared via site-directed mutagenesis of LctA and the processing 
enzyme LctM to yield peptides with altered antimicrobial potencies (19, 76).   
1.4.2 Production of lanthipeptides in E. coli and their native producing 
strains 
Production of lanthipeptides inside the cells has many other advantages 
compared to the in vitro techniques. Firstly, reconstitution of enzyme activity in 
vitro is a laborious process as it can be difficult to identify the small molecules 
needed for activity. In addition, the proteins that are active in vivo might not be 
stable in vitro, and in the cases where heterologous strains are used for 
expression, problems with codon usage can arise. Finally, in vivo techniques can 
result in a higher yield of pure lanthipeptides as many steps, for instance 
purification of enzymes is avoided.  
Many lanthipeptides from the first three classes have been expressed and 
isolated from the producing strains (77-80).  In addition, E. coli production of 
several lanthipeptides including nisin (56), lacticin 481 (56), haloduracin (56), 
prochlorosins (81), cinnamycin (16), two lantibiotics from Geobacillus 
thermodenitrificans (82), lichenicidin (83), bovicin HJ50 (84), and 
ala(0)actagardine (85) has been described.  
1.4.3 Engineering of lanthipeptides via employing leader peptides 
Lanthionine processing enzymes modify the C-terminal core region of the 
precursor peptides via guidance of the leader peptide as described above. The 
presence of the leader peptide is crucial for enzyme activity, however as it needs 
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to be removed for bioactivity of the product it presents drawbacks for in vitro 
studies with synthetic substrates, which require ligation strategies. A study 
performed on the lacticin 481 lantibiotic synthetase, LctM, showed that the leader 
region of LctA, can be attached to the N-terminus of the enzyme to make it act in 
vitro on the core peptides without leader peptides (19). Also, this engineered 
enzyme allowed the processing of lacticin 481 analogues containing non-
proteinogenic amino acids (19). 
The fact that different core regions can be processed by different 
lantibiotic synthetases as long as the matching leader peptide is attached to the 
core region (13) opens up new possibilities to engineer new lanthipeptides.  
Discovery of 29 natural lanthipeptides called prochlorosins, which are formed by 
the action of a single enzyme called ProcM, shows that nature already exploits 
the substrate substrate tolerant property of these enzymes (86). These findings 
suggest that lantibiotic synthetases can be used to engineer natural products, 
perhaps with desired properties and defined ring structures (86-87).  This 
approach can also be used to make lanthipeptide libraries. Recently, a study 
showed that bacterial display of lanthipeptide libraries with defined structures can 
be achieved by post-translational modification of the peptides by lanthionine-
synthetase enzymes in Lactococcus lactis, followed by export and sortase-
mediated covalent coupling to the lactococcal cell wall (88).  In addition, a library 
with 1011 different lanthionine containing peptides was formed using in vitro 
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translation coupled with an enzyme-free protocol for post-translational 
modification (89).  
Lanthionine synthetases have also uses for preparation of a unique 
functional group for chemoselective modification to label lanthipeptides and thus 
visualize their cellular localization. For example, the cellular locations of lacticin 
481, haloduracin α, and haloduracin β were identified by aminooxy-derivatized 
alkyne or fluorophore labeling an α-ketoamide, which was spontaneously 
generated by hydrolysis of  the N-terminal enamine as a result of introduction of 
an N-terminal dehydro amino acid by the cognate biosynthetic enzymes (57).  
1.4.4 Engineering of the enzymes involved in biosynthesis of lanthipeptides  
 Engineering of the enzymes involved in biosynthesis of lanthipeptides is 
another way to utilize the lanthipeptide biosynthesis machinery. Lanthionine 
synthetases in classes II, III, and IV have been shown to activate serine and 
threonine residues in the core region by phosphorylation, which is followed by 
elimination. This property of lanthionine synthetases was exploited in a study 
where the class II lanthipeptide synthetase ProcM was engineered to generate a 
variety of peptides containing O-phosphoserine (pSer) and O-phosphothreonine 
(pThr) residues, either in vitro or in vivo (90). Phosphorylation is an abundant 
post-translational modification involved in a myriad of cell signaling pathways 
thus through the help of this study one can prepare pharmaceutically valuable 
phosphorylated peptides to study cell signaling enzymes and processes (91-92).  
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1.4.5 Chemical synthesis  
Chemical synthesis of lanthipeptides is a challenging task, since these 
molecules are composed of several thioether crosslinks at different locations. In 
addition, these molecules contain other post-translational modifications in 
addition to lanthionines and introduction of these modifications on a peptide with 
a variety of reactive groups of the amino acid side chains is tough chemically 
(67). However, although challenging, in recent years scientists developed 
creative ways to synthesize these large molecules. The first successful total 
chemical synthesis of a lanthipeptide was the remarkable solution-phase 
synthesis of nisin (93). After this successful representation and with the 
employment of orthogonally protected Lan amino acid, chemical synthesis of the 
α-peptide of lacticin 3147  containing overlapping rings (94), lactocin S (74), 
analogs of the β-peptide of the lacticin 3147 (94-95), epilancin 15X (96), and 
lacticin 481 (97) have also been achieved.  
1.4.6 Summary and outlook 
Natural product discovery is an important way to combat the growing 
bacterial resistance problem observed in clinical settings (98). The current pool of 
antibiotics is unable to handle the challenges arising in this field. One way to fight 
so-called superbugs is to discover new antimicrobials with different modes of 
action. Lanthipeptides have proved to be pharmaceutically valuable, which 
includes having antimicrobial activity against clinically-relevant bacterial 
pathogens including drug-resistant strains. Investigations on the biosynthesis and 
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mode of action of lanthipeptides would be usefull for engineering of these 
peptides to obtain better pharmacological properties. In this thesis, biosynthesis 
of several lanthipeptides belonging to the cinnamycin group of peptides is 
described, and the biosynthetic enzymes of cinnamycin were studied in detail. In 
Chapter II, the biosynthesis of cinnamycin was investigated by reconstitution of 
the cinnamycin biosynthetic enzyme activities in vitro, and through heterologous 
expression of the cinnamycin biosynthetic genes in E. coli. These two 
approaches employed to produce cinnamycin have their own advantages. For 
instance, in vitro reconstitution of the lantibiotic synthetase CinM and the tailoring 
enzyme CinX allowed for detailed studies of these enzymes as described in 
Chapter III. On the other hand, through production of cinnamycin in E. coli, the 
activity of a new enzyme called Cinorf7 was discovered, which could not be 
achieved in the in vitro experiments. Therefore, Chapter III also contains our 
attempts to identify the catalytically important residues of Cinorf7 by mutational 
studies. These experiments on cinnamycin biosynthesis set the stage for the 
biosynthesis of other lanthipeptides in the cinnamycin-group of peptides, which is 
described in Chapter IV. Lanthipeptide synthetases have been shown to have 
relaxed substrate specificity, creating new possibilities in the engineering of these 
molecules for desired functions. Peptide libraries have been commonly used for 
engineering and selection of pharmaceutically valuable molecules. 
Lanthipeptides have great potential for drug development compared to linear 
peptides as they are chemically and metabolically more stable because of the 
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thioether crosslinks. Therefore, large molecular libraries of lanthipeptides with 
designed ring structure would be useful. In Chapter V, phage display of the well-
known lanthipeptide nisin is described, which will form a platform for the 
production and selection of lanthipeptide libraries.  
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CHAPTER II: NINE POSTTRANSLATIONAL MODIFICATIONS DURING THE 
BIOSYNTHESIS OF CINNAMYCIN1 
2.1 INTRODUCTION 
 Cinnamycin is a 19 amino acid lantibiotic with antimicrobial activity against 
gram-positive rods such as bacilli, Clostridium botilinum, and mycobacteria (1). 
The compound also causes transbilayer phospholipid movement in the cell 
membrane of mammalian cells to access phosphotidylethanolamine (PE) 
residing in the inner leaflet of the membrane (2). The interaction of cinnamycin 
with PE renders the compound pharmacologically valuable. For example, 
duramycin, a close structural analog of cinnamycin, promotes chloride secretion 
in lung epithelial cells by binding to PE; this activity in turn promotes mucus 
clearance from the lungs. As a result, the compound is in phase II clinical trials 
for the treatment of cystic fibrosis, a common genetic disorder characterized by 
abnormal chloride ion transport (2-3). Cinnamycin has also been suggested as 
an alternative treatment for atherosclerosis through its ability to inhibit 
phospolipase A2 by binding to its substrate PE (4-5). Cinnamycin has a compact 
globular and relatively rigid structure with one lanthionine (Lan) and two 
methyllanthionine (MeLan) rings in addition to an unusual lysinoalanine (Lal) 
crosslink formed from lysine 19 and serine 6 (Figure 2.1). 
                                            
1
 Reproduced in part with permission from “Nine Post-translational Modifications during the 
Biosynthesis of Cinnamycin” J. Am. Chem. Soc. 2011, 133, 13753-13760. Copyright 2011 ACS 
Publications.  
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Unlike most lantibiotics, the rings are generated in a bidirectional manner such 
that the MeLan bridges are formed by cysteines that are located N-terminally to 
the dehydrobutyrine residues with which they react, and the Lan bridge is formed 
from a cysteine located C-terminal to the dehydroalanine with which it reacts 
(Figure 2.1). Similarly, the Lal crosslink is generated from a Lys located C-
terminal to the serine with which it forms a bridge. Unlike the Lan and MeLan 
structures, which have D-stereochemistry at the α-carbon originating from 
dehydroalanine/dehydrobutyrine (Dha/Dhb), the Lal crosslink has the L-
configuration at the α-carbon originating from Ser, raising the question whether it 
is formed with the intermediacy of a Dha or not (6-8). In addition to the 
macrocyclic structures, cinnamycin also contains an erythro-3-hydroxy-L-aspartic 
acid resulting from the hydroxylation of L-aspartate at position 15 (Figure 2.1) (6-
8). The binding of cinnamycin to its target PE is primarily mediated by interaction 
of this posttranslational modification with the ammonium group of PE (4).  
The cinnamycin biosynthetic gene cluster (cin) from Streptomyces cinnamoneus 
cinnamoneus DSM 40005 was reported providing opportunities to investigate the 
biochemistry of its biosynthetic pathway (9). The cinnamycin gene cluster 
contains 21 open reading frames (17,083 bp), which include the genes for 
cinnamycin production, regulation, and self-resistance (Figure 2.2) (9). The 
cinnamycin precursor peptide, CinA, consists of a C-terminal core region that is 
19 residues long and that will be transformed into cinnamycin through 
posttranslational modifications. Appended to the N-terminus of the core peptide 
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is an unusually long 59 amino acid leader sequence that is not modified. Instead 
of a GG or GA protease cleavage motif seen in most class II lantibiotics, an AXA 
motif is present between the leader sequence and the core region of CinA 
(Figure 2.1). This sequence is recognized by type I signal peptidases of the 
general secretory (sec) pathway, which explains the absence of a cinnamycin-
specific protease in the gene cluster (10).  The CinM sequence shows high 
homology with other class II LanM enzymes which are bifunctional enzymes that 
catalyze both dehydration and cyclization (9, 11).  However, the enzymes 
responsible for Asp hydroxylation and Lal bridge formation have not been 
explored. After the core peptide is processed, the leader peptide is removed 
proteolytically to afford the mature, biologically active compound (12).  
Understanding the biosynthetic pathway of cinnamycin may be used to generate 
analogs with potentially improved properties for treatment of cystic fibrosis or 
clostridium infections. Herein, we investigated the biosynthetic machinery of 
cinnamycin in vitro and characterized the enzymes involved in the formation of 
the thioether crosslinks and the β-hydroxylation of aspartate 15. In addition, we 
developed a coexpression system in E. coli that resulted in fully modified CinA 
and identified cinorf7, an open reading frame of unknown function, as a critical 
determinant for lysinoalanine formation. 
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Figure 2.1 The structure of cinnamycin. Lan and MeLan are shown in red and blue 
respectively, Lal is depicted in purple, and the hydroxylated Asp is shown in green. The sequence 
of the CinA core and leader peptides is depicted as well as the residues that form the crosslinks. 
The sec-cleavage sequence at the end of the leader peptide is shown in bold underlined font.  
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Figure 2.2 The gene cluster for cinnamycin production, regulation, and immunity from 
Streptomyces cinnamoneus cinnamoneus DSM 40005 (9).  
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2.2 RESULTS 
2.2.1 In vitro reconstitution of the enzymatic activity of the lanthionine 
synthetase, CinM 
 The gene for the precursor peptide CinA was cloned into a pET15b vector 
and the gene encoding CinM was cloned into a pET16b vector to generate N-
terminal histidine tagged fusion proteins upon heterologous expression. Site-
directed mutagenesis was used to mutate the alanine residue at the last position 
of the leader peptide of CinA (position –1) to lysine (Dr. Lisa E. Cooper, Thesis 
2009).  The resulting His6-CinA(A–1K) mutant enables removal of the leader 
peptide using the commercial endoproteinase LysC for bioactivity assays. This 
substrate analog was used as a precursor peptide throughout this study. Both 
His6-CinA(A–1K) and His10-CinM were heterologously expressed in E. coli BL21 
DE3 cells and purified by immobilized metal ion affinity chromatography (IMAC). 
Approximately 6-10 mg of His10-CinM was obtained per liter of cell culture. The 
His6-CinA(A–1K) peptide was further purified after IMAC by reversed-phase high-
performance liquid chromatography (RP-HPLC) resulting in 40 mg of purified 
peptide per liter of cell culture that was detected as the Na+ adduct after LysC 
protease cleavage (Figure 2.3A). The enzyme CinM migrated as a protein of 
approximately 120 kDa by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and gel filtration analysis, close to the predicted 
monomeric molecular weight of His10-CinM (118.8 kDa) (Figure 2.4A).  
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          In order to evaluate dehydration activity, His6-CinA(A–1K) (20 μM) was 
incubated with His10-CinM (5 μM) at 25 ºC for 6 h in the presence of adenosine 
triphosphate (ATP), MgCl2, and immobilized tris(2-carboxyethyl)phosphine 
(TCEP). Use of immobilized reducing agent was required to prevent unwanted 
additions of reducing agents (TCEP/ dithiothreitol) to the dehydrated precursor 
peptide. Analysis of the core  peptide by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) after 
LysC endoproteinase treatment revealed a mass corresponding to loss of four 
water molecules (Figure 2.3B).  This finding demonstrates that CinM is 
responsible for the dehydration of the two threonine (Thr11 and Thr18) and two 
serine residues (Ser4 and Ser6) in the core region of CinA. Addition of cysteine 
thiols to the dehydroamino acids does not cause a change in mass, which 
prevents observation of cyclization by MALDI-ToF MS. To investigate the 
cyclization activity of CinM, iodoacetamide (IAA), a thiol alkylating agent that 
induces a mass increase upon reaction with cysteine thiols, was used. His6-
CinA(A–1K) and His6-CinA(A–1K) modified by His10-CinM were treated with IAA 
and LysC protease and then subjected to MALDI-ToF MS analysis. As expected, 
His6-CinA(A–1K) that had not been treated with His10-CinM showed a mass 
increase corresponding to alkylation of the three cysteines in the core peptide 
(Figure 2.3D). In contrast, only minor alkylation products were observed in the 
His10-CinM treated sample (Figure 2.3C).  The data strongly support conversion 
of the majority of the free thiols to thioether rings by His10-CinM, although one 
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Cys appears to be less efficiently cyclized resulting in some peptide with one IAA 
adduct (Figure 2.3C). Taken together, these results demonstrate that CinM 
functions as a bifunctional LanM enzyme that catalyzes both dehydration and 
cyclization reactions to form the thioether crosslinks. CinM did not, however, form 
the lysinoalanine crosslink (vide infra). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 MALDI-ToF MS analysis of IAA modification assay of CinA modified in vitro by 
CinM. (A) MALDI-ToF MS of His6-CinA(A–1K) treated with LysC, (B) MALDI-ToF MS of His6-
CinA(A–1K) after incubation with His10-CinM followed by LysC treatment, (C) MALDI-ToF MS of 
His6-CinA(A–1K) after incubation with His10-CinM followed by IAA and LysC treatment, and (D) 
MALDI mass spectrum of His6-CinA(A–1K) after IAA and LysC treatment. CP = CinA core 
peptide. 
   
+
Calculated mass for CP + Na
+
 + H = 2097.3 + 23 + 1 = 2121 Da, Osrvd: 2120.27 Da; CP – 4 
H2O + H; 2097.3 – 4 * 18 + 1 = 2026.3, Osrvd: 2026.2 Da; CP – 4 H2O + IAA + H (M’); 2097.3 – 4 
* 18 + 57 + 1 = 2083.3, Osrvd: 2084.6 Da; CP + 3 IAA + H = 2097.3 + 3 *57 + 1 = 2269 Da, 
Osrvd: 2271.3 Da.  
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2.2.2 In vitro reconstitution of CinX 
          The cinX gene was cloned into pET28b and was heterologously expressed 
in E. coli with an N-terminal His6-tag, and purified by immobilized metal ion 
affinity chromatography (IMAC). His6-CinX migrated as a monomer protein of 
approximately 38 kDa in gel filtration and SDS-PAGE analysis (Figure 2.4B). 
Sequence analysis suggested that CinX may be a member of the non-heme 
Fe(II)-dependent family of enzymes that utilizes β-ketoglutarate (α-KG) as 
cofactor. 
          His6-CinA(A–1K) was modified with His10-CinM followed by His6-CinX 
treatment in the presence of Fe(II) and α-KG for 2 h. After subsequent digestion 
with LysC, four dehydrations and a hydroxylation were observed in the core 
region of CinA by MALDI-ToF MS (Figure 2.5). In the absence of either Fe(II) or 
α-KG, no mass change corresponding to hydroxylation was observed, which 
supports the hypothesis from its sequence that CinX is an α-KG/Fe(II)-dependent 
hydroxylase.  
 The order in which CinM and CinX carry out their posttranslational 
modifications was also investigated. In vitro these two enzymes did not have a 
compulsory order of action as His10-CinM was able to dehydrate and cyclize His6-
CinA that had been hydroxylated by His6-CinX (Figure 2.6), and His6-CinX was 
able to hydroxylate His6-CinA that had been dehydrated and cyclized (Figure 
2.5). To validate the site of hydroxylation, aspartate 15 was mutated to alanine 
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and the mutant CinA peptide was incubated with His6-CinX. MALDI-ToF MS 
analysis showed no change in the mass of the mutant peptide (data not shown).  
 
Figure 2.4 Tris-HCl 4-20% Gradient SDS-PAGE for (A) His10-CinM (121,312 Da) and (B) His6-
CinX (MW 38,859 Da) after purification by IMAC. 
 
 
 
Figure 2.5 MALDI-ToF MS analysis of hydroxylation by CinX. His6-CinA(A–1K) modified by 
His10-CinM and subsequently digested with LysC is shown in black. His6-CinA(A–1K) modified by 
His10-CinM and then His6-CinX and subsequent digestion with LysC is shown in red.  CP = CinA 
core peptide. 
   
+
Calculated mass for black; CP – 4 H2O + H (SM); 2097.3 – 4 * 18 + 1 = 2026.3, Obsrvd: 
2026.2 Da, red; CP – 4 H2O + OH + H (SM); 2097.3 – 4 * 18 + 16 + 1 = 2042.3, Obsrvd: 2043.7 
Da.  
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 In lantibiotics, the leader peptide is required for activity of most of the 
biosynthetic enzymes (12). To evaluate if this was also the case for His10-CinM 
and His6-CinX, the core peptide of CinA (CinA1-19) was synthesized by solid 
phase peptide synthesis. As expected, His10-CinM showed no activity in the 
absence of the leader peptide (Figure 2.7A). In contrast, His6-CinX was capable 
of hydroxylating CinA(1-19) (Figure 2.7B). LC-MS/MS analysis of the product 
further verified that the hydroxylation occurs on Asp15 (Figure 2.8). 
 
 
Figure 2.6 Order of CinM and CinX post-translational modifications for CinA. MALDI-TOF 
mass spectra of CinA peptide modified by CinX before (black line) and after incubation with CinM 
(red line). Samples were cleaved with LysC prior to MS analysis. A peptide fragment arising from 
LysC cleavage of CinX (CinA A25-51) causes suppression of the other peaks.   
   
+
Calculated mass for M – 4 H2O + OH + H (M’); 2097.3 – 4 * 18 + 16 + 1 = 2042.3, Obsrvd: 
2043.4 Da.  
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Figure 2.7 Importance of the leader sequence for enzymatic activity of CinM and CinX. (A) 
MALDI mass spectrum of CinA1-19 treated with His10-CinM, (B) MALDI mass spectrum of CinA1-
19 treated with His6-CinX. 
   
+
Calculated mass for CinA 1-19; M + OH + H; 2097.3 + 16 + 1 = 2114.3 Da. M Obsrvd: 2099.95 
Da, M + OH Obsrvd: 2113.92 Da.  
 
 
 
Figure 2.8 Tandem MS/MS analysis of CinA1-19 treated with His6-CinX in vitro. The y’’4 and 
y’’5 ions define Asp15 as the site of hydroxylation, which is also consistent with all other observed 
fragment ions. 
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2.2.3 Lysinoalanine formation and bioactivity assays 
 Genetic studies in the producing organism have shown that cinA, cinM, 
cinX and cinorf7 are required for formation of cinnamycin (13). Having assigned 
the function of the first two enzymes, we investigated whether Cinorf7 was 
responsible for Lal formation. Cinorf7 was expressed and purified as an N-
terminal hexa histidine fusion protein and added to various assays containing 
His6-CinA and His10-CinM and/or His6-CinX, with various orders of addition and 
supplementation with cofactors. Unfortunately, Lal was not formed under any 
defined conditions as determined using a variety of assays (see Chapter III for 
detailed description). Non-enzymatic formation of Lal, which results in both L and 
D configurations, has been observed in food products under alkaline conditions 
by chemical dehydration of Ser and non-selective conjugate addition of lysine to 
the resulting Dha (14). Based on these observations, we investigated the non-
enzymatic in vitro formation of the Lal ring under mild alkaline conditions (pH 9.5) 
after the precursor peptide His6-CinA(A–1K) had been processed with His10-CinM 
and His6-CinX. The leader peptide was removed with LysC endoproteinase, and 
the resulting product was analyzed for Lal formation. The product was first 
hydrolyzed in strongly acidic conditions and the resulting amino acids were 
derivatized to the corresponding methyl esters and pentafluoropropionyl amides 
(15-16). Authentic cinnamycin was subjected to the same treatment to provide a 
standard. Subsequent analysis by gas chromatography-tandem mass 
spectrometry (GC-MS/MS) demonstrated that derivatized Lal from authentic 
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cinnamycin eluted as two peaks, probably due to epimerization during the acidic 
hydrolysis. The same retention times for these two peaks were observed for Lal 
derived from both authentic cinnamycin and the in vitro assay sample (Figure 
2.9A & B).  The fragmentation pattern of the peaks in the GC-MS were also 
identical and consistent with those in the literature for lysinoalanine derivatives 
(Figure 2.9C & D) (17). Thus, these experiments verify formation of the 
lysinoalanine ring at increased pH, but because the Lal residue originating from 
authentic cinnamycin was epimerized, we were unable to establish whether non-
enzymatic Lal formation was stereoselective.  
 To investigate if the non-enzymatic Lal cyclization product has the correct 
stereochemistry, an antimicrobial assay was employed, under the assumption 
that cyclization with the incorrect stereochemistry would give an inactive product. 
A well diffusion assay against the indicator strain B. subtilis LH45 demonstrated 
clear antimicrobial activity of cinnamycin synthesized in vitro. A sample that was 
not treated under alkaline conditions did not produce a zone of growth inhibition, 
which demonstrates the requirement of Lal for antimicrobial activity of 
cinnamycin. Unfortunately, this in vitro process to produce cinnamycin did not 
allow quantitative comparison of its bioactivity with authentic cinnamycin because 
the sample contained unknown amounts of material derived from the biosynthetic 
enzymes, the leader peptide, and LysC. Therefore, the concentration of 
cinnamycin within the sample was not known. Attempts to purify the cyclized core 
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peptide by RP-HPLC produced very low quantities of cinnamycin, preventing 
comparison with authentic cinnamycin. 
 
 
Figure 2.9 Detection of lysinoalanine. (A) GC-MS analysis of His6-CinA(A–1K) processed with 
His10-CinM and His6-CinX in vitro followed by LysC protease treatment, acid hydrolysis, and 
derivatization (B) GC-MS analysis of cinnamycin standard (Novacta) after acidic hydrolysis and 
derivatization (C) Mass spectrum of the lysinoalanine (Lal) peak of the sample in A, (D) Mass 
spectrum of the lysinoalanine (Lal) peak of cinnamycin standard (Novacta). All samples were 
treated with 6 M HCl and derivatized as described in the Methods section.The major peaks 
observed in panels C and D are 190 Da (CF3CF2CONHC2H4), 230 Da (CF3CF2CONHC5H8), 465 
Da (M − CF3CF2CONHCHCO- OCH3), 405 Da (465 Da-CH3OCOH), 433 Da (465 Da-CH3OH), 
640 (M − CH3OCO), M is Lal: 699 Da. 
 
2.2.4 Coexpression of CinA, CinM, CinX in E. coli  (NB10, p28, p35) 
 Quantification of Lal formation after alkaline treatment by GC-MS has 
been challenging because of the large background resulting from the leader 
peptide and the biosynthetic enzymes. In an effort to improve both the amounts 
45 
 
of material and their purity, we turned to coexpression of the CinA peptide and 
the CinM and CinX modification enzymes in E. coli. Recent studies in several 
laboratories have demonstrated the feasibility of conducting the post-translational 
modifications that generate lantibiotics in this heterologous host (18-21). In our 
laboratory, pRSFDuet-1 and pACYCDuet-1 plasmids were used for these 
studies, which offer a convenient purification approach of the post-translationally 
modified peptide using IMAC because of a His6-tag at the N-terminus of the 
leader peptide of the substrate peptide (20). A similar approach was employed 
here in an attempt to obtain higher quantities of peptide processed by CinM and 
CinX.   
The gene encoding CinA(A–1K) with an N-terminal flag tag was inserted 
into multiple cloning site I (MCSI) of the pRSFDuet-1 vector to generate His6-
Flag-CinA(A–1K) (22). The gene encoding CinM was inserted into MCSII of the 
same plasmid resulting in a protein without a His-tag, thus preventing co-
purification of the CinM enzyme, which complicated the in vitro experiments. 
Similarly, cinX was cloned into MCSII of the pACYCDuet-1 vector, which also 
produces CinX without a His-tag. 
46 
 
 
Figure 2.10 MALDI-ToF MS analysis of His6-CinA(A–1K) modified by CinM and CinX in E. 
coli. (A) MALDI mass spectrum of His6-CinA(A–1K) modified by CinM and CinX in E. coli and 
treated with LysC; (B) MALDI mass spectrum of iodoacetamide (IAA) treatment of the 
coexpression product followed by LysC cleavage. The ion marked with an asterisk is M – 4 H2O.  
   
+
Calculated mass for M – 4 H2O + OH + H (M’); 2097.3 – 4 * 18 + 16 +1 = 2042.3, Obsrvd: 
2043.1 Da, M’ + IAA = 2042.3 + 57 = 2099.3 Da, Obsrvd: 2099.5 Da.  
 
Coexpression of CinM and CinX together with His6-Flag-CinA(A–1K) 
yielded 2 mg of His6-Flag-CinA(A–1K) peptide per liter of cell culture after IMAC 
purification and subsequent RP-HPLC. MALDI-ToF MS analysis of the LysC-
treated peptide showed a mass difference with respect to unmodified core 
peptide corresponding to four dehydrations and one hydroxylation (Figure 
2.10A). In vivo thioether cyclization activity was investigated by IAA treatment 
and analysis by MALDI-ToF MS as previously described. Similar to the in vitro 
results, CinM formed predominantly three thioether rings in the CinA core region 
(Figure 2.10B).  
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The peptide obtained from coexpression did not have antimicrobial activity 
towards the indicator strain B. subtilis LH45 similar to the observations for the 
product of CinM and CinX treatment in vitro. However, when Lal cyclization was 
induced by mild alkaline treatment, the peptide showed strong antimicrobial 
activity comparable to authentic cinnamycin (Figure 2.11).  
 
 
Figure 2.11 Bioassay with the indicator strain B. subtilis LH45. Sector 1, authentic 
cinnamycin; sector 2, His6-CinA(A–1K) modified by CinM and CinX in E. coli and treated with 
LysC followed by incubation at pH 9.5; sector 3, His6-CinA(A–1K) modified by CinM and CinX in 
E. coli treated with LysC (no alkaline treatment); sector 4 was not used.  
 
 With larger quantities of material in hand, the peptide produced in E. coli 
was used to investigate non-enzymatic Lal formation in more detail. o-
Phthalaldehyde (OPA) is a reagent that reacts selectively with primary amines in 
the presence of a thiol such as β-mercaptoethanol but does not react with 
secondary amines (23). Thus, OPA was used to monitor conversion of the 
primary ε-amine of Lys to the secondary amine in Lal. CinA(A–1K) that had been 
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modified by CinM and CinX in E. coli and then incubated with LysC was treated 
with OPA, causing a mass increase corresponding to two OPA additions in the 
core region. These two OPA adducts originate from the N-terminal amino group 
and the ε-amino group of Lys. Furthermore, one β-mercaptoethanol addition was 
observed as a consequence of Michael-type addition to dehydroalanine 6 (Figure 
2.12A). 
 
 
 
 
 
Figure 2.12 Use of o-phthalaldehyde (OPA) to monitor lysinoalanine formation. (A) CinA(A–
1K) modified by CinM and CinX, and treated with LysC was incubated with OPA and β-
mercaptoethanol. (B) CinA(A–1K) modified by CinM and CinX followed by alkaline treatment and 
removal of the leader peptide with LysC was incubated with OPA and β-mercaptoethanol. (C) 
Authentic cinnamycin was incubated with OPA and β-mercaptoethanol. SM = mass of core 
peptide after 3 dehydrations and one hydroxylation. Asterisk indicates fourfold dehydrated core 
peptide that did not react with OPA. 
   
+
Calculated mass for CP – 4 H2O + OH + H (SM); 2097.3 – 4 * 18 + 16 + 1 = 2042.3, SM + 
OPA = 2042.3 + 180.1 = 2222.4, Obsrvd: 2221.84 Da, Cinnamycin + OPA: SM + OPA, Obsrvd: 
2220.2 Da, SM + 2 OPA + BME + H = 2042.3 + 2 *180.1 + 78.1 = 2481.6, Obsrvd: 2481.4 Da.  
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 Collectively, these data clearly show the absence of a lysinoalanine 
crosslink. In contrast, the OPA assay of the same sample after alkaline treatment 
resulted in only one OPA addition and no β-mercaptoethanol adducts, which was 
also observed when authentic cinnamycin was used as a positive control (Figure 
2.12B, C). The absence of the peak corresponding to the formation of two OPA 
and one β-mercaptoethanol adducts in this sample suggests that the cyclization 
occurred with near quantitative efficiency. 
2.2.5 Coexpression of CinA, CinM, CinX and Cinorf7 in E. coli  
 The in vitro studies did not provide any insights into the possible role of 
Cinorf7 in cinnamycin biosynthesis. In an alternative approach, the coexpression 
system in E. coli was used to investigate whether Cinorf7 is involved in formation 
of the Lal crosslink in vivo. For this purpose, the cinorf7 gene was cloned into 
MCSI of pACYCDuet-1 that already contained the gene encoding CinX in MCSII. 
The resulting plasmid was used with the pRSFDuet-1 vector containing the 
genes for CinA(A–1K) and CinM for coexpression in E. coli. The resulting peptide 
was purified by IMAC, treated with LysC and analyzed with the OPA assay. The 
resulting mass spectrum showed that the Lal crosslink was formed without the 
need of raising the pH (Figure 2.13A). Also, an antimicrobial assay towards the 
indicator strain B. subtilis LH45 verified that the activity of cinnamycin 
synthesized heterologously in E. coli was similar to the antimicrobial activity of 
authentic cinnamycin (Figure 2.13B). Because in the absence of Cinorf7 both the 
OPA assay and the antimicrobial assay were negative for the peptide produced 
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in E. coli, these results reveal that Cinorf7 is required for the formation of the Lal 
crosslink.   
 
 
 
Figure 2.13 Use of o-phthalaldehyde (OPA) to monitor lysinoalanine formation and 
bioassay for the peptide obtained from coexpression studies. (A, top) CinA(A–1K) modified 
in E. coli by CinM, CinX, and Cinorf7 followed by in vitro LysC cleavage; (A, middle) The peptide 
form the top spectrum analyzed by OPA assay as described in the text; (A, bottom) Authentic 
cinnamycin analyzed by OPA assay as a positive control. (B) The outer ring of spots shows 
various concentrations of authentic cinnamycin, the inner ring of spots shows LysC-cleaved 
coexpression product (CinA(A–1K), CinM, CinX, Cinorf7). Concentrations: spot 1: 60 μg/mL, 2: 
30 μg/mL, 3: 15 μg/mL, 4: 10 μg/mL, 5: 7.5 μg/mL, 6: 5 μg/mL, 7: 2.5 μg/mL, 8: 1 μg/mL.  
   
+
Calculated mass for CP – 4 H2O + OH + H (M’); 2097.3 – 4 * 18 + 16 = 2042.3, M’ + OPA = 
2042.3 + 180.13 + 1 = 2222.4 Observed mass (B) 2221.8 Da, (C) 2218.36 Da.  
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2.3 DISCUSSION 
 The in vitro biosynthesis of cinnamycin was achieved in this work by 
reconstitution of the activities of two enzymes in the biosynthetic pathway, CinM 
and CinX. His10-CinM dehydrated two threonine and two serine residues in the 
core region of His6-CinA and catalyzed the subsequent cyclization by cysteine 
thiols to form three thioether rings. The observation that CinM dehydrated Ser6 
confirms that the Lal crosslink is formed with the intermediacy of a 
dehydroalanine despite the L-stereochemistry at the α-carbon of the former Ser 
residue. Although His10-CinM dehydrated Ser6, it did not catalyze the formation 
of the Lal ring. Considering that LanC/LanM enzymes typically stereoselectively 
protonate the enolate formed during the Michael-type addition to provide D-
stereochemistry at the α-carbon, it is not surprising that Lal formation, which 
results in the L-configuration at the newly formed stereogenic  
center, is not catalyzed by CinM. In addition, CinM is much better suited to 
activate a thiol nucleophile with the Zn2+ in its active site than to activate a 
primary amine (24-25). 
 CinX was shown to be an Fe(II)/α-ketoglutarate-dependent hydroxylase 
that catalyzes the β-hydroxylation of Asp15 in the CinA precursor peptide. 
Interestingly, His6-CinX accepted the core region of CinA as a substrate without 
the need of the leader sequence. Similar observations were made for the 
oxidative decarboxylases MrsD and EpiD (26-27), suggesting that tailoring 
enzymes that introduce post-translational modifications beyond dehydration and 
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cyclization may not require the leader peptide. However, as observed for other 
lanthionine synthetases (28-30), His10-CinM required the leader peptide for 
efficient processing. Changing the order of incubation of the precursor peptide 
with His10-CinM or His6-CinX resulted in the same product.   
 In vitro biosynthesis of cinnamycin was accomplished by inducing non-
enzymatic formation of the Lal by raising the pH after treatment of CinA with 
His10-CinM and His6-CinX in vitro or after heterologous coexpression of CinM and 
CinX with the precursor peptide in E. coli. The high bioactivity of the resulting 
peptide suggests that the non-enzymatic cyclization occurs with high 
stereoselectivity, assuming that cinnamycin with a Lal residue with incorrect 
stereochemistry has no or low antimicrobial activity. High stereoselectivity for 
non-enzymatic formation of Lan and MeLan has been demonstrated previously 
(31-36), but no such investigations have been conducted for Lal formation. The 
Lan and MeLan residues generated by CinM may pre-organize the conformation 
of the peptide to favor stereoselective formation of Lal, similar to a recent 
proposal for a lanthionine synthetase that generates a large number of thioether 
crosslinks of high structural diversity (16).    
 Genetic studies have identified the cinorf7 gene to be essential in the 
biosynthesis pathway of cinnamycin (13). This gene, composed of just 360 
nucleotides, is located immediately upstream of cinA and the two genes are 
cotranscribed (9). We show here that Cinorf7 is required for lysinoalanine 
formation. Unfortunately, in vitro reconstitution of its activity has been 
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unsuccessful to date. Sequence analysis of Cinorf7 shows that it does not have 
significant homology to other functionally-characterized proteins. Two other 
genes encoding proteins with high sequence similarity to Cinorf7 were identified 
in the protein databases (Figure 2.14A). One of these, found in the genome of 
Lyngbya majuscule, has two nearby likely precursor peptides whereas the 
second, found in the genome of Frankia Sp., has one gene encoding a possible 
precursor peptide nearby (Figure 2.14B). Both cinorf7 orthologs also are near 
LanM-like genes. Although the sequences of the predicted leader peptides of 
these putative precursor peptides vary, their core regions showed very high 
sequence identity to the cinnamycin group (Figure 2.14B), suggesting these gene 
clusters have the genetic capacity to generate cinnamycin-like peptides. 
Experimental investigations of cinnamycin-like gene clusters are presented in 
Chapter IV.  
 In summary, I demonstrated in the studies described in this chapter that 
CinM is responsible for dehydration of two Ser and two Thr residues and also 
generates the three thioether crosslinks in cinnamycin. Furthermore, CinX 
hydroxylates a single Asp in a 78-residue substrate and also accepts just the 
core peptide as substrate. Finally, the data indicate that Cinorf7 is critical for the 
formation of the unique lysinoalanine crosslink.  
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Figure 2.14 Two other genes with high sequence similarity to cinorf7 were identified in the 
protein databases. (A) The ortholog from Lyngbya majuscula (ZP_08425231) has two possible 
precursor peptides close by in the genome. These two peptides are shown in panel B 
(ZP_08425235_02840 and ZP_08425237_02860). The second orthologs was found in Frankia 
Sp. It has one possible precursor peptide nearby (ZP_06416733_6431 in panel B) in addition to 
having one LanM-like gene. (B) The sequences of the predicted leader peptide of the three 
putative precursor peptides vary, but the core region showed very high sequence similarity to 
cinnamycin group of peptides. The predicted start of the core peptide is indicated with a vertical 
black line. 
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2.4 MATERIALS 
Oligonucleotide primers for mutagenesis were synthesized by Operon 
Technologies. Taq and Platinum Pfx DNA polymerases, DpnI, restriction 
endonucleases, and bacteriophage T4 DNA ligase were purchased from 
Invitrogen. Fusion DNA polymerase was purchased from  New England Biolabs. 
Cloning vectors (pET and pDuet) were obtained from Novagen. Gel extraction, 
plasmid mini-prep, and PCR purification kits were purchased from Qiagen. All 
strains were grown in media acquired from Difco laboratories. Other items 
procured include isopropyl-1-thio-D-galactopyranoside (IPTG, CalBiochem), 
iodoacetamide (IAA, Acros Organics), tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP, Aldrich), and dithiothreitol (DTT, Sigma). Endoproteinase 
LysC was purchased from Roche Applied Science.  
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2.5 GENERAL METHODS 
Molecular biological manipulations were carried out using standard 
techniques (37). PCR was performed using an automatic thermocycler (PTC 150, 
MJ Research) and DNA sequencing was performed at the Biotechnology Center 
of the University of Illinois at Urbana-Champaign (UIUC). Escherichia coli DH5α 
cells (UIUC Cell Media Facility) and E. coli BL21 (DE3) cells (Stratagene) were 
used for plasmid DNA preparation and protein expression, respectively. Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF 
MS) was carried out on a Voyager-DE-STR (Applied Biosystems). Liquid 
chromatography electrospray ionization tandem mass spectrometry (LC/ESI-
MS/MS) was carried out and processed using a Synapt ESI quadrupole ToF 
Mass Spectrometry System (Waters) equipped with an Acquity Ultra 
Performance Liquid Chromatography (UPLC) system (Waters).  GC/MS-MS 
analysis (Agilent HP 5973 mass spectrometer and a Supelco SPB-1701 30 m x 
0.25 mm fused silica capillary column) was performed at the Metabolomics 
Center of the Roy J. Carver Biotechnology Center, University of Illinois at 
Urbana-Champaign.  
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2.6 EXPERIMENTAL METHODS 
2.6.1 Procedure for LysC cleavage 
 Enzymatic assay products were separated from the immobilized TCEP gel 
by centrifugation and dried on a centrivap concentrator. The products were 
resuspended in 19 μL of 100 mM Tris, pH 8.3 and 2 μL of LysC (0.4 μg/mL in 
100 mM Tris, pH 8.3) was added. The cleavage reaction was incubated at 37 ºC 
for 3 h and then desalted using by ZipTip (Millipore). The product was eluted in 5 
μL of sinapinic acid and analyzed by MALDI-ToF MS. 
2.6.2 CinM cyclization activity assay (NB2, p54) 
 CinM dehydration and cyclization activities in vitro CinM assay 
components consisted of 50 mM MOPS, pH 7.5, 10 mM MgCl2, 20 μM CinA(A–
1K) peptide, 2.5 mM ATP, 5 μM enzyme and 1 mM tris(2-carboxyethyl) 
phosphine hydrochloride (TCEP) or dithiothreitol (DTT).  MALDI-ToF analysis 
after LysC treatment showed that CinM is responsible for four dehydrations in the 
core region. However, assays using TCEP and DTT formed side products of 
+180 Da or +250 Da for TCEP and +154 Da for DTT (Dr. Lisa E. Cooper, Thesis 
2009). In order to prevent the formation of these adducts, enzyme assays were 
conducted in the presence of TCEP-immobilized gel (20 μL, Thermo Scientific) in 
50 mM MOPS, pH 7.5, 10 mM MgCl2, and 2.5 mM ATP (60 μL final volume) for 6 
h while gently rocking the suspension. 
 After incubation of His6-CinA(A–1K) with His10-CinM, the assay 
components were separated from the immobilized TCEP resin by centrifugation 
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and products were dried in an eppendorf tube on a centrivap concentrator. The 
assay products were resuspended in 100 mM Tris, pH 8.3, 1 mM TCEP, and 5 
mM iodoacetamide and then incubated at 25 ºC for 90 min in the dark, desalted 
using ZipTipC18, and subjected to MALDI-ToF MS. 
2.6.3 Hydroxylation activity assay with CinX (NB5, p61) 
 A solution with the final concentrations of 100 mM MOPS pH 7.5, 1 mM α-
ketoglutaric acid sodium salt (Sigma), 2 mM of L-(+)-ascorbic acid (Acros), 0.1 
mM ferrous sulfate 7-hydrate (Mallinckrodt Chemicals), 20 μM peptide, and 25 
μM of CinX was prepared in a final volume of 25 μL and incubated at room 
temperature for 1 h. The assay was quenched by the addition of TFA to a final 
concentration of 0.1% and the assay mixture was desalted using a C18 ZipTip 
and eluted with 5 μL of sinapinic acid. Then, the samples were analyzed by 
MALDI-ToF MS analysis. 
2.6.4 Tandem MS analysis to determine the hydroxylation site (NB4, p66) 
 CinA was modified by CinX in vitro and the leader peptide removed by 
LysC. The resulting products were first treated with 5 mM TCEP to reduce the 
disulfides that might have formed and then analyzed by LC-ESI-MSMS using a 
Synapt ESI quadrupole ToF Mass Spectrometry System (Waters) equipped with 
an Acquity Ultra Performance Liquid Chromatography (UPLC) system (Waters).   
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2.6.5 Coexpression of CinA(A–1K), CinM, and CinX with and without 
Cinorf7 in E. coli (NB8. p50) 
 In order to coexpress CinA(A–1K), CinM and CinX, E. coli BL21 (DE3) 
cells were transformed with a pRSFDuet-1 vector containing cinA(A–1K) and 
cinM and a pACYCDuet-1 vector containing cinX. Similarly, for coexpression of 
CinA(A–1K), CinM and CinX together with Cinorf7, E. coli BL21 (DE3) cells were 
transformed with a pRSFDuet-1 vector containing cinA(A–1K) and cinM and a 
pACYCDuet-1 vector containing cinX and cinorf7.  Single colony transformants 
were grown in a 37 ºC shaker for 12-15 h in 50 mL of Luria-Bertani (LB) medium 
supplemented with 25 μg/mL kanamycin/12.5 μg/mL chloramphenicol. A 20 mL 
aliquot was centrifuged at 5000×g for 10 min, the spent LB medium was 
discarded, and the cell pellet was resuspended in fresh LB medium. The 
resuspended cells (20 mL) were added to 2 L of LB supplemented with the 
appropriate antibiotics, and the culture was grown aerobically at 37 ºC until the 
A600 was ~ 0.6 to 0.8. IPTG was added to a final concentration of 0.5 mM and the 
culture was transferred to 18 ºC for aerobic growth for an additional 20 h. Cells 
were harvested by centrifugation at 5000×g for 20 min at 4 ºC. The cell paste (~ 
3-4 g) was stored at –80 ºC until use. 
 Peptides were purified from E. coli BL21 (DE3) cultures as described for 
other His6-LanA peptides (38) by use of a 5 mL HiTrap chelating HP nickel 
affinity column (GE Healthcare) followed by HPLC.  
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2.6.6 Bioactivity assays with B. subtilis LH45 (NB8, p54) 
 CinM (5 μM) was incubated with 50 mM MOPS, pH 7.5, 10 mM MgCl2, 20 
μM CinA(A–1K) peptide, 2.5 mM ATP, and 150 μL immobilized TCEP (600 μL 
total volume) at 25 oC for 6 h. Enzymatic assay products were separated from the 
TCEP immobilized resin by centrifugation and dried via on a centrivap 
concentrator. The CinM-modified peptide was resuspended in CinX assay 
components and hydroxylation was carried out for 2 h as described for the CinX 
assay. Then the leader peptide was cleaved with 15 μL of LysC (0.4 μg/mL in 
100 mM Tris, pH 8.3) at 37 ºC for 12 h.  The pH of the solution was carefully 
increased to pH 9.5 by addition of 5 M NaOH and the solution was incubated at 
room temperature for 12 h. A solid phase extraction column (SPE, 1 mL, 
Discovery DSC-18) was used to partially purify the peptide from the assay 
components. The C18 column was first washed with 2 mL of 80% acetonitrile 
(ACN)/water and equilibrated with 2 mL of water and then the sample was 
applied. The column was washed with 4 mL of water and the sample was eluted 
with 1 mL 80% ACN/water solution. The sample was dried on a centrivap 
concentrator and the peptide was dissolved in 10 μL of 100 mM Tris pH 7.5, 
analyzed by MALDI-ToF MS, and used for the bioassay. 
 Similarly, 0.5 mg modified peptide obtained from the coexpression of CinM 
and CinX (sample A) and from coexpression of CinM, CinX and, Cinorf7 (sample 
B) were separately dissolved in 1 mL of 100 mM Tris-HCl pH 8.3 buffer and 
digested with 50 μL of LysC (0.4 μg/mL in 100 mM Tris, pH 8.3) at 37 ºC for 12 h. 
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Then, the pH of sample A was carefully increased to pH 9.5 by addition of 5 M 
NaOH and the solution was incubated at room temperature for 12 h for non-
enzymatic formation of Lal. Both samples were then further purified by SPE as 
described above.   
 B. subtilis LH45 was grown at 37 ºC for 15 h in 5 mL of LB supplemented 
with 0.1% D-(+)-glucose (Calbiochem). LB medium containing 1.5 % agar was 
autoclaved and cooled to 42 ºC in a water bath, and 15 mL of this solution was 
mixed with 375 μL of B. subtilis LH45 culture and with a D-(+)-glucose solution to 
give a 0.1% final glucose concentration. The agar was poured into sterile plates 
and shallow wells were generated after the agar solidified. The peptide samples 
(10 μL in 50 mM Tris Buffer) were spotted and the plates were incubated for 10 h 
at 25 oC.   
2.6.7 Cloning of cinA, cinM, cinX and cinorf7 and construction of 
expression plasmids (NB7, NB9, p6) 
The genes cinA, cinM, cinX and cinorf7 were cloned from S. 
cinnamoneous genomic DNA. The amplification of cinA was conducted via 30 
cycles of denaturing (98 ºC for 10 s), annealing (55 ºC for 30 s), and extending 
(72 ºC for 135 s) using CinA_wt_FP_NdeI_pET15b and 
CinA_wt_RP_BamHI_pET15b as forward and reverse primers (Table 2.1). The 
PCRs (50 μL) included 1x HF buffer (Finnzymes), DMSO (4%), Fusion DNA 
Polymerase (Finnzymes) (0.02 unit/μL), dNTPs (1 mM), S. cinnamoneous 
genomic DNA, and primers (1 μM each). Amplification of the final PCR product 
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was confirmed by 2% agarose gel electrophoresis, and the products were 
purified using QIAquick PCR purification kits (QIAGEN). The resulting DNA 
fragment and the pET15b vector were digested in 1 x NEBuffer 4 (New England 
Biolabs) with NdeI (for 15 h) and BamHI at 37 ºC (for 3 h). The digested products 
were purified by agarose gel electrophoresis followed by use of a QIAquick gel 
extraction kit (QIAGEN). The resulting DNA insert was ligated with the digested 
pET15b vector at 16 ºC for 15 h using T4 DNA ligase. 
The ligation reaction mixture was diluted 5 times with water prior to 
transformation. E. coli DH5α cells were transformed with the ligation product via 
heat shock, plated on LB-ampicilin agar plates, and grown at 37 ºC for 15 h. 
Colonies were picked and incubated in 5 mL of LB-ampicilin medium at 37 ºC for 
15 h, followed by isolation of the plasmids using a QIAprep Spin Miniprep Kit 
(QIAGEN). The sequences of the resulting plasmids were confirmed by DNA 
sequencing. 
Similarly, cinM, cinX and cinorf7 were amplified using appropriate primers 
(Table 2.1) by PCR. The reactions contained 1xFailSafe PreMix G (PICENTRE 
Biotechnologies), DMSO (4%), Platinum Pfx DNA polymerase (0.025 unit/μL), 
Taq DNA polymerase (0.05 unit/μL), and primers (1 μM each). Amplification of 
the final PCR products were confirmed by 1% agarose gel electrophoresis and 
the products were purified using QIAquick PCR purification kits. The resulting 
DNA fragments and the pET16b and pET28b vectors were digested in 1 x 
NEBuffer 4 with NdeI and XhoI at 37 ºC (for 15 h). The digested products were 
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purified by agarose gel electrophoresis followed using a QIAquick gel extraction 
kit. The resulting DNA inserts were ligated with the digested corresponding 
vectors at 16 ºC for 15 h using T4 DNA ligase to generate cinM-pET16b, cinX-
pET28b and cinorf7-pET28b. The ligation reaction mixture was diluted 5 times 
with water prior to transformation. E. coli DH5α cells were transformed with the 
ligation product via heat shock, plated on LB-ampicilin (for pET16b) and LB-
kanamycin (for pET28b) agar plates, and grown at 37 ºC for 15 h. Colonies were 
picked and incubated in 5 mL of LB-ampicilin/kanamycin medium at 37 ºC for 15 
h, followed by isolation of the plasmids using a QIAprep Spin Miniprep Kit. The 
sequences of the resulting plasmids were confirmed by DNA sequencing. 
2.6.8 Construction of the CinA (A−1K) (NB5) 
Site-directed mutagenesis of cinA was performed by multistep overlap 
extension PCR. First, the amplification of cinA was conducted via 30 cycles of 
denaturing (94 ºC for 20 s), annealing (55 ºC for 30 s), and extending (72 ºC for 
120 s) using the cinA-NdeI-FP primer and CinA-K_RP_(A−1K)_pET15b reverse 
primer (see Table 2.1) to yield a 5’ fragment of the mutated CinA(A–1K) gene 
(FP reaction). The PCR mixtures included 1x FailSafe PreMix G, DMSO (4%), 
Platinum Pfx DNA polymerase (0.025 unit/μL), Taq DNA polymerase (0.05 
unit/μL), and primers (1 μM each). In parallel, a PCR using CinA-
K_FP_(A−1K)_pET15b forward primer and the CinA_wt_RP_BamHI_pET15b 
primer was also conducted to produce the 3’ fragment of the mutated CinA(A–
1K) gene using the same PCR conditions that were used for the FP reaction (RP 
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reaction). The overlapping products from the FP reaction and RP reaction were 
combined in equal amounts  and extended by five cycles of denaturing, 
annealing, and extending in a solution containing 1x FailSafe PreMix G, DMSO 
(4%), and Platinum Pfx DNA polymerase (0.025 unit/μL). Following the 
extension, the CinA_NdeI_FP and CinA_wt_RP_BamHI_pET15b primers were 
added (final concentration of 2 μM), and the reaction mixture was incubated for 
25 additional cycles of denaturing, annealing, and extending.  
Amplification of the final PCR product was confirmed by 2% agarose gel 
electrophoresis, and the products were purified using QIAquick PCR purification 
kits. The resulting DNA fragment and the pET28 vector were digested in 1x 
NEBuffer 4 with NdeI (15 h) and BamHI (3 h) at 37 ºC. The digested products 
were purified by agarose gel electrophoresis followed using a QIAquick gel 
extraction kit. The resulting DNA insert was ligated with the digested pET15b 
vector at 16 ºC for 15 h using T4 DNA ligase. The ligation reaction mixture was 
diluted 5 times with water prior to transformation. E. coli DH5α cells were 
transformed with the ligation product via heat shock, plated on LB-ampicilin agar 
plates, and grown at 37 ºC for 15 h. Three colonies were picked and incubated in 
5 mL of LB-ampicilin medium at 37 ºC for 15 h, followed by isolation of the 
plasmids using a QIAprep Spin Miniprep Kit. The sequences of the resulting 
plasmids were confirmed by DNA sequencing. 
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2.6.9 Generation of a coexpression system in E. coli (NB9, p8) 
The genes encoding CinA(A–1K), CinM, CinX and Cinorf7 were amplified 
using appropriate primers (Table 2.1) using CinA(A–1K)-pET15b, CinM-pET16b, 
CinX-pET28b and Cinorf 7-pET28b as templates following the protocols 
described above. The gene encoding CinA(A–1K) with an N-terminal FLAG-tag 
(DYKDDDDKF) was placed into multiple cloning site I (MCSI) of pRSFDuet-1 by 
using AscI and HindIII restriction sites, whereas cinM was placed into MCSII of 
the same vector by using EcoRV and KpnI restriction sites. Double digestion for 
the corresponding gene and the corresponding vector was carried out with AscI 
and HindIII-HF enzymes by use of 1x NEBuffer 4 for 10h at 37 ºC. Similarly, 
double digestion for the corresponding gene and the corresponding vector was 
carried out with EcoRV-HF and KpnI-HF enzymes by use of 1x NEBuffer 4 for 
10h at 37 ºC.  In addition, two pACYCDuet-1 vectors were constructed, one 
contains only cinX in MCSII, and one contains cinorf7 in MCSI and cinX in 
MSCII. NcoI and HindIII restriction sites were used to introduce c inorf7 whereas 
EcoRV and XhoI cut sites were used to place cinX into pACYCDuet-1. For NcoI 
and HindIII, a double digest reaction was carried out in 1x NEBuffer 2  at 37 oC 
for 10 h, whereas for EcoRV and XhoI, a double digest reaction was carried out 
in the presence of 1x NEBuffer 3  together with 1x BSA (NEB) for 10 h at 37 ºC.  
The digested products were purified by agarose gel electrophoresis followed 
using a QIAquick gel extraction kit. The resulting DNA inserts were ligated with 
the digested corresponding vectors at 16 ºC for 15 h using T4 DNA ligase. The 
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ligation reaction mixture was diluted 5 times with water prior to transformation. E. 
coli DH5α cells were transformed with the 10 μL of the ligation product via heat 
shock, plated on LB-kanamycin plates for pRSFDuet-1 vector, LB-
chloramphenicol agar plates for pACYCDuet-1 vector, and grown at 37 ºC for 15 
h. Three colonies were picked and incubated in 5 mL of LB-
kanamycin/chloramphenicol medium at 37 ºC for 15 h, followed by isolation of the 
plasmids using a QIAprep Spin Miniprep Kit. The sequences of the resulting 
plasmids were confirmed by DNA sequencing. 
2.6.10 Overexpression and purification of His6-CinA, His6-CinA A−1K, and 
His6-CinA A−1K D15A (NB7, p18, p36) 
Peptides were overexpressed and purified from E. coli BL21 (DE3) 
cultures as described for other His6-LanA peptides (38). Briefly, purification was 
accomplished by solubilizing the inclusion bodies from the overexpression 
experiments using 4 M guanidine hydrochloride and loading this solution onto a 5 
mL HiTrap chelating HP nickel affinity column (GE Healthcare). The desired 
peptides were eluted in 1-2 column volumes of elution buffer containing 4 M 
guanidine hydrochloride, 20 mM sodium phosphate, pH 7.5, 100 mM NaCl, and 1 
M imidazole. Desalting was achieved by preparative RP-HPLC on a Waters 
system using a C4 PrepLC column. Solvents for preparative RP-HPLC were 
solvent A (0.1% TFA in water) and solvent B (0.086% TFA in 80% ACN/20% 
water). A gradient of 2 – 100 % of solvent B over 45 min was executed with a 
flow rate of 8 mL/min. Peptides were detected by absorbance at 220 nm. 
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Lyophilized powder was analyzed by matrix-assisted laser desorption/ionization-
time of flight mass spectrometry MALDI-ToF MS) and desired products were 
stored at – 20 ºC. MALDI-ToF MS was carried out on a Voyager-DE-STR mass 
spectrometer (Applied Biosystems). 
2.6.11 Overexpression of his10-cinM and his6-cinX (NB5, 34, 73; NB1, p17- 
19, p41) 
E. coli BL21 (DE3) cells were transformed with pET16b-cinM and pET28b-
cinX. Single colony transformants were grown in a 37 ºC shaker for 12-15 h in 50 
mL of Luria-Bertani (LB) medium supplemented with 100 μg/mL ampicillin (for 
pET16b-cinM) or 50 μg/mL kanamycin (for pET28b-cinX). A 20 mL aliquot was 
centrifuged at 5000×g for 10 min, the spent LB medium was discarded, and the 
cell pellet was resuspended in fresh LB medium. The resuspended cells (20 mL) 
were added to 2 L of LB supplemented containing corresponding antibiotic, and 
the culture was grown aerobically at 37 ºC until the A600 was ~ 0.6 to 0.8. IPTG 
was added to a final concentration of 1 mM and the culture was transferred to 18 
ºC for aerobic growth for an additional 20 h. Cells were harvested by 
centrifugation at 5000×g for 20 min at 4 ºC. The cell paste (~ 4 g) was stored at – 
80 ºC until use. 
2.6.12 Purification of His10-CinM and His6-CinX (NB7, p26; NB5, p34) 
Both His10-CinM and His10-CinX were kept at 4 ºC for the duration of the 
purification process. For each enzyme, the cell paste was resuspended in ~ 20 
mL of LanM Start Buffer (20 mM Tris, pH 7.6, 500 mM NaCl, 10 % glycerol) and 
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lysed by sonication (35% amplitude, 4.0 s pulse, 9.9 s pause, 15 min). The 
sample was centrifuged at 23,700×g for 45 min (Beckman JA-20 rotor) and the 
supernatant was clarified through 0.45 μm syringe filters (Corning). The sample 
was then loaded onto a 5 mL HisTrap HP column (GE Healthcare Life Sciences). 
The column was washed with 20 mL each of start buffer containing 25 and 50 
mM imidazole and then 10 mL each of start buffer containing 100, 200, and 500 
mM imidazole. The eluent was collected in several fractions, which were 
analyzed by Tris-SDS-PAGE (4-20% acrylamide gradient). The fractions 
containing the desired protein (200-500 mM imidazole) were combined and 
concentrated using an Amicon Ultra-15 centrifugal filter unit (30 kDa molecular 
mass cut off for His6-CinM, 10 kDa molecular mass cutoff for His6-CinX, Millipore) 
to less than 2 mL. Buffer exchange of the concentrated proteins with LanM Final 
Buffer (20 mM Tris, pH 7.6, 500 mM KCl, and 10% glycerol) was conducted twice 
via size exclusion chromatography (GE Healthcare Life Sciences). The resulting 
protein samples were aliquoted, frozen with liquid nitrogen, stored at −80 ºC. 
Protein concentrations were determined using A280 measurements and were 
calculated with theoretical extinction coefficient obtained from the ProtParam 
function on the ExPASy Proteomics Server (His10-CinM, ε280 = 158,180 M
-1cm-1, 
His6-CinX, ε280 = 62,005 M
-1 cm-1). For CinM, typical protein yields ranged from 
6 -10 mg per liter of overexpressed cells, whereas for CinX protein yields ranged 
from 1.7 mg to 2 mg per liter of overexpressed cells.  
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2.6.13 Detection of lysinoalanine (Lal) on CinA by gas chromatography-
mass spectrometry analysis (GC-MSMS) (NB5, 94-95) 
The presence of Lal in CinA modified with CinM and CinX followed by 
LysC protease cleavage and alkaline treatment was confirmed via hydrolysis and 
derivatization of the peptide, followed by analysis by gas chromatography mass 
spectrometry (GC/MS) with comparison to Lal in authentic cinnamycin (Novacta) 
treated in the same way. Modified CinA  (~ 0.9 mg) prepared in vitro as described 
above was dissolved in 6 M HCl (3 mL) and heated with stirring at 110 ºC in a 
high-pressure, sealed vessel for 22 h. The reaction was cooled and concentrated 
under reduced pressure. Methanol (3 mL) was chilled in an ice-water bath, and 
acetyl chloride (1 mL) was added dropwise. This solution was added to the 
hydrolysate, and the mixture was heated at 110 ºC for 45 min. The reaction was 
again allowed to cool and concentrated under reduced pressure to dryness, then 
chilled in an ice-water bath. Dichloromethane (2.5 mL) and pentafluoropropionic 
anhydride (1 mL) were added, and the mixture was heated at 110 ºC for 15 min. 
The reaction was allowed to cool and was dried under a stream of nitrogen. The 
residue was taken up in 100 μL of methanol, transferred to a clean vial and dried 
under a stream of nitrogen. Similarly, cinnamycin (Novacta; 0.9 mg) was 
hydrolyzed and derivatized in the same way. The sample and the standard were 
analyzed individually by GC/MS using an Agilent HP 5973 mass spectrometer 
and a Supelco SPB-1701 30 m x 0.25 mm fused silica capillary column. Samples 
were dissolved in methanol and introduced to the instrument via splitless 
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injection and a flow rate of 1.5 mL/min. The temperature gradient used was 100 
ºC for 5 min, then 100 ºC to 280 ºC over 18 min, then held at 280 ºC for 1 min.  
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Table 2.1 List of primers.  
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CHAPTER III: BIOCHEMICAL CHARACTERIZATION OF THE TAILORING 
ENZYMES CINX AND CINORF7 INVOLVED IN CINNAMYCIN BIOSYNTHESIS 
3.1 INTRODUCTION 
Enzymes that share the same mechanism usually possess similar amino 
acid sequences (1). Conserved residues in the amino acid sequences are 
commonly used to explore enzyme mechanism as they may be necesary for 
catalysis. Mutational studies have been useful for understanding the mechanism 
of the enzymes in lantibiotic biosynthesis as described for several lantibiotics (2-
6). Understanding the mechanism of lantibiotic enzymes may allow for 
preparation of non-natural analogs of a lantibiotic, thus potentially contributing to 
drug design. 
 The work presented in the previous chapter showed that four genes (cinA, 
cinM, cinX, and cinorf7) are essential for cinnamycin biosynthesis (7). Sequence 
alignment of CinX with other enzymes indicated that it is a member of the 
Fe(II)/α-ketoglutarate (αKG)-dependent hydroxylases, a group of enzymes that 
catalyzes hydroxylation through oxidative decomposition of αKG (11). 
Hydroxylases dependent on αKG have a characteristic iron/αKG binding motif of 
H-X-D/E-Xn-H-Xm-R, where n=43-153 and m=8-19 (8-9).  The H-X-D/E-Xn-H 
motif is responsible for binding to the Fe(II) while the arginine has been shown to 
be important in binding the distal carboxylate of αKG. Analysis of the CinX 
sequence identified four possible binding motifs; H158-R-D160-X73-H233-X9-R244 
n=73, m=9, H188-V-D190-X43-H233-X8-R242  n=43, m=8, H188-V-D190-X75-H265-X13-
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R279  n=75, m=13, and H188-V-D190-X106-H296-X9-R306  n=106, m=9. In vitro 
reconstitution of the CinX enzyme by former post-doctoral researcher Dr. Emily J. 
Fogle demonstrated that this enzyme indeed catalyzes the β-hydroxylation of 
Asp15 in the CinA precursor peptide.  Further studies performed together with 
post-doctoral researcher Dr. Remco Merkx on the CinX enzyme showed that it 
does not require the leader peptide and is capable of hydroxylating substrates 
CinA-(1-19) and CinA-(10-19).  
 A small protein encoded by cinorf7 was shown in Chapter II be critical for 
 the formation of the lysinoalanine (Lal) crosslink, which is important for the 
bioactivity of cinnamycin (7). The Cinorf7 protein has no significant sequence 
homology to other functionally-characterized proteins. Six other genes encoding 
proteins with high sequence similarity to Cinorf7 were identified in the protein 
databases and in the genome of the duramycin producing organism, 
Streptoverticillium cinnamoneum forma azacoluta (ATCC 12686), that was 
sequenced by our laboratory as discussed in Chapter IV. These cinorf7 orthologs 
also are near lanM-like genes. Although the sequences of the predicted leader 
peptides of the putative precursor peptides located near these Cinorf7 orthologs 
vary, their core regions have very high sequence similarity to those of the 
cinnamycin group, suggesting that these gene clusters have the genetic capacity 
to generate cinnamycin-like peptides.  
Herein, we investigated the tailoring proteins CinX and Cinorf7 through a 
series of in vitro and in E. coli experiments. The order of CinX and Cinorf7 
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modifications were investigated by coexpression of CinA, CinM and Cinorf7 
excluding CinX in E. coli. Furthermore, Cinorf7 activity was investigated in E. coli 
by mutating the residues that are conserved in Cinorf7 and six Cinorf7-like 
protein sequences, found in various genomes (Figure 3.1). Additionally, trials to 
crystallize and reconstitute the in vitro activity of Cinorf7 were undertaken. The 
substrate tolerance of CinX was also explored by testing its activity using several 
short synthetic peptides, and N-terminal truncations of CinX were prepared for 
crystallization studies.  
 
 
 
Figure 3.1 Sequence alignment of Cinorf7-like genes. Durorf7 was found in the genome of the 
duramycin producing organism Streptoverticillium cinnamoneum forma azacoluta (ATCC 12686), 
Noc7 was found in the genome of Nocardiopsis potens, Osc7 was found in the genome of  
Oscillatoria sp. PCC 10802, Lyn7 was found in the genome of Lyngbya majuscule, Fran7 was 
found in the genome of Frankia Sp., and Act7 was found in the genome of Actinomadura 
atramentaria.  
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3.2 RESULTS  
3.2.1 Order of modification by CinX and Cinorf7 
  The ability of Cinorf7 to form Lal in the absence of CinX was tested by the 
coexpression of cinA(A−1K), cinM and cinorf7 in E. coli. For this purpose, the 
cinorf7 gene was cloned into the first multiple cloning site of pACYCDuet-1 and 
used for the coexpression with a pRSFDuet-1 plasmid containing his6-
cinA(A−1K) and cinM genes. The His6-CinA(A−1K) peptide from CinM and 
Cinorf7 coexpression in E. coli was purified by immobilized metal ion affinity 
chromatography (IMAC) followed by reversed-phase high-performance liquid 
chromatography (RP-HPLC) resulting in 2-3 mg of purified peptide per liter of cell 
culture. Analyses of the core peptide by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) after 
LysC endoproteinase treatment revealed a mass difference corresponding to 
loss of four water molecules as expected. This finding demonstrates that CinM 
was able to dehydrate the two threonine (Thr11 and Thr18) and two serine 
residues (Ser4 and Ser6) in the core region of CinA in the presence of Cinorf7.  
Addition of cysteine thiols to the dehydroamino acids does not cause a change in 
mass, which prevents observation of cyclization by MALDI-ToF MS. To 
investigate the cyclization activity of CinM in the absence of CinX, iodoacetamide 
(IAA) was used. The peptide obtained from the coexpression system was treated 
with IAA followed by LysC protease incubation. The analysis of the peptide by 
MALDI-ToF MS showed only minor alkylation products, whereas the positive 
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control, unprocessed peptide His6-CinA(A–1K), showed a mass increase 
corresponding to alkylation of the three cysteines in the core peptide. This result 
showed that the (Me)Lan residues obtained from coexpression of CinM and 
Cinorf7 were formed successfully. The presence of the lysinoalanine (Lal) 
crosslink in this peptide was tested by o-phthalaldehyde (OPA), which as 
described in Chapter II, reacts selectively with primary amines in the presence of 
a thiol such as β-mercaptoethanol but does not react with secondary amines 
(Figure 3.2D) (10). CinA that had been modified by CinM and CinX in E. coli did 
not possess Lal, because a mass increase corresponding to two OPA additions 
and one β-mercaptoethanol addition in the core peptide was observed (Figure 
3.2A). These two OPA adducts originated from the N-terminal amino group and 
the ε-amino group of Lys, and one β-mercaptoethanol addition as a consequence 
of Michael-type addition to dehydroalanine 6. The OPA assay of CinM- and 
Cinorf7-modified peptide resulted in only one OPA addition and no β-
mercaptoethanol adducts, which was also observed when authentic cinnamycin 
was used as a positive control (Figure 3.2B, 3.2C). This observation clearly 
shows that in the presence of CinM and Cinorf7 Lal was formed and that CinX 
was neither involved nor important for the formation of this crosslink. In the 
bioassay of this peptide towards indicator strain B. subtilis after cleavage of the 
leader peptide with LysC, no zone of inhibition was observed (Figure 3.3A), 
suggesting the (Me)Lan and Lal crosslinks are not sufficient for bioactivity.  Next, 
the CinM and Cinorf7 modified peptide was treated with CinX in vitro. 
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Surprisingly, CinX was not able to hydroxylate this peptide as no mass change 
was observed in mass spectrometry studies after LysC cleavage (Figure 3.3B). 
Thus, no zone of inhibition was observed for this CinX treated peptide in the 
bioactivity assay towards the indicator strain (Figure 3.3A). In comparison, CinX 
was able to hydroxylate CinM-modified precursor peptide as expected based on 
the data in Chapter II (Figure 3.3C). These results strongly suggest that 
hydroxylation is required for antimicrobial activity of cinnamycin, and that CinX 
only acts on the substrate before Lal crosslink formation.   
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Figure 3.2 Use of o-phthalaldehyde (OPA) to monitor lysinoalanine formation. MALDI-TOF 
analysis of (A) CinA(A–1K) modified by CinM and CinX in E. coli, and treated with LysC and with 
OPA and β-mercaptoethanol. (B) CinA(A–1K) modified by CinM and Cinorf7 in E. coli and treated 
with LysC was incubated with OPA and β-mercaptoethanol. (C) Authentic cinnamycin was 
incubated with OPA and β-mercaptoethanol. Asterisk indicates four-fold dehydrated core peptide 
that did not react with OPA. (D) Chemical reaction of o-phthalaldehyde (OPA) reagent with 
primary amines in the presence of a thiol. AMX = CinA(A–1K) modified by CinM and CinX in E. 
coli followed by LysC treatment, AM7 = CinA(A–1K) modified by CinM and Cinorf7 in E. coli 
followed by LysC treatment.  
   
+
Calculated mass for (A) AMX + 2 OPA + BME = 2042.3 + 2 *180.1 + 78.1 = 2480.6 Da, (B) 
AM7 + OPA; 2027 + 180.1 = 2207.1 Da, (C) M + OPA; 2042.3 + 180.1 = 2222.4 Da. Obsrvd 
mass for (A) AMX + 2 OPA + BME is 2474.7 Da, (B) AM7 + OPA is 2219.9 Da, (C) M + OPA is 
2220.19 Da.  
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Figure 3.3 Order of CinX and Cinorf7 modification. (A) Inhibition assay of in vitro CinX treated 
His6-CinA(A–1K) which was modified by CinM and Cinorf7 in E. coli followed by LysC treatment. 
The activity is towards B. subtilis 6633. Spot 1: Authentic cinnamycin, Spot 2: His6-CinA(A−1K) 
modified by CinM and Cinorf7 in E. coli and then treated with lysC and CinX, (B) MALDI-ToF MS 
analysis of the peptide used for spot 2, (C) MALDI-ToF MS analysis of in vitro CinX assay 
performed with His6-CinA(A–1K) modified with CinM in E. coli, followed by LysC treatment , CP = 
CinA core peptide. 
   
+
Calculated mass for (B) CP – 4 H2O + H; 2097.3 – 4 * 18 +1 = 2026.3, (C) CP – 4 H2O + OH 
+H; 2097.3 – 4 * 18 + 1 = 2042.3. Observed mass (B) 2026.3 Da, (C) 2043.1 Da.  
 
3.2.2 Purification and Characterization of Cinorf7 
 Although, Cinorf7 purification was demonstrated by Dr. Lisa Cooper, a 
previous PhD student in our laboratory, by use of a pET28b vector, a method for 
the purification of this protein from the coexpression system of CinA(A−1K), 
CinM, CinX and Cinorf7 was developed. A His6-tag was introduced at the N-
terminus of the cinorf7 gene through insertion of cinorf7 into MCS I of 
pACYCDuet-1 containing the cinX gene in MSC II. Use of this plasmid together 
with a pRSFDuet-1 vector containing cinA(A−1K) and cinM genes resulted in 
His6-tagged Cinorf7 that was purified by IMAC and desalted by gel filtration. 
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Purified Cinorf7 samples were treated with 5 mM DTT and boiled for 20 minutes, 
and analyzed by SDS-PAGE. Interestingly, after protein staining, two bands were 
observed on the gel; one corresponding to the size of monomeric Cinorf7, and a 
second corresponding to the size of dimerized Cinorf7 (Figure 3.4). Increasing 
the DTT concentration from 5 mM DTT to 100 mM resulted in decrease of the 
thickness of the band corresponding to the dimer. Indeed, in gel digestion of the 
two bands with trypsin endoproteinase followed by MALDI-ToF-MS analysis 
confirmed that the second band was dimerized Cinorf7. Close analysis of the 
peaks from the monomeric and dimeric form also showed that Cinorf7 is not 
post-translationally modified during the biosynthesis of cinnamycin. Gel filtration 
studies showed that the majority of IMAC-purified His6-Cinorf7 migrated as if it 
was a trimer, although dimer and monomer were also observed. Circular 
dichroism (CD) analysis of the purified His6-Cinorf7 showed that the protein was 
predominantly α-helical (Figure 3.5).  To confirm that the addition of the His tag 
did not interfere with Cinorf7 function, CinA(A−1K) peptide was purified from the 
coexpression of His6-CinA(A−1K), CinM, CinX and His6-Cinorf7 in E. coli by 
IMAC followed by RP-HPLC. His6-Cinorf7 was highly soluble, whereas modified 
His6-CinA(A−1K) was found in the pellet. Therefore, IMAC purification of His6-
CinA(A−1K) was performed by applying the insoluble fraction onto the Ni-NTA 
column after solubilization with guanidine hydrochloride. Mass spectrometric 
analysis of the LysC-cleaved peptide showed that four dehydrations and a 
hydroxylation were introduced. The bioassay of LysC-cleaved peptide towards 
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the indicator strain B. subtilis resulted in a zone of growth inhibition, which 
suggests that the peptide contained Lal, which is crucial for antimicrobial activity. 
To conclude, the His tag does not interfere with Cinorf7 function. 
 
 
Figure 3.4 Cinorf7 purification and dimer formation analyzed by SDS-PAGE. (A) SDS-PAGE 
analysis of His6-Cinorf7.  
 
Figure 3.5 Circular dichroism (CD) analysis of the purified His6-Cinorf7. Results suggests 
that Cinorf7 has alpha-helical secondary structure.   
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3.2.3 Crystallization Trials 
Initial attempts to crystallize Cinorf7 have been unsuccessful, possibly due 
to the presence of multimeric forms of the protein after purification. Cinorf7 has 
only one cysteine residue at position 26, which might be responsible for the 
dimer formation by forming disulfide bonds. In an attempt to increase the 
solubility and stability of this small protein for crystallization studies, Cys26 was 
mutated to a serine residue.  To determine if this mutation impacted the activity 
of Cinorf7, the bioactivity of modified CinA(A−1K), purified after coexpression 
with His6-CinA(A−1K), CinM, CinX, and Cinorf7-Cys26Ser, was tested towards 
the indicator strain after LysC endoproteinase cleavage of the leader peptide. A 
zone of growth inhibition was observed suggesting that the mutation Cys26Ser in 
Cinorf7 does not hamper activity and thus can be used for crystallizations 
studies. His-tagged Cinorf7-Cys26Ser co-expressed from a pACYCDuet-1 vector 
that also encoded CinX was purified by IMAC. Interestingly, the mutation did not 
prevent the formation of the dimer in SDS-PAGE analysis. It is possible that 
polymerization is due to hydrophobic and/or hydrophilic interactions between 
Cinorf7 proteins.  
3.2.4 Mutational studies of Cinorf7  
  At the time of this study, two other genes encoding proteins with high 
sequence similarity to Cinorf7 were identified in the protein databases. One of 
these is present in the genome of Lyngbya majuscule, which encodes two nearby 
likely precursor peptides, whereas the second, found in the genome of Frankia 
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Sp., has one gene encoding a possible precursor peptide nearby. Both cinorf7 
orthologs also are near lanM-like and lanX-like genes, suggesting these gene 
clusters may be responsible for the biosynthesis of cinnamycin-like peptides.  
  Comparison of Cinorf7 with these orthologs allowed the identification of 
conserved residues, which may be important in the catalysis of Lal formation. 
Thus, the conserved residues in Cinorf7 (Figure 3.6A), with the exception of 
Cys26, were individually mutated to alanine. The plasmid pACYCDuet-1 
containing cinorf7 mutants and cinX genes together with pRSFDuet-1 containing 
His6-cinA(A−1K) and cinM were used to co-express these genes in E. coli. His6-
CinA(A−1K) peptide was purified by IMAC followed by RP-HPLC. After LysC 
cleavage, the bioactivity of the peptide modified by each mutant towards the 
indicator strain was tested (Table 3.6B). Several modifications of Cinorf7 did not 
prevent Lal formation. Interestingly, removal of 20 amino acids from either the N-
terminus or C-terminus of this protein also did not abolish Lal formation. Mutation 
of Arg52 and Trp87 to alanine individually reduced the efficiency, whereas 
mutation of Trp68 to alanine resulted in loss of Cinorf7 activity in E. coli. 
Reduction of the efficiency of Lal formation was evaluated based on weaker 
bioactivity when the same amount of peptide was applied in the bioassay. 
However, due to solubility problems of the peptides, quantitative analysis of Lal 
formation could not be performed, which will be needed for understanding the 
loss of activity better.  
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Figure 3.6. Mutational studies on Cinorf7. (A) Two proteins with high sequence similarity to 
cinorf7 were identified in the databases. The orthologs originate from Lyngbya majuscula 
(ZP_08425231) and Frankia Sp. (ZP06416732). The mutations introduced are highlighted in red, 
(B) List of the mutations introduced to the cinorf7 gene, and results for bioactivity tests conducted 
towards the indicator strain B. subtilis 6633.  
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3.2.5 Interaction of Cinorf7 with CinM 
   It has been unclear whether Cinorf7 is an enzyme catalyzing Lal formation 
or if it is acting as a chaperone for CinM, allowing CinM to catalyze the reaction. 
To test this latter hypothesis, a pull down experiment with Cinorf7 was 
performed. A DNA sequence encoding an His6-tag was placed at the N-terminus 
of cinorf7 in pACYCDuet-1 containing cinX, and this vector was used to co-
express His6-CinA(A−1K) and CinM from pRSFDuet-1 together with CinX and 
His6-Cinorf7. The protein His6-Cinorf7 was purified by IMAC as explained in the 
purification procedure above. SDS-PAGE analysis of different imidazole fractions 
of purified Cinorf7 showed that CinM co-eluted, suggesting an interaction 
between these two proteins (Figure 3.7).   
 
 
Figure 3.7 Pull-down experiment with His10-Cinorf7. Lane 1: Broad range marker, Lane 2: 
His6-Cinorf7 from coexpression purification pulls down CinM.  
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3.2.6 Substrate specificity for CinX hydroxylation in E. coli 
 In the coexpression studies, CinX successfully hydroxylated CinM-
modified CinA. A system where CinX hydroxylation occurs without CinM would 
be beneficial for substrate specificity analysis of this enzyme in E. coli. Therefore, 
his6-cinA(A−1K), inserted in MCSI of pRSFDuet-1, was co-expressed with cinX, 
inserted in pACYCDuet-1 MCS II. The His6-CinA(A−1K) was purified by IMAC 
followed by RP-HPLC, and after LysC cleavage, the peptide was analyzed by 
MALDI-ToF MS. However, the hydroxylated product could not be identified. In 
order to simplify the construct and possible problems arising from a two plasmid 
system, cinX was cloned into the MCS II of pRSFDuet-1 containing cinA(A−1K) 
in MCS I, and these two genes were co-expressed in E. coli. Although the mass 
of the hydroxylated peptide was identified using this construct, the peak intensity 
was very low (Figure 3.8). Both CinA core peptide and its hydroxylated form do 
not ionize well in MALDI-ToF MS analysis. In addition, the presence of a sodium 
adduct further complicates detection of this peptide.  Hence, we were unable to 
use coexpression in E. coli to investigate substrate selectivity. 
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Figure 3.8 Hydroxylation of CinA(A−1K) by CinX in E. coli. His6-CinA(A−1K) modified by CinX 
in E. coli and treated with LysC to give M (core region) and M+OH.  
   
+
Calculated mass for M + OH; 2097.3 + 16 = 2113.3. Obsrvd: 2113.1 Da.  
 
 
 
3.2.7 CinX substrate specificity studies 
  Tandem MS studies described in Chapter II showed that CinX can 
hydroxylate both CinA (1-19) and CinA (10-19) in the absence of the leader 
sequence, allowing analysis of the substrate specificity of CinX by using peptides 
synthesized by solid phase peptide synthesis. In this study, twelve different 
peptides were tested for CinX activity (Figure 3.9). The site of hydroxylation in 
the peptides that served as a substrate was investigated by tandem mass 
spectrometry. Peptides 1-6 were designed to identify the importance of the amino 
acids located directly N-terminal and C-terminal to Asp15, whereas peptides 9-11 
were used to investigate the importance of the position of the aspartate. The 
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possibility of double hydroxylation in one sequence was also investigated with 
peptide 12, which has two potential Asp hydroxylation sites in the sequence 
FTFVCDGRFTFVCDG.  
 
 
 
Figure 3.9 Peptides tested for CinX activity. Peptides 1-6 (in red) are N-terminal or C-terminal 
truncations of CinA (10-19), whereas in peptides 7-11 the location of the aspartic acid is varied.  
Peptide 12 has two possible hydroxylation sites.  
 
  The peptides were synthesized and purified by Dr. Remco Merkx. The 
CinX assays with peptides 1-6 showed that peptides 1, 2, and 6 were 
hydroxylated (confirmed via MALDI-ToF MS analysis for peptides 1 and 2, and 
MS/MS analysis for peptide 6). This observation demonstrates that phenylalanine 
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10 and threonine 11 N-terminal to Asp15 at the N-terminus and asparagine, 
threonine and lysine (NTK) at the C-terminus of Asp15 are not necessary for the 
execution of hydroxylation. Because CinX can accept both 2 and 6 as a 
substrate, the FVCDG sequence appears sufficient for CinX substrate 
recognition. Prolyl-4-hydroxylase and lysyl 5-hydroxylase, other members of the 
Fe(II)/αKG dependent enzyme family, can hydroxylate their targets with a 
minimum chain length of six amino acids containing a Xaa-Pro/Lys-Gly sequence 
(11). Our results suggest that the recognition sequence for hydroxylation by CinX 
might be Xaa-Asp-Gly. However, the presence of additional amino acid residues 
around this consensus sequence might be needed for substrate-enzyme 
complex formation, which could explain the inability of CinX to process peptides 
3, 4 and 5.  
  Among peptides 6-11, CinX only accepted peptide 8 as a substrate 
showing the importance of flanking residues at the modification site, which 
explains the inability of CinX to process 6, 7, 9, 10, and 11. The difference 
between wild-type substrate and peptide 8 is that this peptide has a VDCG amino 
acid sequence at the site of modification instead of VCDG.  Mass spectrometry 
analysis of the processed peptide showed that the modification on the aspartate 
residue resulted in a mass increase of 12 instead of 16 normally observed upon 
hydroxylation (Figure 3.9A, B). CinX might further oxidize the hydroxylated Asp to 
form a ketone and a desaturated C-N bond in peptide 8, accounting for this mass 
difference (Figure 3.10C). In the hydroxylation reaction of Fe(II)/αKG dependent  
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Figure 3.10 CinX assay analysis of peptide 8 (A) MALDI-TOF MS analysis for peptide 8 (red 
line) treated with CinX in vitro (black line). (B) Tandem MS/MS analysis of peptide 8 treated with 
His6-CinX in vitro. The y’’5 and y’’6  ions define Asp15 as the site of modification, which is also 
consistent with all other observed fragment ions. (C) Proposed product structure after reaction.  
   
+
Calculated M + H = 1131.2 + 1 = 1132.2 Da, Obsrvd: 1132.2 Da; M + H + 12 Da = 1144.2 Da, 
Obsrvd: 1144.2 Da.  
 
hydroxylases, the primary substrate is bound near the metal in the active site (9). 
The positioning of the substrate towards the active site might be the determining 
factor for the type of reaction that this group of enzymes carries out, as they can 
catalyze a variety of reactions such as desaturation, oxidation, and ring 
expansion/closure using the same active site and co-substrates that are used for 
hydroxylation (9).  
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 The assay with peptide 12 showed that CinX can introduce one or two 
hydroxyl groups to the FTFVCDGRFTFVCDG sequence; however, double 
hydroxylation occurs with low efficiency (Figure 3.11). The placement of the two 
possible hydroxylation sites close to each other might account for the low activity.  
 
 
Figure 3.11 CinX assay with peptide 12. Two aspartic acids in this peptide were hydroxylated 
with low efficiency. M is the mass of unmodified peptide 12.  
   
+
Calculated M + OH + H; 1713.9 + 16 +1 = 1730.9 Da, M + 2 OH + H = 1746.9 Da. Observed 
M: 1712.13 Da, M + OH + H: 1729.5, M + 2 OH + H: 1744.8 Da.  
 
 
3.2.8 Attempts to characterize the kinetics of CinX catalysis 
An enzyme coupled assay was developed to perform kinetic studies on 
CinX with the twelve substrates tested previously in vitro. The assay was 
designed such that succinate produced by CinX activity is used by another 
enzyme causing a signal to be detected. In this assay, succinic acid (succinate) 
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produced by CinX is converted to succinyl-CoA in the presence of adenosine-5’-
triphosphate (ATP) by the enzyme succinyl-CoA synthetase (SCS), with the 
concurrent formation of adenosine-5’-diphosphate (ADP) and inorganic 
phosphate (Pi). Then, pyruvate kinase uses the ADP produced to react with 
phosphoenolpyruvate (PEP) to form pyruvate and ATP. The pyruvate produced 
is reduced to L-lactate by L-lactate dehydrogenase (L-LDH) in the presence of 
reduced nicotinamide adenine dinucleotide (NADH), with the production of NAD+. 
The amount of NAD+ formed in this coupled reaction pathway is stoichiometric 
with the amount of succinic acid produced. Thus, the rate of succinic acid 
production can be obtained by assessing NADH consumption, which is 
measured by the decrease in absorbance at 340 nm. However, in the 
experiments using this system, low solubility of the peptides under the reaction 
conditions prevented accurate kinetic characterization.  
3.2.9 Crystallization studies of CinX 
  Although CinX was obtained in high purity, attempts to obtain crystals by 
Vinayak Agarwal in the Nair laboratory, including by use of Cd2+ and α-
ketoglutarate, have not been successful to date. Interestingly, 49 amino acids at 
the N-terminal region of CinX are not present in the newly identified CinX-
analogs in Lyngbya majuscule and Frankia Sp. genomes (Figure 3.12). This 
region shows homology to a Nif11 domain, which is found in a nitrogen fixation 
protein of unknown function. Nif11 was also shown to have high sequence 
homology to the leader region of ProcA which is recognized by ProcM to yield 29 
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different lanthipeptides named prochlorosins (Figure 3.13) (12). Genome mining 
experiments have shown that several cyanobacterial genomes contain Nif11 
domains on peptides surrounded by lanthionine biosynthetic machinery (13). For 
one such system in Prochlorococcus lantibiotic biosynthesis has been 
established (12). In this system, the leader peptide shows homology with the 
Nif11 domain. Hypothesizing that the N-terminal region of CinX may cause 
instability in crystallization studies, four N-terminal truncated forms of CinX; −20 
(amino acid), −35, −50 and −75 were prepared, and their activities were tested in 
the coexpression studies. For this purpose, N-terminal truncated forms of CinX 
were cloned into MCS II of pACYCDuet-1 containing Cinorf7 in MCS I, and this 
vector was used for coexpression experiments with His6-CinA(A−1K), CinM, 
Cinorf7 and CinX analogs in E. coli. The peptide His6- CinA(A−1K) produced was 
purified by IMAC followed by RP-HPLC. Bioassay and MALDI-ToF MS studies 
performed after LysC cleavage of the peptide were used to evaluate the activity 
of CinX. The results showed that only the −20 CinX was able to efficiently 
hydroxylate CinA and a very small extent of hydroxylation was observed with the 
−35 CinX truncated protein. Thus, −20 cinX and −35 cinX were cloned into 
pET28b with a His-tag to facilitate purification. The protein produced from these 
vectors will be used in future crystallization studies.  
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Figure 3.12 Nif11 sequence in CinX.  The Nif11-like sequence of CinX is shown in red.  
Sequence alignment of CinX with its analogs from Lyngbya majuscule (LYNGBM3L_02810) and 
Frankia Sp. EUN1f (WP_006544296.1). 
 
 
 
 
Figure 3.13 Sequence alignment of Nif11 sequence with CinX and ProcA 2.8 leader.  
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3.3 DISCUSSION 
  This chapter described further analysis of Cinorf7 and CinX showing that 
CinX must hydroxylate the precursor peptide CinA before the action of Cinorf7. 
The knowledge of the order of the modifications in cinnamycin biosynthesis is 
valuable for making cinnamycin derivatives. Previously, coexpression studies in 
E. coli showed that CinM dehydrates Ser6 in CinA core region, and that Cinorf7 
is required for lysinoalanine (Lal) formation with Dha6. Coexpression of CinA-K 
with CinM and Cinorf7 was sufficient to introduce (Me)Lan and Lal modifications. 
This finding clearly shows that it is possible to make a cinnamycin-like peptide 
that has all post-translational modifications except for hydroxylation.  
  The efforts towards the in vitro reconstitution of Cinorf7 activity and 
crystallization of this enzyme are still ongoing. Gel filtration analysis suggested 
that the protein exists in several different oligomerization states. The hypothesis 
that Cinorf7 may act as a chaperone for CinM was investigated by purification of 
Cinorf7 from E. coli expressing all of the cinnamycin biosynthetic genes. Affinity 
purification of His6-Cinorf7 pulled-down CinM, which supports an interaction 
between these proteins. However, considering that LanM enzymes typically 
stereoselectively protonate the enolate formed during the Michael-type addition 
to provide D-stereochemistry at the α-carbon, it may be that Lal formation, which 
results in the L-configuration at the newly formed stereogenic center, (14-15) is 
not carried out by CinM. Conversely, recent studies have shown that several 
LanM proteins can protonate the enolate with either stereochemistry (16).  
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  Mutational studies on Cinorf7 were carried out as well. Several 
modifications to Cinorf7 did not affect its activity drastically. Mutation of Arg52 
and Trp87 to alanine individually reduced the efficiency of Lal formation, whereas 
mutation of Trp68 to alanine resulted in loss of Cinorf7 activity. Currently, it is 
unknown whether these mutations directly affected Lal formation or 
folding/solubility of the protein, which would also result in loss of activity. It is 
possible that these mutations are important for the interaction of Cinorf7 with 
CinM and/or the precursor peptide CinA. Further studies to assess the loss of 
activity are needed for the mutants that caused partial loss of function. In future 
studies, the exact Lal amount on a peptide can in principle be determined by use 
of the o-phthalaldehyde reagent, which was employed for identification of Lal in 
this study as a sensitive fluorescent detection reagent for amines.  
   CinX showed promiscuity towards various substrate peptides. It accepted 
substrates as small as 7 amino acids without the need of the leader sequence. 
However, it was unable to process the core region of CinA containing (Me)Lan 
and Lal modifications. The NMR structure of cinnamycin bound to PE clearly 
shows that Asp15 is facing the interior of the cylinder formed by this molecule 
around its target (17-18). Thus, formation of the Lal crosslink might lock this 
peptide in a state where Asp15 is not available for CinX hydroxylation. The 
inability of CinX to hydroxylate CinM- and Cinorf7-modified peptide also indicates 
that Cinorf7 acts after CinX modification. Therefore, if hydroxylation needs to be 
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incorporated on the cinnamycin or its derivatives, the precursor peptide should 
be treated with CinX before the action of Cinorf7 to form Lal. 
  The peptide that lacked the hydroxylation on Asp15 compared to 
cinnamycin was not bioactive towards indicator strain B. subtilis 6633. This 
observation is not surprising as cinnamycin binds to its substrate 
phosphotidylethanolamine (PE) with a binding constant of 107-108 M-1, primarily 
through the interaction between the β-hydroxyl group of the hydroxylated aspartic 
acid and the ammonium ion of PE, and inhibits the growth of certain Gram-
positive bacteria by disrupting membrane integrity through this binding (19-20). 
Hence, the absence of the hydroxyl group on Asp likely results in a much lower 
affinity for PE.  
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3.4 MATERIALS 
  Oligonucleotide primers for mutagenesis were synthesized by Operon 
Technologies. Taq and Platinum Pfx DNA polymerases, DpnI, restriction 
endonucleases, and bacteriophage T4 DNA ligase were purchased from 
Invitrogen. Fusion DNA polymerase was purchased from New England Biolabs. 
Cloning vectors (pET and pDuet) were obtained from Novagen. Gel extraction, 
plasmid mini-prep, and PCR purification kits were purchased from Qiagen. All 
strains were grown in media acquired from Difco laboratories. Other items 
procured include isopropyl-1-thio-D-galactopyranoside (IPTG, CalBiochem), 
iodoacetamide (IAA, Acros Organics), tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP, Aldrich), and dithiothreitol (DTT, Sigma). Endoproteinase 
LysC was purchased from Roche Applied Science.  
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3.5 GENERAL METHODS  
 Molecular biological manipulations were carried out using standard 
techniques (21). PCR was performed using an automatic thermocycler (PTC 150, 
MJ Research) and DNA sequencing was performed at the Biotechnology Center 
of the University of Illinois at Urbana-Champaign (UIUC). Escherichia coli (E. 
coli) DH5α cells (UIUC Cell Media Facility) and E. coli BL21 (DE3) cells 
(Stratagene) were used for plasmid preparation and protein expression, 
respectively. Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-ToF MS) was carried out on a Voyager-DE-STR (Applied 
Biosystems). Liquid chromatography electrospray ionization tandem mass 
spectrometry (LC/ESI-MS/MS) was carried out and processed using a Synapt 
ESI quadrupole ToF Mass Spectrometry System (Waters) equipped with an 
Acquity Ultra Performance Liquid Chromatography (UPLC) system (Waters).  
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3.6 EXPERIMENTAL METHODS 
3.6.1 Cloning 
3.6.1.1 Cloning of cinA, cinM, cinX and cinorf7 and generation of a 
coexpression system in E. coli (NB6) 
 Cloning of the genes cinA, cinM, cinX and cinorf7 from S. cinnamoneous 
genomic DNA into pRSFDuet-1 and pACYCDuet-1 was described previously (7). 
In this study, a histidine tag was inserted at the N-terminus of CinM in MCSII of 
pRSFDuet-1, and Cinorf7 in MCSI of pACYCDuet-1 respectively. For His10-CinM 
cloning, two primers His10-CinM_pRSFDuet-1_MCSII_EcoRV_FP and 
CinM_pRSFDuet-1_MCSII_KpnI_RP (Table 3.1) were used for the amplification 
of the cinM gene from a template pET16b plasmid containing a gene encoding 
His10-CinM (obtained from previous PhD student Dr. Lisa Cooper) whereas for 
His6-Cinorf7 cloning of the gene encoding for His6-Cinorf7, Cinorf7_pACYCDuet-
1_NcoI_His6-Tag_FP and Cinorf7_pACYCDuet-1_HindIII_RP (Table 3.1) were 
used for the amplification of the cinorf7 gene from a template pET28b containing 
His6-Cinorf7 (obtained from Dr. Lisa Cooper). The reactions contained 1xFailSafe 
PreMix G (PICENTRE Biotechnologies), DMSO (4%), Platinum Pfx DNA 
polymerase (0.025 unit/μL), Taq DNA polymerase (0.05 unit/μL), and primers (1 
μM each). Amplification of the final PCR products were confirmed by 1% agarose 
gel electrophoresis and the products were purified using QIAquick PCR 
purification kits. The resulting DNA fragments and the corresponding vectors 
were digested in 1 x NEBuffer 4 with EcoRV-HF and KpnI-HF at 37 ºC (for 15 h) 
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for insertion of CinM, and NcoI-HF and HindIII-HF for insertion of Cinorf7. The 
digested products were purified by agarose gel electrophoresis followed using a 
QIAquick gel extraction kit. The resulting DNA inserts were ligated with the 
digested corresponding vectors at 16 ºC for 15 h using T4 DNA ligase to 
generate His6-CinA/His10-CinM/pRSFDuet-1, His6-Cinorf7/CinX/pACYCDuet-1. 
The ligation reaction mixture was diluted 5 times with water prior to 
transformation. E. coli DH5α cells were transformed with the ligation product via 
heat shock, plated on 50 mg/mL LB-kanamycin (for pRSFDuet-1) and 25 mg/mL 
LB-chloramphenicol (for pACYCDuet-1) agar plates, and grown at 37 ºC for 15 h. 
Colonies were picked and incubated in 5 mL of LB-kanamycin or LB-
chloramphenicol medium at 37 ºC for 15 h, followed by isolation of the plasmids 
using a QIAprep Spin Miniprep Kit. The sequences of the resulting plasmids were 
confirmed by DNA sequencing. 
  Similarly, cinX was cloned into pRSFDuet-1 containing CinA(A−1K) by use 
of CinX pRSFDuet-1 MCSII EcoRV FP and CinX pRSFDuet-1 MCSII PvuI RP as 
forward and reverse primers (Table 3.1). Cloning of DNA encoding N-terminal 
truncations of CinX into MCSII of pACYCDuet-1 containing cinorf7 in MCSI was 
performed using the primers listed in Table 3.1. The reactions contained 
1xFailSafe PreMix G (PICENTRE Biotechnologies), DMSO (4%), Platinum Pfx 
DNA polymerase (0.025 unit/μL), Taq DNA polymerase (0.05 unit/μL), and 
primers (1 μM each). Amplification of the final PCR products were confirmed by 
1% agarose gel electrophoresis and the products were purified using QIAquick 
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PCR purification kits. The resulting DNA fragments and the corresponding 
vectors were digested in 1 x NEBuffer 4 with EcoRV-HF and PvuI-HF at 37 ºC 
(for 15 h) for insertion of CinX into pRSFDuet-1, and EcoRV-HF and XhoI-HF for 
insertion of short CinX forms into pACYCDuet-1. The digested products were 
purified by agarose gel electrophoresis followed using a QIAquick gel extraction 
kit. The resulting DNA inserts were ligated with the digested corresponding 
vectors, use to transforme E. coli cells, purified, and sequenced as described 
above. A similar process was followed for cloning the genes for −20 CinX and 
−35 CinX cloning into pET28b by use of the primers indicated in Table 3.1.  
3.6.1.2 Cloning of Cinorf7 mutants (NB 9-10, p25-28) 
  The amplification of Cinorf7/CinX/pACYCDuet-1 was conducted via 30 
cycles of denaturing (98 οC for 10 s), annealing (60 οC for 30 s), and extending 
(72 οC for 135 s) using appropriate mutant primers (see Table 3.1  for 
oligonucleotide sequences). The PCRs (50 μL) included 1_ HF buffer 
(Finnzymes), DMSO (4%), Fusion Hot Start High-Fidelity DNA Polymerase 
(Finnzymes) (0.04 unit/μL), dNTPs (2 mM), Cinorf7/CinX/pACYCDuet-1 (20 ng), 
and primers (1 μM each). The PCR product was checked on a 1% agarose gel 
and purified using a QIAquick PCR purification kit (QIAGEN). The resulting DNA 
was treated with DpnI at 37 οC for 15 h to digest the methylated template, and E. 
coli DH5R cells were transformed. The desired mutations were confirmed by 
DNA sequencing. 
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3.6.2 In vitro Cinorf7 assays (NB9, p. 13-16, 49, 53) 
His6-CinA(A–1K) modified by CinM and CinX in E. coli (0.5 mg) was treated with 
10% reaction buffer from RTS 100 E. coli HY kit, 20% cell extract prepared 
according to the literature (7), 2 mM ATP, 10 mM MgCl2, 2.5 mM DTT, 5 μM 
Cinorf7, 5 μM CinM, and 20 μM CinX followed by incubation with LysC.  
3.6.3 Circular dichroism spectrometry measurements of Cinorf7 (NB8, p75) 
  A solution of 100 mM Na2HPO4 was used as a blank in a 1 cm cuvette. 
The CD spectrometer (Prof. Martin Gruebele Lab) was adjusted to 80 mV, 1 nm 
step resolution and 100 mdeg sensitivity.  The CD spectrum of 3.6 μM His6-
Cinorf7 in 50 mM sodium phosphate buffer pH 7.5 was measured between 200-
250 nm after 100 mM Na2HPO4 was used as a blank in a 1 cm cuvette. The web 
page Expasy APSSP2 was used for the estimation of the secondary structure.  
3.6.4 OPA Assay (NB7, p.70) 
 CinA(A−1K) (~0.5 mg), which had been modified by CinM and CinX, and 
CinA(A−1K) (~0.5 mg), which had been modified by CinM and Cinorf7 in E. coli, 
were incubated with LysC endoproteinase (50 μL, 1 mg/ mL) followed by SPE 
purification as described in Chapter I. Then the samples were purified and 
concentrated by solid phase extraction column (SPE, 1 mL, Discovery DSC-18). 
The C18 column was first washed with 2 mL of 80% ACN/water and equilibrated 
with 2 mL of water, and then the sample was applied. The column was washed 
with 4 mL of water and the sample was eluted with 1 mL of 80% ACN/water 
solution. The sample was dried on a centrivap concentrator and the peptide was 
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dissolved in 25 μL of autoclaved water, and analyzed by MALDI-ToF MS.  The 
samples and 25 μL of authentic cinnamycin (0.1 mg/mL) were separately 
incubated with 75 μL of a solution containing 35 mg of OPA, 0.5 mL of methanol , 
and 42.5 mL of buffer (25 g/L boric acid, 0.3 % Brij 35, 0.2 % β-mercaptoethanol) 
for 1 h. Then, the samples were analyzed by MALDI-ToF MS.   
3.6.5 Tandem mass spectrometry analysis to determine the hydroxylation 
site in CinA (NB4, p65-66; NB8, p59) 
 The peptides were modified by CinX in vitro and analyzed by LC-ESI-
MSMS using a Synapt ESI quadrupole ToF Mass Spectrometry System (Waters) 
equipped with an Acquity Ultra Performance Liquid Chromatography (UPLC) 
system (Waters). A collision energy ramp of 15-50 V was used over 20 min in the 
LC MS program with a C18 column using a mass range of 50-2000 Da. In most 
of the peptides analyzed, the +2 charged ions were the dominant peaks, which 
were used as parent ion for fragmentation.  
3.6.6 Overexpression and purification of His6-CinA(A−1K) from 
coexpression studies (NB9, p37) 
  Peptides were co-expressed with different enzymes and purified from E. 
coli BL21 (DE3) cultures as described in previous coexpression studies (7).  
Briefly, purification was accomplished by solubilizing the inclusion bodies from 
the coexpression experiments using 4 M guanidine hydrochloride as even in the 
modified form, CinA stays in the insoluble fraction during purification. Then this 
solution was loaded onto a 5 mL HiTrap chelating HP nickel affinity column (GE 
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Healthcare). The desired peptides were eluted in 1-2 column volumes of elution 
buffer containing 4 M guanidine hydrochloride, 20 mM sodium phosphate, pH 
7.5, 100 mM NaCl, and 1 M imidazole. Desalting was achieved by preparative 
reversed phase high performance liquid chromatography (RP-HPLC) on a 
Waters system using a C4 PrepLC column. Solvents for preparative RP-HPLC 
were solvent A (0.1% TFA in water) and solvent B (0.086% TFA in 80% 
ACN/20% water). A gradient of 2 – 100 % of solvent B over 45 min was executed 
with a flow rate of 8 mL/min. Peptides were detected by absorbance at 220 nm. 
Lyophilized powder was analyzed by MALDI-ToF MS and the desired products 
were stored at – 20 ºC.  
3.6.7 Purification of His6-Cinorf7 and His10-CinM from the coexpression 
system in E. coli (NB 8, p97-98) 
  E. coli BL21 (DE3) cells were co-transformed with His6-CinA(A−1K)/CinM/ 
pRSFDuet-1 and CinX/ His6-Cinorf7/pACYCDuet-1 for His6-Cinorf7 purification, 
whereas the cells were co-transformed with His6-CinA(A−1K)/His10-
CinM/pRSFDuet-1 and CinX/Cinorf7/pACYCDuet-1 for His10-CinM purification. 
Single colony transformants were grown in a 37 ºC shaker for 12-15 h in 50 mL 
of Luria-Bertani (LB) medium supplemented with 25 μg/mL kanamycin (for 
pRSFDuet-1) and 12.5 μg/mL chloramphenicol (for pACYCDuet-1). A 20 mL 
aliquot was centrifuged at 5000×g for 10 min, the spent LB medium was 
discarded, and the cell pellet was resuspended in fresh LB medium. The 
resuspended cells (20 mL) were added to 2 L of LB containing the two 
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antibiotics, and the culture was grown aerobically at 37 ºC until the A600 was ~ 
0.6 to 0.8. IPTG was added to a final concentration of 0.5 mM and the culture 
was transferred to 18 ºC for aerobic growth for an additional 20 h. Cells were 
harvested by centrifugation at 5000×g for 20 min at 4 ºC. The cell paste (~ 4 g) 
was stored at –80 ºC until use. 
  Both CinM and Cinorf7 were kept at 4 ºC for the duration of the purification 
process. For each enzyme, the cell paste was resuspended in ~ 20 mL of LanM 
Start Buffer (20 mM Tris, pH 7.6, 500 mM NaCl, 10 % glycerol) and lysed by 
sonication (35% amplitude, 4.0 s pulse, 9.9 s pause, 15 min). The sample was 
centrifuged at 23,700×g for 45 min (Beckman JA-20 rotor) and the supernatant 
was clarified through 0.45 μm syringe filters (Corning). The sample was then 
loaded onto a 5 mL HisTrap HP column (GE Healthcare Life Sciences). The 
column was washed with 20 mL each of start buffer containing 25 and 50 mM 
imidazole and then 10 mL each of start buffer containing 100, 200, and 500 mM 
imidazole. The eluent was collected in several fractions, which were analyzed by 
Tris-SDS-PAGE (4-20% acrylamide gradient). The fractions containing the 
desired protein (200-500 mM imidazole) were combined and concentrated using 
an Amicon Ultra-15 centrifugal filter unit (30 kDa molecular mass cut off for His10-
CinM, 3 kDa molecular mass cut off for His6-Cinorf7, Millipore) to less than 2 mL. 
Buffer exchange of the concentrated proteins with Final Buffer (20 mM Tris, pH 
7.6, 500 mM KCl, 10% glycerol) was conducted twice via size exclusion 
chromatography (GE Healthcare Life Sciences). The resulting protein samples 
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were aliquoted, frozen with liquid nitrogen, and stored at −80 ºC. Protein 
concentrations were determined using absorbance at 280 nm and were 
calculated with a theoretical extinction coefficient obtained from the ProtParam 
function on the ExPASy Proteomics Server (His10-CinM, ε280 = 158,180 M-1cm-
1, His6-Cinorf7, ε280 = 17,990 M-1 cm-1). For CinM, typical protein yields ranged 
from 6 -10 mg per liter of overexpressed cells, whereas for Cinorf7 protein yields 
ranged from 1.5 mg to 2 mg per liter of overexpressed cells. 
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Table 3.1. List of primers.  
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CHAPTER IV: BIOSYNTHESIS OF CINNAMYCIN-LIKE NATURAL 
PRODUCTS 
4.1 INTRODUCTION  
The currently known members of the family of cinnamycin-like peptides 
share the same post-translational modifications with cinnamycin, which are one 
lanthionine, two methyllanthionines, a lysinoalanine linkage and, with the 
exception of ancovenin, an erythro-3-hydroxyl-L-aspartate residue (Figure 2.1). 
These peptides, including cinnamycin, duramycin, duramycins B, duramycin C, 
and ancovenin have been isolated and structurally characterized (1-3). However, 
many putative cinnamycin-like peptides have yet to be isolated and studied; their 
biosynthetic gene clusters have only been predicted bioinformatically.  
A BLAST search on the NCBI genome database identified fourteen cinnamycin-
like peptides including the previously isolated peptides (Figure 4.1). Interestingly, 
three sets of two cinnamycin-like peptides, which could be two-component 
lantibiotics, were also identified (Figure 4.1). From these, the gene clusters found 
in Moorea producens, and Oscillatoria sp. PCC 10802 contain cinX-like and 
cinorf7-like genes like the other members of the cinnamycin group of peptides; 
however the cluster identified in Cylindrospermum stagnale PCC 7417 does not 
contain these genes. Among the precursor peptides, OscA1, OscA2, and CylinA2 
have interesting amino acid sequences where double cinnamycin-like core 
sequences are attached to each other after putative leader peptide sequences 
(Figure 4.2A). Also, MooA2, OscA2, and CylinA2 lack the Ser to make the Lal 
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crosslink (Figure 4.2A). OscA2 and CylinA2 show high sequence identity, both 
having two cinnamycin-like core regions connected by the amino acids PN. 
However, OscA1 and CylinA1 differ from each other; CylinA1 has a second 
cinnamycin-like core sequence, whereas OscA1 does not (Figure 4.2B).   
Duramycin and duramycin B are closely related to cinnamycin with the 
exception of a substitution in each peptide, arginine 2 to lysine and phenylalanine 
10 to leucine, respectively. Duramycin C differs from cinnamycin by five amino 
acids, which are arginine 2 to lysine, glutamine 3 to asparagine, phenylalanine 7 
to tyrosine, phenylalanine 12 to tryptophan, and valine 13 to serine (4). 
Cinnamycin, duramycin, duramycin B, and duramycin C strictly bind to the 
phosphatidylethanolamine (PE) within the membrane and form a 1:1 complex (4-
7). These peptides cannot bind phospholipids closely related to PE, such as 
phosphatidylcholine (8). The NMR structures of cinnamycin and the duramycins 
showed that the four crosslinks form a cylindrical shape offering a binding 
scaffold for the recognition of the glycerol moiety of PE (4, 9-11). Specific 
interactions between a region spanning the 7th and 15th amino acids of 
cinnamycin and the head group of the phospholipid ensures that only PE can 
bind to cinnamycin (9). Specifically, 3-hydroxyaspartic acid at position 15 is 
involved in the binding of the free amino group of PE and the hydrophobic 
residues, and Gly-8, Pro-9 and Val-13 are involved in the binding to the glycerol 
moiety (4, 9). The amino acids involved in the binding of the amino group and the 
glycerol moiety are conserved in several of the putative group members 
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suggesting that these cinnamycin-like peptides may also be involved in binding to 
PE or other phospholipids.  
Cinnamycin, duramycin, and duramycins B and C inhibit phospholipase 
A2 (PLA2) by sequestering its substrate PE with micromolar affinity (8, 12). PLA2 
utilizes PE as a substrate to form arachidonic acid, which leads to the 
biosynthesis of prostaglandins and other mediators of inflammation (13). 
Inflammation is an important contributing factor to atherosclerosis and increases 
the risk of high blood pressure, heart disease and stroke (14-15). Duramycin has 
also been shown to mitigate pulmonary secretions related to cystic fibrosis (CF) 
and is currently in clinical trials for the treatment of CF (16). Duramycin binds to 
PE and induces pore formation, which leads to an increase of the net chloride ion 
secretion in airway epithelium. Therefore, duramycin contributes to increased 
fluidity of the mucus and alleviation of blocked  tubes (16). This mode of action of 
duramycin suggests that cinnamycin, also a PE binder, may play a similar role for 
the treatment of CF (17). The duramycin biosynthetic gene cluster had not been 
described prior to the studies described in this chapter, which allowed production 
of duramycin in E. coli.  
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Figure 4.1 Alignment of cinnamycin-like peptide precursors. The bacteria for which the 
sequences for precursor peptides have been identified are as follows: NocA in Nocardiopsis 
potens, ActA in Actinomadura atramentaria, DurA in ATCC 12686 Streptoverticillium 
cinnamoneum forma azacoluta, OscA in Oscillatoria sp. PCC 10802, MooA1 and MooA2 in 
Moorea producens, OscA1 and OscA2 in Oscillatoria sp. PCC 10802, and CylinA1 and CylinA2 in 
Cylindrospermum stagnale PCC 7417. However the latter gene cluster does not have a cinorf7-
like gene while others depicted here except ancovenin do. Duramycins B and C have been 
isolated from Streptoverticillium strain R2075 and Streptomyces griseoluteus R2107, ancovenin 
was isolated from the culture broth of a Streptomyces species. 
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Figure 4.2 OscA1, OscA2, and CylinA2 are cinnamycin-like peptides with interesting amino 
acid sequences, where double cinnamycin-like sequences are attached to each other after 
each putative leader peptide. (A) OscA2 and CylinA2 have high sequence identity and have two 
cinnamycin-like core regions attached to each other separated by the amino acids PN (in red). 
However OscA1 and CylinA1 differ from each other such that CylinA1 has a second cinnamycin-
like core sequence whereas OscA1 does not (B).   
 
Ancovenin is a potent inhibitor of angiotensin-converting enzyme (ACE), a 
well-studied enzyme known to regulate inflammation. ACE inhibitors decrease 
systemic vascular resistance without increasing heart rate and are effective in the 
treatment of hypertension, (3, 18-22).  The biosynthetic gene cluster of 
ancovenin is not known, therefore, it is not possible to produce ancovenin in vitro 
currently. Furthermore, the ancovenin producing strain is claimed to be lost at 
Fujirebio Diagnostics, Inc (23). This chapter describes an alternative route to 
ancovenin.  
Cinnamycin biosynthesis was previously described by our group (24) and 
is used as a representative system for the study of the other members and 
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unnatural analogs described in this chapter. The mode of action and/or binding 
partner of cinnamycin-like lanthipeptides other than cinnamycin, duramycins and 
ancovenin are currently unknown. A biotinylated derivative of cinnamycin that 
retains high specificity to PE has been used as a probe for the investigation of 
the transbilayer movement of PE (7, 25). It is valuable to find small peptide 
ligands for different phospholipids as they can be used as a marker for cancer, 
viral infections and related diseases (26). For example, 99mTc or biotin labeled 
duramycin has been used for the detection of cancer, apoptosis, acute cardiac 
cell death in mice, vascular PE as a critical anticoagulant, and rat cerebral 
ischemia-reperfusion injury in rat brain after middle cerebral artery (MCA) 
occlusion (25, 27-29).  
 The cinnamycin-like group of peptides has the potential to bind to 
phospholipids with diverse head groups. Amino acids recognizing the glycerol 
moiety and aspartic acid 15 that is hydroxylated are conserved within the 
members of the group. Hydroxylation within the peptide is crucial for the 
interaction with the amino group in the phospholipid PE (24) and CinX-like 
proteins are responsible for this hydroxylation and were found in most, but not all, 
of the biosynthetic gene clusters of uncharacterized peptides. Lanthionine and 
lysinoalanine crosslinks on cinnamycin can be formed successfully in the 
absence of CinX as described in Chapter II. Therefore, it is possible to make 
cinnamycin analogs without the hydroxylation on Asp15 and investigate their 
binding properties.  Moreover, as cinnamycin-like peptides exhibit different 
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properties towards the pulmonary and cardiovascular systems it would be 
valuable to study their biosynthesis. Biosynthesis of duramycin, ancovenin, and a 
peptide from Frankia Sp. EUNf1 (frankisin), whose biosynthetic gene cluster 
contains a biosynthetic cluster that is very similar to the cinnamycin biosynthetic 
genes, was studied in this chapter. Computer modeling studies performed by 
Prof. Ming Zhao`s group at Northwestern University suggested analogs of 
cinnamycin and duramycin could bind to different phospholipids. Thus, several 
analogs of cinnamycin and duramycin were prepared by site directed 
mutagenesis and tested for binding to phosphotidylcholine (PC), 
phosphatidylinositol (PI), and phosphatidylserine (PS) by isothermal calorimetry 
(ITC).   
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4.2 RESULTS  
4.2.1 Duramycin Biosynthesis 
4.2.1.1 Duramycin gene cluster from Streptoverticillium cinnamoneum 
forma azacoluta (ATCC 12686) 
  I extracted the genomic DNA from Streptoverticillium cinnamoneum forma 
azacoluta, which was sequenced by Dr. Yun-juan Chang, by Illumina shot gun 
sequencing. According to the sequencing results, the duramycin gene cluster 
contains four biosynthetic genes as in the case of the cinnamycin biosynthetic 
gene cluster (Figure 4.3). Similar to the findings for the cinnamycin precursor 
peptide, DurA consists of a C-terminal core region that is 19 residues long and 
that is transformed into duramycin through post-translational modifications. 
Appended to the N-terminus of the core peptide is a 59 amino acid leader 
sequence that is not modified. Instead of a GG or GA protease cleavage motif 
seen in most class II lantibiotics, an AXA motif is present between the leader 
sequence and the core region of DurA (Figure 4.3). This sequence is recognized 
by type I signal peptidases of the general secretory (sec) pathway (30), which 
explains the absence of a duramycin-specific protease in the gene cluster.  DurA 
(78 aa), the precursor peptide for duramycin, showed 92% identity to CinA with 
100% sequence coverage. The DurM sequence shows high homolgy with other 
class II LanM enzymes, which are bifunctional enzymes that catalyze both 
dehydration and cyclization (31-32).  In particular, DurM (1083 aa) and CinM 
(1088 aa) showed 85% identity with 100% coverage. Furthermore, DurX (327 aa) 
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and CinX (325 aa) showed 80% identity with 100% coverage, suggesting that 
DurX is a member of the non-heme Fe(II)-dependent family of enzymes that 
utilizes β-ketoglutarate (α-KG) as cofactor for catalyzing the hydroxylation of the 
β-carbon on Asp15. Durorf7 (125 aa) and Cinorf7 (119 aa) showed 89% identity 
with 97% coverage, which suggests that this protein is involved in Lal formation 
in duramycin biosynthesis. After the core peptide is processed by these 
enzymes, the leader peptide is removed proteolytically to afford the mature, 
biologically active compound (33).  
 
 
Figure 4.3 Duramycin biosynthesis. (A) Genomic DNA from duramycin producing strain, 
Streptoverticillium cinnamoneum forma azacoluta ATCC 12686 producing the duramycin 
biosynthetic gene cluster was sequenced by Illimuna short gun sequencing and compared to the 
cinnamycin biosynthetic gene cluster from S. cinnamoneus, (B) Representation of biosynthesis of 
duramycin from the precursor peptide DurA. The directionality of the formation of the thioether 
crosslinks (black) and Lal (blue) is shown. Hydroxylation of Asp15 is represented in red. The 
sequence of the DurA core and leader peptides is depicted as well as the residues that form the 
crosslinks. The sec-cleavage sequence at the end of the leader peptide is shown in underlined 
font. 
 
 In addition to the genes required for duramycin biosynthesis, the gene 
sequences showing high sequence identity and coverage to cinY, cinZ, cinZ, 
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cinH, cinT, and cinorf4 were also identified in the gene cluster in the same 
locations compared to the corresponding genes in the cinnamycin gene cluster 
(Figure 4.4). From these genes durorf4 (570 bp) encodes a helix–turn–helix 
DNA-binding motif similar to the pfam TETR family.  DurT and durH (864 and 870 
bp, respectively) encode for subunits of an ABC transporter. DurT appears to be 
the ATP-binding subunit and is a member of the pfam family of ABC transporters; 
it shows 94% identity to CinT. The protein DurH appears to be an integral 
membrane subunit of the pfam family of ABC-2 type transporters commonly 
involved in drug efflux and resistance, or carbohydrate export. The durY gene 
(945 bp) encodes a protein that may possess an N-terminal signal peptide, 
suggesting that it may be exported, but displays no other significant homologies 
to known proteins. The durZ gene has a length of 627 bp and the encoded 
protein appears to be a member of a family of proteins (pfam UPF0029) of 
unknown function.  
 
 
 Figure 4.4 The gene cluster for duramycin production, regulation, and immunity from 
Streptoverticillium cinnamoneum forma azacoluta ATCC 12686.  
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4.2.1.2 Coexpression of durA, durM, cinX, and cinorf7 in E. coli  
           Recent studies in several laboratories have demonstrated the feasibility of 
conducting the post-translational modifications that generate lantibiotics in E. coli 
(34-38). In our laboratory, pRSFDuet-1 and pACYCDuet-1 plasmids were used 
for these studies, which offer a convenient purification approach of the post-
translationally modified peptide using IMAC because of a His6-tag appended to 
the N-terminus of the leader peptide of the substrate peptide (36). A similar 
approach was employed here in an attempt to obtain duramycin.  
The gene encoding for DurA was inserted into multiple cloning site I 
(MCSI) of the pRSFDuet-1 vector to generate His6-DurA. The gene encoding for 
DurM was inserted into MCSII of the same plasmid resulting in a protein without 
a His-tag, thus preventing co-purification of the DurM enzyme. Similarly, durX 
was cloned into MCSII and durorf7 was cloned into MCSI of the pACYCDuet-1 
vector, which also produces DurX and Durorf7 without a His-tag (24). 
Coexpression of durM, durX, and durorf7 together with his6-durA caused the cells 
to die and this experiment has not been repeated. However, when his6-durA and 
durM were coepressed with cinX and cinorf7, ~2 mg of modified His6-DurA 
peptide per liter of cell culture after IMAC purification and subsequent RP-HPLC 
was obtained. Removal of the leader peptide was accomplished by GluC 
protease cleavage, which cleaves at the C-terminus of Glu located at the −4 
position, followed by aminopeptidase treatment of the peptide to remove the AFA 
amino acid sequence at the N-terminus. Since duramycin starts with a cysteine 
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that is involved in lanthionine crosslink formation, aminopeptidase does not 
recognize this amino acid, and thus aminopeptidase treatment results in removal 
of the AFA sequence to yield duramycin. MALDI-ToF MS analysis of the GluC 
and aminopeptidase treated peptide showed a mass difference with respect to 
unmodified core peptide corresponding to four dehydrations and one 
hydroxylation (Figure 4.5A). In vivo thioether cyclization activity was investigated 
by iodoacetemide (IAA) treatment and analysis by MALDI-ToF MS as previously 
described. Only minor amounts of IAA adducts were observed indicating that 
DurM formed predominantly three thioether rings in the DurA core region (Figure 
4.5B). An agar diffusion assay of the modified core region of DurA towards B. 
subtilis 6633 confirmed that the peptide was bioactive, and thus duramycin was 
successfully prepared by heterologous expression of the genes encoding for 
DurA, DurM, CinX, and Cinorf7 in E. coli (Figure 4.6B). 
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Figure 4.5 MALDI-ToF MS analysis of His6-DurA modified by DurM, CinX, and Cinorf7 in E. 
coli. (A) MALDI-ToF MS analysis of His6-DurA modified by DurM, CinX, and Cinorf7 in E. coli and 
treated with GluC followed by aminopeptidase treatment; (B) MALDI-ToF MS analysis of 
iodoacetamide (IAA) treatment of the coexpression product followed by GluC cleavage and 
aminopeptidase treatment.  *DurA core region with different numbers of dehydrations. 
**Duramycin with an alanine at −1 position that remains from the leader peptide due to less than 
100% efficiency of leader peptide removal by aminopeptidase. 
   
+
Calculated mass for M – 4 H2O + OH + H (M’); 2069.3 – 4 * 18.0 + 16 +1 = 2014.3 Da, Obsrvd: 
2013.3 Da (B) M’ + IAA = 2013.3 + 57 = 2071.3 Da; Obsrvd M’:2013.4 Da. M* + IAA = 2071.7 Da. 
 
 In Chapter II, the Lal crosslink was also formed in vitro by treating the 
dehydrated, cyclized, and hydroxylated CinA in alkaline solution overnight. 
Similar experiments were performed for the formation of the Lal crosslink in 
duramycin. The formation of the crosslink in this peptide was investigated by o-
phthalaldehyde (OPA) (39). IMAC purified His6-DurA that had been modified by 
DurM and DurX in E. coli were incubated with GluC followed by aminopeptidase. 
Subsequently, the proteolyzed peptides were treated with OPA resulting in three 
OPA adducts originating from the N-terminal amino group and the ε-amino 
groups of Lys2 and Lys19. However, when His6-DurA that had been modified by 
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DurM and CinX in E. coli and authentic duramycin were treated with OPA a mass 
increase corresponding to two OPA additions in the core region was observed 
(Figure 4.7A, B). These two OPA adducts originate from the N-terminal amino 
group and the ε-amino groups of Lys2 with Lys19 not involved in a Lal crosslink. 
In addition, one β-mercaptoethanol addition was observed, presumably as a 
consequence of Michael-type addition to dehydroalanine 6 (Figure 4.7C).     
 
 
Figure 4.6 Bioassay with the indicator strain B. subtilis 6633. (A) Sector 1, authentic 
duramycin; sector 2, His6-DurA modified by DurM and DurX in E. coli and treated with GluC and 
aminopeptidase followed by incubation at pH 9.5; sector 3, His6-DurA modified by DurM and 
DurX in E. coli treated with GluC and aminopeptidase (no alkaline treatment); sector 4 was not 
used. (B)  Sector 1, authentic duramycin; sector 2, His6-DurA modified by DurM, CinX, and 
Cinorf7 in E. coli and treated with GluC and aminopeptidase.  
      
 The bioactivity analysis of the DurA core peptide containing 
(Me)Lanthionine crosslinks and hydroxylated Asp before and after the alkaline 
treatment also suggested that Lal formed at pH 9.5 as alkaline treated peptide 
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formed a zone of inhibition, whereas the untreated peptide did not (Figure 4.6A). 
As observed with cinnamycin, these results show that Lal is crucial for the 
bioactivity of these peptides and that this crosslink can be formed in vitro by 
increasing the pH. 
 
 
Figure 4.7 Use of o-phthalaldehyde (OPA) to monitor lysinoalanine formation. (A) MALDI-
ToF MS of authentic duramycin incubated with OPA and β-mercaptoethanol. M = mass of core 
peptide after 4 dehydrations and one hydroxylation. (B) DurA was modified by DurM and CinX 
followed by alkaline treatment and removal of the leader peptide with GluC and aminopeptidase. 
The resulting peptide was then incubated with OPA and β-mercaptoethanol and analyzed by 
MALDI-ToF MS. (C) MALDI-ToF MS of DurA modified by DurM and DurX, and treated with GluC 
and aminopeptidase incubated with OPA and β-mercaptoethanol.  
   
+
Calculated mass for authentic duramycin + 2 * OPA + H = 2013 + 2 * 180 + 1 = 2374 Da, for 
GluC digested fully-modified is 2302.6 Da (M); M + OPA + βME +H; 2302.6 + 180 + 78 +1 = 
2561.6 Da, M+ 2 * OPA + H; 2302.6 + 2 * 180 + 1= 2663.6 Da, M + 2 OPA + BME + H; 2013.3 + 
2 * 180 + 78 +1 = 2741 Da, M + 3 OPA + BME + H; 2302.6 + 3 *180 + 78 +1 = 2921.6 Da,  
Obsrvd (A) authentic duramycin + 2 OPA + H: 2365.0 Da, (B) M + 2 OPA + H: 2656 Da, (C) M + 
3 OPA + BME + H = 2924 Da.  
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4.2.1.3 One step removal of the leader peptide of DurA with commercially 
available proteases  
 As aminopeptidases are expensive, we aimed to remove the leader 
peptide of DurA in one step by testing two constructs; DurA A−1E and DurA 
A−1M whose encoding genes were prepared by site directed mutagenesis. His6-
DurA A−1E and A−1M were purified by IMAC after coexpression with the genes 
encoding for DurM, CinX, and Cinorf7. Then, the peptides were analyzed by 
mass spectrometry after GluC digestion. The mass spectrometry results showed 
that both of these two mutant peptides had undergone four dehydrations and a 
hydroxylation (Figure 4.8A, B). Bioactivity analysis of the DurA core region 
obtained from digestion of these peptides isolated from the coexpression studies 
showed that fully-modified, and bioactive duramycin can be obtained for both of 
these mutants (Figure 4.9). However, large peaks corresponding to the 
unmodified core peptide and/or hydroxylated core peptide were also observed for 
both DurA A−1M and DurA A−1E mutant peptides (Figure 4.8). In addition, GluC 
activity was partially inhibited by the thioether crosslink at the Cys1 position and 
thus partially cleaved precursor peptide was observed when the DurA A−1E 
peptide was digested. To summarize, these results suggests that although it is 
more expensive, the best way to remove the leader sequence of modified DurA 
is via cleavage of the wild-type precursor peptide by GluC followed by 
aminopeptidase treatment.   
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Figure 4.8 Removal of leader peptide with commercially available proteases in one step. 
MALDI-ToF MS analysis of (A) His6-DurA A−1E purified by IMAC from coexpression of this 
peptide with the genes encoding for DurM, CinX, and Cinorf7 followed by GluC digestion; (B) 
His6-DurA A−1M purified by IMAC from coexpression of this peptide with the genes encoding for 
DurM, CinX, and Cinorf7 followed by GluC digestion. M: core peptide and M* is AFM attached to 
the N-terminus of the core peptide.  
      
+
Calculated mass for M – 4 H2O + OH + H (M`); 2069.3 – 4 * 18.0 + 16 + H = 2014.3 Da, M* + 
OH + H; 2416.7 + 16 +1 = 2433.7 Da, M* – 4 H2O + OH + H; 2416.7 – 4 * 18 + 16 + 1 = 2361.7 
Da, Obsrvd M’ (A) 2012.2 Da (B) M* – 4 H2O + OH + H; 2362.5 Da.  
 
 
 
 Figure 4.9 Bioassay with His6-DurA A−1E purified by IMAC from coexpression of this 
peptide with the genes encoding for DurM, CinX, and Cinorf7 followed by GluC digestion. 
Sector 1, authentic duramycin; sector 2, Soluble fraction of His6-DurA modified by DurM, CinX, 
and Cinorf7 in E. coli and treated with GluC; sector 3, Insoluble fraction of His6-DurA modified by 
DurM, CinX, and Cinorf7 in E. coli and treated with GluC. 
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4.2.1.4 Isothermal calorimetry (ITC) studies of duramycin and cinnamycin 
for binding to PE 
 Both cinnamycin and duramycin have been shown to bind specifically to 
PE by ITC experiments (5, 11). In order to test the binding activity of the peptides 
that are synthesized in our laboratory, binding experiments with both duramycin 
and cinnamycin were carried out. The association constant for binding of 
cinnamycin to PE in octyl glucoside (OG) micelles was (1.0 ± 0.4) x107 M-1 for 1:1 
binding (Figure 4.10B, D), whereas it was found to be (3 ± 1) x 106 M-1 in the 
paper published by Prof. Seelig (5). This slight difference in the results might be 
arising from the low solubility of cinnamycin.  For duramycin, 200 μm diameter 
liposomes consisting of a 1:1 ratio of  1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphotidylcholine (POPC) to 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphotidyl 
ethanolamine (POPE) (0.925 mM, 1 μL additions in the ITC titration) were used 
to titrate 200 μM duramycin at 37 ºC and the Ka was found to be 6.1 x 10
6 M-1, 
whereas Kd is 164 nM (N= 0.97, ΔH = 22.9 kJ /mol) (Figure 4.10A, C). In the 
previous studies, the binding constants of the 1:1 complexes of cinnamycin and 
duramycin to PE were determined with isothermal titration calorimetry to be 107-
108 M-1 depending on the size and composition of the liposomes for the 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine matrix (5).  
ITC studies with cinnamycin and its mutants have been challenging due to 
the low solubility of the peptide (~ 50-100 μM), which can also be observed from 
the ITC data of wild-type cinnamycin titrated with PE (Figure 4.10B, D). In 
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comparison, duramycin has higher solubility (~ 500 μM) as a solvent exposed 
Arg2 is replaced with Lys (4, 10).  
 
 
 
 
 
Figure 4.10 ITC data for the titration of (A) duramycin, and (B) cinnamycin with 
phosphatidylethanolamine-containing POPC liposomes and OG micelles, respectively. (C) 
duramycin and PE, (D) cinnamycin and PE binding curve. (A & D) Authentic duramycin (200 
μM, 350 μL) was titrated with 200 μm diameter liposomes consisting of a 1:1 ratio of 1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphotidylcholine (POPC) to 1-palmitoyl-2-oleoyl-sn-glycero-3- 
phosphotidylethanolamine (POPE) (0.925 mM) at 37 ºC. (B & D) Authentic cinnamycin (0.025 
μM, 350 μL) was titrated with phosphatidylethanolamine (0.267 mM) in 36 mM OG solution. 1 μL 
was used for each titration.  
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4.2.2 Frankisin Biosynthesis 
4.2.2.1 Frankisin biosynthetic gene cluster from Frankia Sp. EUN1f  
 Frankia sp. EUNf1 is a nitrogen-fixing bacterium that lives in the soil and 
has a symbiotic relationship with many plants (40). It supplies most or all of the 
host plant`s nitrogen needs, and thus can establish a nitrogen-fixing symbiosis 
with host plants where nitrogen is the limiting factor in the growth of the host. 
Phospholipid analysis of the cell membranes of this organism shows that they 
contain phosphatidylinositol, phosphatidylinositol mannosides, and 
diphosphatidylglycerol; however, nitrogen-containing phospholipids such as PE 
and PC are absent (41). 
  The genomic sequence of the bacterial strain Frankia Sp. EUN1f was 
determined and genomic DNA was kindly provided by Prof. Tisa S. Louis 
(University of New Hampshire) (42). The BLAST analysis of the genome 
identified a gene cluster that contains four putative lanthipeptide biosynthesis 
genes as in the case of the cinnamycin and duramycin biosynthetic gene clusters 
and in this study the peptide that could be produced by this gene cluster is 
named frankisin (Figure 4.11A). The putative precursor peptide FranA consists of 
a C-terminal core region that is 19 residues long. Appended to the N-terminus of 
the core peptide is a 65 amino acid leader sequence. Instead of a GG or GA 
protease cleavage motif seen in most class II lantibiotics or the sec-cleavage site 
found in CinA and DurA, no known motif is present between the leader sequence 
and the core region of FranA (Figure 4.11B). The FranA core region contains four 
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threonines and two serines, which could be processed by a lantibiotic synthetase 
in the biosynthetic cluster (Figure 4.11B). FranA drastically differs from CinA and 
DurA in the leader region. However, the core region varies from cinnamycin at 
only 6 positions; R2K, Q3S, T4S, F7S, F10I, and F12I. Interestingly, these 
variations introduce two more dehydratable amino acids. The FranM sequence 
shows high identity with other class II LanM enzymes, which are bifunctional 
enzymes that catalyze both dehydration and cyclization (31-32).  In particular, 
FranM (1116 aa) and CinM (1088 aa) show 52% identity with 95% coverage. 
Furthermore, FranX (253 aa) and CinX (325 aa) show 51% identity with 91% 
coverage, suggesting that FranX is a member of the non-heme Fe(II)-dependent 
family of enzymes that utilized β-ketoglutarate (α-KG) as cofactor and that it 
catalyzes the hydroxylation of Asp15. Franorf7 (110 aa), when compared to 
Cinorf7 (119 aa) showed 40% identity with 80% coverage, which suggests that 
this protein is involved in Lal formation in frankisin biosynthesis. After the core 
peptide is processed by these enzymes, the leader peptide is likely removed 
proteolytically to afford the mature, biologically active compound as observed in 
other lantibiotics (33).  
 The putative genes involved in frankisin biosynthesis franA, franM, franX 
and franorf7 are not similar to those in the cinnamycin biosynthetic gene cluster 
(Figure 4.12).  Upstream of the biosynthetic genes, two putative aliphatic 
sulfonate ABC transporter ATP-binding proteins T1 (280 aa) and T2 (111 aa) are 
found, which might be responsible for the transport of the mature natural product 
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outside the producing strain. In addition, FranR (952 aa), located upstream of the 
transporter, is a transcriptional regulator from the LuxR family containing the 
pfam:PF00196 motif. The genes labeled as 1 and 2 encode for small proteins (84 
aa and 43 aa, respectively) with unknown functions, and the gene labeled as 3 
encodes for a protein (197 aa), which shows similarity to Het-C heterokaryon 
incompatibility gene suggesting that this protein might be a cell wall protein (43). 
 
 
Figure 4.11 Biosynthesis of frankisin. (A) Biosynthetic gene cluster and phosphatidylinositol-
specific phospholipase C region identified downstream of the biosynthesis genes, (B) 
Biosynthesis of frankisin. The crosslinks on the modified FranA are drawn based on the structure 
of the known cinnamycin group of peptides, (C) Structure of phosphatidylinotisol. The cleavage 
point of phospholipase C enzymes, which is between phosphorus and oxygen, is shown in red on 
the structure.  
 
 
 The gene labeled as PIC encodes for phosphotidylinotisol specific 
phospholipase C (731 aa), which catalyzes the production of inositol phosphate 
(IP) and diacylglycerol (DAG) (Figure 4.11C). This enzyme is considered to be 
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involved in phosphotidylinotisol (PI) breakdown in cells, which occurs in response 
to several external stimuli. Hydrolysis of membrane PI of a number of eukaryotic 
cells and tissues by the bacterial PIC has been shown to cause substantial 
release of acetylcholinesterase, alkaline phosphatase and 5′-nucleotidase in free, 
soluble form (44). As stated above, removal of the leader sequence is required 
for lanthipeptides to be biologically active and several lanthipeptides have genes 
encoding for unique protease proteins for the removal of their leader sequences 
(45-46). No protease sequence was found within the frankisin biosynthetic 
cluster. This lack of protease gene might be due to the short contig that ends 
right after the PIC gene. It is possible that there are other genes downstream of 
PIC that are important for other functions such as leader peptide removal and 
immunity. These genes may not have been assembled in the draft genome 
 
 
 
Figure 4.12 Biosynthetic gene cluster of frankisin.   
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4.2.2.2 Coexpression of franA, franM, franX, and franorf7 in E. coli  
Similar to the approach taken to produce duramycin, pRSFDuet-1 and 
pACYCDuet-1 plasmids were employed for coexpression of the four Frankia sp. 
genes. The gene encoding for FranA was inserted into multiple cloning site I 
(MCSI) of the pRSFDuet-1 vector to generate His6-FranA. The gene encoding 
FranM was inserted into MCSII of the same plasmid resulting in a protein without 
a His-tag, thus preventing co-purification of the FranM enzyme. Similarly, franX 
was cloned into MCSII and franorf7 was cloned into MCSI of the pACYCDuet-1 
vector, which also produces FranX and Franorf7 without a His-tag (24). 
Coexpression of franM, franX, and franorf7 together with his6-franA yielded ~0.5 
mg of His6-FranA peptide per liter of cell culture after HiTrap IMAC column 
purification and subsequent reversed-phase high performance liquid 
chromatography (RP-HPLC). Removal of the leader peptide was achieved by 
treatment with the ArgC protease, which cleaves at the C-terminus of Arg at the 
−2 position (Figure 4.11B), followed by aminopeptidase treatment of the peptide 
to remove aspartic acid at position −1. MALDI-ToF MS analysis of the peptide 
treated with ArgC followed by aminopeptidase showed a mass difference with 
respect to the unmodified core peptide corresponding to six dehydrations and 
one hydroxylation (Figures 4.13). This result suggests that all four threonines and 
two serines in the core region are dehydrated (Figure 4.11B). Thioether 
cyclization activity of FranM was investigated by IAA treatment and analysis by 
MALDI-ToF MS as previously described. However, after IAA assay no mass 
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corresponding to the core region or its IAA adducts was observed, which may be 
due to low ionization of the peptide in MALDI-ToF analysis. Thus, in future 
studies cyclization and formation of the Lal crosslink on FranA should be 
confirmed and the residues forming the thioether crosslinks should be identified 
as there are multiple possibilities due to the presence of two additional 
dehydrated residues with compared cinnamycin and duramycin.  
The peptide obtained from coexpression was tested for antimicrobial 
activity towards several indicator strains including B. subtilis 6633, B. subtilis 168, 
B. simulance, Micrococcus luteus, Bacillus thuringiensis 4 AWL, Streptococcus 
agalactiae, and Lactococus lactis HP. However, no zone of inhibition was 
observed indicating that the peptide obtained is not bioactive towards these 
strains. This result might arise due to several reasons, which are discussed in the 
discussion section.  
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Figure 4.13 MALDI-ToF mass spectrum of His6-FranA modified by FranM, FranX, and 
Franorf7 in E. coli. His6-FranA modified by FranM, FranX, and Franorf7 in E. coli and treated 
with ArgC protease followed by aminopeptidase.  
      
+
Calculated mass for M – 6 H2O + OH (M`); 1928.2 – 6 * 18.0 + 16 = 1836.2 Da, Obsrvd; 
1835.1 Da.  
 
4.2.3 Engineering of cinnamycin analogs  
4.2.3.1 Biosynthesis of ancovenin  
  The biosynthetic gene cluster for ancovenin is not known because the 
producing strain appears to have been lost at Fujirebio Diagnostics, Inc. (23).  
Ancovenin differs at only four positions (Val2, Leu10, Trp12, and Ser13) from 
cinnamycin (Arg2, Phe10, Phe12, and Val13) allowing ancovenin production as a 
cinnamycin analog. Using site-directed mutagenesis, four mutations were 
introduced in CinA(A–1K) to yield a peptide consisting of the cinnamycin leader 
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peptide attached to the ancovenin core region. Then, his6-cinA(A–1K) 
R2V/F10L/F12W/V14S and cinM and cinorf7 were coexpressed and, modified 
His6-CinA(A–1K)  R2V/F10L/F12W/V14S peptide was purified by IMAC followed 
by RP-HPLC. Ancovenin does not contain the hydroxylation on the Asp15 (1), 
therefore cinX was not used in the coexpression. Analysis of the peptide by 
MALDI-ToF MS after the removal of the leader peptide by LysC endoproteinase 
showed a mass corresponding to the core region with 4 dehydrations in addition 
to a peak with 3 dehydrations (Figure 4.14). Cyclization of the cysteines was 
investigated with the IAA assay of LysC-cleaved peptide by MALDI-ToF MS 
analysis. The results showed no IAA adducts suggesting that all three cysteines 
were crosslinked to the dehydrated amino acids (Figure 4.14).  
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Figure 4.14 Biosynthesis of ancovenin. (A) MALDI-ToF MS analysis of the IAA assay for the 
sample obtained as follows. His6-cinA(A–1K) R2V/F10L/F12W/V14S, two copies of cinM, and 
cinX were coexpressed, and modified His6-CinA(A–1K) peptide was purified by IMAC column 
purification followed by RP-HPLC. Analysis of the peptide by MALDI-ToF MS after the removal of 
the leader peptide by LysC endoproteinase showed that the major peak corresponds to the core 
region with 4 dehydrations in addition to a peak with 3 dehydrations.  No IAA adducts were 
observed.  
      
+
Calculated mass for M – 4 H2O + H (M`); 2033.3 – 4 * 18 + 1 = 1962.3 Da, Obsrvd; 1962.2 
Da.  
 
4.2.3.2 Preparation of cinnamycin and duramycin analysis containing 
Phe7Val or Phe7Leu mutations  
Molecular dynamics (MD) studies performed by Prof. Ming Zhao at 
Northwestern University suggested that cinnamycin and/or duramycin with the 
mutations Phe7Val and Phe7Leu might bind phosphatidylserine (PS), which 
differs from PE by a carboxyl group at the head group (Figure 4.15A, D). NMR 
studies also clearly show that the amino group of PE points towards Phe7 and 
thus its mutation to smaller amino acids such as Leu and Val might create more 
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space in the binding scaffold and accommodate the carboxylate of PS (Figure 
4.15D) or possibly the three methylations on the amino group of PC (Figure 
4.15B).  Therefore, the genes encoding CinA Phe7Leu and Phe7Val, and DurA 
Phe7Leu and Phe7Val were prepared via site-directed mutagenesis, followed by 
coexpression with the appropriate LanM, LanX and Lanorf7 enzymes, and 
purification by IMAC. Then, the leader peptides were removed using the 
appropriate proteases, as specifically described for cinnamycin in Chapter II and 
for duramycin in section 4.2.1.2. The peptides were analyzed by MALDI-ToF MS 
and determined to contain the three (Me)Lan and one Lal crosslinks as well as 
the hydroxylation of Asp15 (Figure 4.16A, B). Interestingly, when the bioactivity 
of these cinnamycin and duramycin mutants were tested, formation of a zone of 
growth inhibition in agar diffusion assays was lost towards B. subtilis 6633, 
suggesting that these mutants no longer bind to PE. To test this hypothesis, the 
four mutant peptides were titrated with PE (1,2-diacyl-sn-glycero-3-
phosphoethanolamine from egg yolk) in OG micelles and the heat exchange was 
monitored by ITC.  
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Figure 4.15 Preparation of cinnamycin analogs for binding to phosphatidylcholine (PC). 
Representation of (A) phosphatidylethanolamine (PE), (B) phosphatidylcholine (PC), (C) 
phosphatidylinotisol (PI), and (D) phosphatidylserine (PS). The differences of PE, PC, and PS are 
highlighted in red, (E) NMR structure of duramycin complexed with PE; Phe7 and hydroxylated 
Asp15 are shown in yellow.   
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Figure 4.16 Mass spectrometry analysis of iodoacetamide treated (A) duramycin Phe7Leu 
and (B) duramycin Phe7Val. The peptides were obtained from the coexpression studies in E. 
coli, and subsequent IMAC and RP-HPLC purification followed by GluC and aminopeptidase 
treatment.  
   +Calculated mass for (A) M – 4 H2O + OH; 2035.3 – 4 * 18.0 + 16 = 1979.3 Da, Obsrvd: 1979.6 
Da; (B) Calculated mass for M – 4 H2O + OH; 2021.3 – 4 * 18.0 + 16 = 1965.3 Da, Obsrvd mass 
(A) 1979.6 Da, (B) 1965 Da.  
 
 
Figure 4.17 ITC studies for cinnamycin Phe7Val with PC containing OG micelles.  
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Although ITC experiments of cinnamycin mutants for binding to PE, PC, 
and PS were performed, the results were not considered convincing due to low 
solubility issues mentioned in the section for cinnamycin ITC studies. Therefore, 
the same experiments were repeated for duramycin Phe7Leu and duramycin 
Phe7Val, which have much higher solubility due to the solvent exposed Lys at 
the second position. The ITC experiments for duramycin mutants showed that 
they no longer bind to PE but started to weakly recognize PC. These results 
resemble the ITC results obtained for the binding of cinnamycin mutants to these 
phospholipids (Figure 4.17). Interestingly, the ITC curves for PC binding do not 
suggest 1:1 binding but suggest that duramycin Phe7Leu and Phe7Val are 
aggregating on the micelles in a PC dependent manner. Therefore, more 
experiments should be performed to confirm the binding interaction between PC 
and these duramycin mutants such as fluorescence resonance energy transfer 
studies. None of the mutants recognized phosphatidylserine (PS), in ITC studies. 
Also, negative control experiments where duramycin was titrated with PC-
containing micelles, peptide buffer was titrated with PC or PE micelles or 
POPE:POPC liposomes, and mutant peptide solution was titrated with micelles 
without any phospholipids showed no interaction as expected.  
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4.3 DISCUSSION 
In this chapter, the biosyntheses of duramycin, ancovenin, and a peptide 
from Frankia Sp. EUNf1 (frankisin), whose genome contains a biosynthetic 
cluster that is very similar to the cinnamycin biosynthetic genes, are described. 
To do so, the genomic DNA from ATCC Streptoverticillium cinnamoneum forma 
azacoluta, which produces duramycin, was sequenced by Dr. Yun-juan Chang at 
the University of Illinois at Urbana-Champaign. The genomic DNA of Frankia Sp. 
EUNf1 was obtained from Prof. Tisa S. Louis (University of New Hamshire). 
Duramycin and frankisin were biosynthesized by heterologous expression of their 
corresponding biosynthetic genes in E. coli. Mass spectrometry analysis 
confirmed that fully-modified duramycin can be formed with this approach; 
however more experiments are needed to confirm the formation of fully-modified 
frankisin.  
The peptide obtained from the coexpression of the putative frankisin 
biosynthetic genes did not show bioactivity towards many strains tested, which 
might be due to several reasons. Firstly, although dehydration of the six Ser/Thr 
residues in the core region of FranA was confirmed, the formation of Me(Lan) 
and Lal crosslinks could not be verified due to difficulties encountered in mass 
spectrometry analysis. Therefore, it is possible that the peptide obtained is not 
fully cyclized. Secondly, it is possible that this peptide is binding to PE as other 
members of the group do, but might not be able to induce bacterial cell death. 
Therefore, ITC experiments should be performed for binding to PE. Thirdly, it is 
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possible that frankisin is not binding to PE but has a different target. The 
cinnamycin biosynthetic cluster contains a SAM-dependent enzyme, which 
methylates the amino group of all the PE in the producing strain, providing 
immunity to the organism (47). Frankia Sp. does not contain this gene, but is also 
does not have PE in its membranes. Therefore, the PIC enzyme found 
downstream of the biosynthetic genes is interesting, as it might be providing 
immunity to Frankia Sp if frankisin was a different target than PE. Similar to the 
other members in the cinnamycin group of peptides, frankisin contains the critical 
amino acids that are involved in direct interaction to the glycerol moiety and the 
phosphate on a phospholipid as identified by NMR studies with cinnamycin and 
duramycins (9). In addition, the FranA core region contains serine and two 
isoleucines in the positions of the bulky amino acid phenylalanine at positions 7, 
10, and 12 in cinnamycin and the duramycins. These substitutions might 
generate space in the binding cavity for a phospholipid like PI with a larger head 
group compared to PE to bind to this peptide. More experiments should be 
performed to test these hypotheses.  
Ancovenin, the third cinnamycin-like peptide studied herein, was obtained 
via site-directed mutagenesis of four amino acids of CinA (Arg2, Phe10, Phe12, 
and Val13) to Val2, Leu10, Trp12, and Ser13 and heterologous expression of the 
resulting CinA mutant together with CinM and Cinorf7 in E. coli. Mass 
spectrometry analysis of the peptide obtained from the coexpression showed that 
CinM was able to process this peptide and form four dehydrations with three 
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(Me)Lan crosslinks. The previous studies where sequence analysis of ancovenin 
was investigated showed that this peptide does not contain the hydroxylation on 
the Asp15, unlike the other members of the group (1). The preparation of this 
using the cinnamycin biosynthetic enzymes provides new opportunities to study 
ancovenin.  
The possibility that cinnamycin and duramycin analogs might bind to 
different phospholipids than their natural binding partner PE was also 
investigated. The cinnamycin and duramycin analogs Phe7Val and Phe7Leu 
were by site-directed mutagenesis and tested for binding to phosphotidylcholine 
(PC), phosphatidylinotisol (PI), and phosphatidylserine (PS) by ITC. All of the 
mutants prepared lost their bioactivity towards B. subtilis 6633, suggesting that 
they lost the ability to recognize PE. This hypothesis was tested by ITC studies, 
which showed that the cinnamycin Phe7Val mutant still recognized PE, whereas 
cinnamycin Phe7Leu lost its ability to bind to PE. On the other hand, both 
cinnamycin Phe7Val and Phe7Leu and duramycin Phe7Leu interacted weakly 
with PC, generating exothermic heat signals, whereas no heat exchange was 
observed in the ITC experiment of cinnamycin or duramycin with PC. However, 
high-quality data could not be obtained from the titrations therefore further 
experiments are needed for definitive conclusions. The experiments to test 
binding of the duramycin mutants to PE have not been performed yet. 
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4.4 MATERIALS 
  Oligonucleotide primers for mutagenesis were synthesized by Operon 
Technologies. Taq and Platinum Pfx DNA polymerases, DpnI, restriction 
endonucleases, and bacteriophage T4 DNA ligase were purchased from 
Invitrogen. Fusion DNA polymerase was purchased from New England Biolabs. 
Cloning vectors (pET and pDuet) were obtained from Novagen. Gel extraction, 
plasmid mini-prep, and PCR purification kits were purchased from Qiagen. All 
strains were grown in media acquired from Difco laboratories. Other items 
procured include isopropyl-1-thio-D-galactopyranoside (IPTG, CalBiochem), 
iodoacetamide (IAA, Acros Organics), tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP, Aldrich), and dithiothreitol (DTT, Sigma). Endoproteinase 
LysC was purchased from Roche Applied Science. 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine (POPE), and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) were purchased from Avanti Lipids (Alabaster, AL). 
Octyl β-D-glucopyranoside was purchased from Sigma Aldrich.  
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4.5 GENERAL METHODS  
Molecular biological manipulations were carried out using standard techniques 
(48). PCR was performed using an automatic thermocycler (PTC 150, MJ 
Research) and DNA sequencing was performed at the Biotechnology Center of 
the University of Illinois at Urbana-Champaign (UIUC). Escherichia coli DH5α 
cells (UIUC Cell Media Facility) and E. coli BL21 (DE3) cells (Stratagene) were 
used for plasmid preparation and protein expression, respectively. Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF 
MS) was carried out on a Voyager-DE-STR (Applied Biosystems). Liquid 
chromatography electrospray ionization tandem mass spectrometry (LC/ESI-
MS/MS) was carried out and processed using a Synapt ESI quadrupole ToF 
Mass Spectrometry System (Waters) equipped with an Acquity Ultra 
Performance Liquid Chromatography (UPLC) system (Waters).  
 
 
 
 
 
 
 
 
153 
 
4.6 EXPERIMENTAL METHODS 
4.6.1 Isolation of genomic DNA from Streptoverticillium cinnamoneum 
forma azacoluta and genomic sequencing (NB 13, p14) 
  Streptoverticillium cinnamoneum forma azacoluta (ATCC 12686) was 
grown in BBLTM Trypticase Soy Broth with shaking at 37 ºC for 1-2 days. Then, 
the bacteria were harvested by centrifugation and washed twice with 0.05 M Tris, 
pH 8. The pellet was resuspended in 25% sucrose-Tris buffer (0.05 M, pH 8) at a 
concentration of 1 g wet weight per 10 mL of buffer. This suspension was 
homogenized in a glass tissue grinder to break up the clumps of mycelium. 
Lysozyme at 10 mg/mL was mixed with the cell suspension and incubated at 37 
ºC for 30 min. The solution of 0.25 M EDTA, pH 8 (5 mL) was added to 20 mL of 
cell suspension and incubated at 37 ºC for another 15 min, which completed the 
cell lysis. Then, the genomic DNA was extracted with Promega Wizard Plus SV 
miniprep kit, which resulted in ~150 ng/μL of DNA. Then 200 μL of this DNA 
solution was submitted for shot-gun sequencing performed by Dr. Yun-juan 
Chang at the Biotechnology Center at UIUC.  
4.6.2 Cloning 
4.6.2.1 Cloning of durA, durM, durX, and durorf7 into pDuet vectors (NB14, 
p7-17) 
The genes durA, durM, durX and durorf7 were cloned from 
Streptoverticillium cinnamoneum forma azacoluta genomic DNA. The 
amplification of durA was conducted via 30 cycles of denaturing (98 ºC for 10 s), 
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annealing (55 ºC for 30 s), and extending (72 ºC for 30 s) using DurA_BamHI_FP 
and DurA_HindIII_RP as primers and using the genomic DNA as a template 
(Table 4.1). Similarly durM was amplified with DurM_EcorV_FP and 
DurM_KpnI_RP primers by denaturing (98 ºC for 10 s) for 30 cycles, annealing 
(55 ºC for 30 s), and extending (72 ºC for 100 s). The PCRs (50 μL) included 1x 
HF buffer (Finnzymes), DMSO (4%), Fusion DNA Polymerase (Finnzymes) (0.02 
unit/μL), dNTPs (1 mM), S. cinnamoneum forma azacoluta genomic DNA, and 
primers (1 μM each). Amplification of the final PCR product was confirmed by 2% 
and 1% agarose gel electrophoresis for durA and durM, respectively, and the 
products were purified using QIAquick PCR purification kits (QIAGEN). The 
resulting DNA fragments and the pRSFDuet-1 vector were digested in 1 x 
NEBuffer 4 (New England Biolabs) with BamHI-HF and HindIII-HF for durA, and 
EcorV-HF and KpnI-HF for durM at 37 ºC (for 15 h). The digested products were 
purified by agarose gel electrophoresis followed by use of a QIAquick gel 
extraction kit (QIAGEN).  
Similarly, durX and durorf7 were amplified using primers 
CinX_EcoRV_pACYCDuet-1_MCSII_FP and CinX_XhoI_pACYCDuet-
1_MCSII_RP for durX, Cinorf7_NcoI_pACYCDuet-1_MCSI_FP and 
Cinorf7_HindIII_pACYCDuet-1_MCSI_RP for durorf7 (Table 4.1) by PCR. The 
reactions contained 1xFailSafe PreMix G (PICENTRE Biotechnologies), DMSO 
(4%), Platinum Pfx DNA polymerase (0.025 unit/μL), Taq DNA polymerase (0.05 
unit/μL), and primers (1 μM each). Amplification of the final PCR products was 
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confirmed by 1% agarose gel electrophoresis and the products were purified 
using QIAquick PCR purification kits. The resulting DNA fragments and the 
pACYCDuet-1 vector was digested in 1 x NEBuffer 4 with EcoRV-HF and XhoI 
for insertion of durX and NcoI-HF and HindIII-HF for durorf7 at 37 ºC (for 15 h). 
The digested products were purified by agarose gel electrophoresis followed by 
use of a QIAquick gel extraction kit.  
The resulting DNA inserts were ligated with the digested corresponding 
vectors at 16 ºC for 15 h using T4 DNA ligase to generate durA- and durM-
containing pRSFDuet-1, and durX- and durorf7-containing pACYCDuet-1. The 
ligation reaction mixture was diluted 5 times with water prior to transformation. E. 
coli DH5α cells were transformed with the ligation product via heat shock, plated 
on LB-chloramphenicol (for pACYCDuet-1b) and LB-kanamycin (for pRSFDuet-
1) agar plates, and grown at 37 ºC for 15 h. Colonies were picked and incubated 
in 5 mL of LB- chloramphenicol/kanamycin medium at 37 ºC for 15 h, followed by 
isolation of the plasmids using a QIAprep Spin Miniprep Kit. The desired 
sequences of the resulting plasmids were confirmed by DNA sequencing. 
4.6.2.2 Cloning of franA, franM, franX, and franorf7 into pDuet vectors 
(NB10, p66; NB11, p24) 
The genes franA, franM, franX and franorf7 were cloned from Frankia Sp. 
EUNf1 genomic DNA provided by Prof. Tisa Louis at the University of 
Hampshire. Similar to the duramycin biosynthetic genes, franA, franM, franX and 
franorf7 were amplified via 30 cycles of denaturing (98 ºC for 10 s), annealing 
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(55-65 ºC for 30 s), and extending (72 ºC for 30-180 s) using appropriate primers 
(Table 4.1). The PCRs (50 μL) included 1x HF buffer (Finnzymes), DMSO (4%), 
Fusion DNA Polymerase (Finnzymes) (0.02 unit/μL), dNTPs (1 mM), Frankia Sp. 
EUNf1 genomic DNA, and primers (1 μM each). Amplification of the final PCR 
product was confirmed by 1- or 2% agarose gel electrophoresis depending on 
the size of the gene, and the products were purified using QIAquick PCR 
purification kits (QIAGEN). The resulting DNA fragments and the pRSFDuet-1 or 
pACYCDuet-1 vector were digested in 1 x NEBuffer 4 (New England Biolabs) 
with EcoRI-HF and HindIII-HF for franA, EcoRV-HF and XhoI for franM, NdeI and 
EcoRV-HF for franX, and NcoI-HF and NotI-HF for franorf7 at 37 ºC (for 15 h). 
The digested products were purified by agarose gel electrophoresis followed by 
use of a QIAquick gel extraction kit (QIAGEN). The resulting DNA inserts were 
ligated with the digested corresponding vectors at 16 ºC for 15 h using T4 DNA 
ligase to generate franA- and franM-containing pRSFDuet-1, and franX- and 
franorf7-containing pACYCDuet-1. The ligation reaction mixture was diluted 5 
times with water prior to transformation. E. coli DH5α cells were transformed with 
the ligation product via heat shock, plated on LB-chloramphenicol (for 
pACYCDuet-1b) and LB-kanamycin (for pRSFDuet-1) agar plates, and grown at 
37 ºC for 15 h. Colonies were picked and incubated in 5 mL of LB- 
chloramphenicol/kanamycin medium at 37 ºC for 15 h, followed by isolation of the 
plasmids using a QIAprep Spin Miniprep Kit. The desired sequences of the 
resulting plasmids were confirmed by DNA sequencing. 
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4.6.2.3 Cloning to generate constructs encoding DurA-A−1E, DurA-A−1M, 
FranA-D−1E, and FranA-D−1M (NB14, p56) 
  The mutations A−1E and A−1M were generated in durA, and D−1E and 
D−1M were made in franA by Quikchange PCR. Briefly, the amplification of these 
genes from pRSFDuet-1 containing durA and durM and pRSFDuet-1 containing 
franA and franM was conducted via 30 cycles of denaturing (98 οC for 10 s), 
annealing (60 οC for 30 s), and extending (72 οC for 240 s) using the primers 
listed in Table 4.1. The PCRs (50 μL) included 1x HF buffer (Finnzymes), DMSO 
(4%), Fusion Hot Start High-Fidelity DNA Polymerase (Finnzymes) (0.04 unit/μL), 
dNTPs (2 mM), corresponding template (20 ng), and primers (1 μMeach). The 
PCR product was checked on a 1% agarose gel and purified using a QIAquick 
PCR purification kit (QIAGEN). The resulting DNA was treated with DpnI at 37 οC 
for 15 h to digest the methylated template, and E. coli DH5α cells were 
transformed. The desired mutations were confirmed by DNA sequencing. 
4.6.2.4 Generation of CinA-K R2V, F10L, F12W, V13S mutations in 
pRSFDuet-1 MCS- I for ancovenin production 
  Generation of the gene encoding the ancovenin precursor peptide was 
performed with multistep PCR reactions to fuse the core region of ancovenin to 
the CinA leader peptide. In the first reaction, CinAK_AscI_ pRSFDuet-1_ 
MCSI_FP and CinA-K_Ancovenin_pRSFDuet-1_MSCI_RP-1 were used as 
forward and reverse primers. The PCRs (50 μL) included 1x HF buffer 
(Finnzymes), DMSO (4%), Fusion DNA Polymerase (Finnzymes) (0.02 unit/μL), 
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dNTPs (1 mM), CinA(A–1K)/pET15b as template DNA (20 ng), and primers (1 
μM each). The amplification was conducted via 30 cycles of denaturing (98 οC for 
10 s), annealing (60 οC for 30 s), and extending (72 οC for 15 s). The final PCR 
product was confirmed by 2% agarose gel electrophoresis, and it was purified 
using a QIAquick gel purification kit (QIAGEN). The second PCR was performed 
by using the first PCR product as a template and 
CinAK_AscI_pRSFDuet1_MCSI_FP and CinA-K_Ancovenin_pRSFDuet1 
_MSCI_RP-2 as forward and reverse primers. The amplification was conducted 
via 30 cycles of denaturing (98 οC for 10 s), annealing (60 οC for 30 s), and 
extending (72 οC for 15 s). The successful generation of the final PCR product 
was confirmed by 2% agarose gel electrophoresis, and it was purified using a 
QIAquick gel purification kit (QIAGEN). The third and final PCR was performed 
by using the second PCR product as a template and, CinA-K_AscI_ pRSFDuet-
1_MCSI_FP and CinA-K_Ancovenin_pRSFDuet-1_MSCI_RP-3_HindIII as 
forward and reverse primers. The PCR was performed under the same 
conditions followed by purification of the PCR product by gel electrophoresis. The 
resulting DNA fragment and the pRSFDuet-1 containing cinM were digested in 1x 
NEBuffer 4 with AscI (15 h) and HindIII-HF (3 h) at 37 ºC and the product purified 
by agarose gel electrophoresis followed by use of a QIAquick gel extraction kit 
(QIAGEN). The resulting DNA insert was ligated with the digested vector at 16 ºC 
for 15 h using T4 DNA ligase. The ligation reaction mixture was diluted 5 times 
with water prior to transformation. E. coli DH5α cells were transformed with the 
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ligation product via heat shock, plated on LB-ampicilin agar plates, and grown at 
37 ºC for 15 h. Colonies were picked and incubated in 5 mL of LB-ampicilin 
medium at 37 ºC for 15 h, followed by isolation of the plasmids using a QIAprep 
Spin Miniprep Kit (QIAGEN). The desired sequences of the resulting plasmids 
were confirmed by DNA sequencing. 
4.6.2.5 Generation of cinA-K Phe7Val and Phe7Leu, and durA Phe7Val and 
Phe7Leu (NB10, p70; NB11, p45) 
  Both Phe7Val and Phe7Leu mutations were made in the genes encoding 
CinA (A−1K) and DurA by Quikchange PCR. Briefly, the amplification of cinA-K- 
and cinM-containing pRSFDuet-1 and durA- and durM-containing pRSFDuet-1 
was conducted via 30 cycles of denaturing (98 οC for 10 s), annealing (60 οC for 
30 s), and extending (72 οC for 180 s) using primers CINA_PHE7VAL_FP or 
CINA_PHE7LEU_FP together with CINA_QC_PHE7VAL_7LEU_RP for both of 
the templates (See Table 4.1 for primer sequences). The PCRs (50 μL) included 
1x HF buffer (Finnzymes), DMSO (4%), Fusion Hot Start High-Fidelity DNA 
Polymerase (Finnzymes) (0.04 unit/μL), dNTPs (2 mM), corresponding template 
(20 ng), and primers (1 μM each). The PCR product was checked on a 1% 
agarose gel and purified using a QIAquick PCR purification kit (QIAGEN). The 
resulting DNA was treated with DpnI at 37 οC for 15 h to digest the methylated 
template, and E. coli DH5α cells were transformed. The desired mutations were 
confirmed by DNA sequencing. 
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4.6.3 Coexpression studies 
4.6.3.1 Coexpression and purification of durA, durM, and cinX with and 
without cinorf7 in E. coli (NB14, p58-60, 63, 65; NB15, p26) 
 In order to coexpress durA, durM and cinX, E. coli BL21 (DE3) cells were 
transformed with a pRSFDuet-1 vector containing durA and durM and a 
pACYCDuet-1 vector containing cinX. Similarly, for coexpression of durA, durM 
and cinX together with cinorf7, E. coli BL21 (DE3) cells were transformed with a 
pRSFDuet-1 vector containing durA and durM and a pACYCDuet-1 vector 
containing cinX and cinorf7.  The durA gene encoded for His6-tagged DurA 
peptide. Single colony transformants were grown in a 37 ºC shaker for 12-15 h in 
50 mL of Luria-Bertani (LB) medium supplemented with 25 μg/mL kanamycin and 
12.5 μg/mL chloramphenicol. A 20 mL aliquot was centrifuged at 5000×g for 10 
min, the spent LB medium was discarded, and the cell pellet was resuspended in 
fresh LB medium. The resuspended cells (20 mL) were added to 2 L of LB 
supplemented with the appropriate antibiotics, and the culture was grown 
aerobically at 37 ºC until the A600 was ~ 0.6 to 0.8. IPTG was added to a final 
concentration of 0.5 mM and the culture was transferred to 18 ºC for aerobic 
growth for an additional 20 h. Cells were harvested by centrifugation at 5000×g 
for 20 min at 4 ºC. The cell paste (~ 3-4 g) was stored at –80 ºC until use. 
Peptides were purified from E. coli BL21 (DE3) cultures as described for other 
His6-LanA peptides (49) by use of a 5 mL HiTrap chelating HP nickel affinity 
column (GE Healthcare) followed by HPLC.  
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4.6.3.2 Coexpression and purification of franA, franM, franX, and franorf7 in 
E. coli (NB14, p59) 
 In order to coexpress franA, franM and franX together with franorf7, E. coli 
BL21 (DE3) cells were transformed with a pRSFDuet-1 vector containing franA 
and franM and a pACYCDuet-1 vector containing franX and franorf7.  The franA 
gene encoded for His6-tagged FranA peptide. Single colony transformants were 
grown in a 37 ºC shaker for 12-15 h in 50 mL of Luria-Bertani (LB) medium 
supplemented with 25 μg/mL kanamycin and 12.5 μg/mL chloramphenicol. A 20 
mL aliquot was centrifuged at 5000×g for 10 min, the spent LB medium was 
discarded, and the cell pellet was resuspended in fresh LB medium. The 
resuspended cells (20 mL) were added to 2 L of LB supplemented with the 
appropriate antibiotics, and the culture was grown aerobically at 37 ºC until the 
A600 was ~ 0.6 to 0.8. IPTG was added to a final concentration of 0.5 mM and the 
culture was transferred to 18 ºC for aerobic growth for an additional 20 h. Cells 
were harvested by centrifugation at 5000×g for 20 min at 4 ºC. The cell paste (~ 
3-4 g) was stored at –80 ºC until use. Peptides were purified from E. coli BL21 
(DE3) cultures as described for other His6-LanA peptides (49) by use of a 5 mL 
HiTrap chelating HP nickel affinity column (GE Healthcare) followed by HPLC.  
4.6.4 Bioactivity assays with B. subtilis 6633 (NB11, p98; NB14, p77) 
 Modified peptide obtained from the coexpressions for duramycin and 
frankisin production (0.5 mg) were separately dissolved in 1 mL of 100 mM Tris-
HCl pH 8.3 buffer and digested with 50 μL of LysC (0.4 μg/mL in 100 mM Tris, 
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pH 8.3) at 37 ºC for 12 h. In the case where non-enzymatic Lal formation was 
induced in vitro, the pH of the solution was carefully increased to pH 9.5 by 
addition of 5 M NaOH and the solution was incubated at room temperature for 12 
h. Both samples were then further purified by SPE as described above.  B. 
subtilis 6633 was grown at 37 ºC for 15 h in 5 mL of LB supplemented with 0.1% 
D-(+)-glucose (Calbiochem). LB medium containing 1.5 % agar was autoclaved 
and cooled to 42 ºC in a water bath, and 15 mL of this solution was mixed with 
375 μL of B. subtilis 6633 culture and with a D-(+)-glucose solution to give a 
0.1% final glucose concentration. The agar was poured into sterile plates and 
shallow wells were generated after the agar solidified. The peptide samples (10 
μL in 50 mM Tris Buffer) were spotted and the plates were incubated for 10 h at 
25 oC.   
4.6.5 Protease cleavage of DurA, FranA, NisA, and CinA-K (NB11, p94) 
To lyophilized peptide (1mg), 50 mM HEPES buffer (1 mL per 5 mg of 
peptide, 1 mM TCEP, pH 7.5) and the necessary protease (5 μL/L 
overexpression culture; stock solutions used: LysC = 3 U/100 μL, GluC = 2 
mg/mL, trypsin = 40 μM) were added. ArgC cleavage was performed according 
to the manufacturers protocol (Roche). The reaction was incubated overnight at 
room temperature (GluC, trypsin, and ArgC) or at 37 °C (LysC). After 12 h the 
progress of the reaction was analyzed by MALDI-TOF MS and additional enzyme 
was added in 5 μL aliquots if the reaction was not complete.  
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4.6.6 Aminopeptidase cleavage of GluC-cleaved DurA and ArgC-cleaved 
FranA and analysis by MALDI-ToF MS (NB14, p 56) 
The DurA and FranA peptides (1mg/mL) digested with GluC and ArgC, 
respectively, in 50 mM HEPES buffer were treated with aminopeptidase (Sigma 
A8200, 6 μL/1 mg peptide, 100 U/mL stock solution). The reaction was incubated 
at 37 °C for 24 h and analyzed by mass spectrometry. After digestion by ArgC 
and aminopeptidase, the FranA peptide was analyzed in negative mode MALDI-
ToF MS with 2,5-dihydroxybenzoic acid (DHB) matrix (1 mg/mL, in 60% 
acetonitrile(ACN):water). DurA digested with GluC and aminopeptidase was 
analyzed in positive mode with sinapinic acid matrix (1 mg/mL, in 60% 
acetonitrile(ACN):water). 
4.6.7 Isothermal Calorimetry (ITC) experiments (NB11, p16, 19, 20, 25, 99) 
  The ITC measurements for cinnamycin were performed using micelles 
composed of octyl β-D-glucopyranoside (OG) as described (5). For this 
experiment, L-α-phosphatidylethanolamine (1,2-diacyl-sn-glycero-3-phospho 
ethanolamine) from egg yolk (Sigma, 0.25 mg) and cinnamycin (Novacta) (25 or 
50 μM) were dissolved in 36 mM OG solution, 10 mM Tris-HCl and 0.1 M NaCl, 
pH 7.4.  Then, cinnamycin/OG solution (350 μL) was titrated with 1 μL of the 
PE/OG micelles (50 μL in total) and measurements were collected. Solutions 
were degassed under vacuum before use.      
  The ITC measurement for duramycin was performed using POPC/POPE 
liposomes (11). Vesicles were prepared as POPC/POPE mixtures (10:1, w/w) at 
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a final lipid concentration of 10 mg/mL. For this purpose, stock solutions of POPC 
and POPE in methanol and chloroform were prepared. The appropriate amount 
of POPC was added to a 5 mL round-bottomed flask and was dried down under 
a stream of nitrogen. Residual solvent was removed by applying vacuum. The 
amount of POPC was controlled by weighing. Next, POPE dissolved in 
chloroform and methanol was added, and the procedure was repeated. A total of 
2 mL of buffer (10 mM Tris-HCl and 0.1 M NaCl, pH 7.4) was added to the dry 
film, and the suspension was extensively vortexed. Then, 1 mL of liposome 
solution was extruded through a filter with 200 μm pore size 20 times and purified 
by a Sephadex column. Liposomes elute from the Sephadex column as an 
opaque dispersion. Then, the concentration of the liposome solution was 
calculated with phosphate quantification using ascorbic acid (50).  
Isothermal titration calorimetry (ITC) was performed with a Nano ITC 
titration calorimeter (TA Instruments). Solutions were degassed under vacuum 
before use. Injection volumes varied between 1 and 3 μL. Peptide concentrations 
varied between 50 and 200 μM. The calorimeter cell had a reaction volume of 
350 μL. The titration pattern was analyzed in terms of a 1:1 peptide-lipid 
complex.  
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Table 4.1 List of primers.  
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CHAPTER V: PHAGE DISPLAY OF LANTHIPEPTIDES  
5.1 INTRODUCTION 
Cyclic peptides are promising candidates to use as molecular scaffolds for 
peptide libraries, which in turn may provide powerful tools for drug design and 
investigation of protein-protein interactions (1). The characteristic thioether 
crosslinks of lanthipeptides provide stability to different physical conditions (pH, 
temperature), resistance to proteases, and form scaffolds to selectively and 
tightly bind to small molecules such as lipid II and phosphotidylethanolamine 
(PE) (2-5). These crosslinks are necessary for the activity of antimicrobial 
lanthipeptides, called lantibiotics, as in the absence of these modifications, 
binding to their target is not observed. Previous studies showed that the 
solubility, stability, and therapeutic effect of lanthipeptides can be improved by 
replacement of amino acids at different positions in the sequence with natural 
and/or unnatural residues (6-7). However, only a few systematic methods for 
discovery of new, pharmaceutically valuable lanthipeptides are available such as 
bacterial display, and in vitro non-ribosomal translation of lanthipeptides with 
designed ring structures (8-9). Therefore, a method that enables selection of a 
desired function of a lanthipeptide would be highly valuable. The molecular 
details of the biosynthesis of several lantibiotics such as nisin, cinnamycin, 
lacticin 481, and haloduracin have been revealed by our laboratory and provide a 
strong basis for engineering of these molecules (Figure 5.1) (10-13).  
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Nisin is a polycyclic antibacterial peptide with 34 amino acid residues and 
five cyclic thioether cross-links of varying sizes. After the precursor peptide NisA 
is synthesized by the ribosome, the cross-links are installed by sequential actions 
of the enzymes NisB and NisC on NisA (Figure 5.2). Then, the mature lantibiotic 
is formed through the cleavage of the leader peptide located at the N-terminus of 
NisA by NisP, a serine protease (Figure 5.2) (14). NisB dehydrates threonines 
and serines in the core region of NisA whereas NisC forms the five thioether 
cross-links by Michael-type addition of cysteine thiols to the dehydrated Thr/Ser. 
Nisin specifically binds to the pyrophosphate group of lipid II and forms pores in 
the cell membrane to kill gram positive bacteria (15), therefore it can potentially 
be used as a scaffold to target other components of the cell wall.  
 
 
 
Figure 5.1 Structural representation of nisin, lacticin 481, cinnamycin and Halα, one of the 
two components of haloduracin. Dha, dehydrolalanine; Dhb, dehydrobutyrine; Abu, 2-
aminobutyric acid. 
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Phage display is widely used for identification of peptide/protein-binders 
from large libraries of peptides (16-17). However, introduction of post-
translational modifications onto the phage-displayed peptides is a fairly new 
concept. Three approaches can be used to introduce modifications on a phage-
displayed peptide. One way to alter the structure of a phage-displayed peptide is 
chemical modification by reagents that selectively react with the peptide (18-20). 
For example, in a recent study peptides containing three cysteine residues 
separated by several random amino acid residues were fused to the phage pIII 
protein and reacted with tris-(bromomethyl)benzene to form bicyclic peptide 
libraries on phage (19). Another way to modify phage-displayed peptides is 
attachment of both the substrate peptide and the modifying enzyme onto the 
phage surface so that the enzyme catalyzes the formation of the product on 
phage. This method has been used to engineer enzymes catalyzing desired 
reactions through directed mutagenesis (21-22). Finally, the third method that 
has been successful to modify the peptide displayed on phage is in vitro 
modification of the peptide by an enzyme (23). The drawbacks of these 
applications include the necessity of reconstitution of the enzyme activity in vitro, 
and efficient substrate recognition and/or appropriate folding of the enzyme 
attached to the phage surface. Therefore, a more efficient method to prepare 
post-translationally modified phage display peptide libraries in vivo would be 
valuable.  
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Previous studies showed that a naturally occurring enzyme in phage 
infected bacteria can modify peptides fused to a phage protein in vivo, which are 
then displayed on the newly formed phage (24). For example, phage designed to 
display a specific 15 amino acid long substrate on their pIII protein was 
biotinylated by the Escherichia coli (E. coli) enzyme called biotin holoenzyme 
synthetase (BHS; product of the birA gene) in vivo (25). Herein, we describe the 
display of the lantibiotic nisin on M13 phage by adapting a previously developed 
nisin production system, in which the precursor peptide NisA is modified by the 
enzymes NisB and NisC in E. coli (26). In this case, phage display of nisin was 
envisioned by heterologous expression of the precursor peptide NisA fused to a 
phage display protein, the modifying enzymes NisB and NisC, and the genes 
required for forming other phage components in E. coli. In this strategy, the NisA 
peptide fused to the phage display protein was expected to be modified in E. coli 
and be incorporated with the phage components into phage displaying the 
corresponding lantibiotic.   
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Figure 5.2 Posttranslational modifications in nisin biosynthesis. NisB dehydrates seven 
threonines/serines in NisA, whereas NisC forms five thioether crosslinks by Michael-type addition 
of cysteine thiols onto the dehydrated amino acids.  
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5.2 RESULTS 
5.2.1 Experimental design 
M13 phage contains five pIII proteins on M13 phage that are responsible 
for the attachment of phage on to the pilus of E. coli during the infection process 
with which the phage propagates. This protein is the most common protein used 
for display of peptides, however fusing a peptide onto pIII impairs its function. In 
conventional phage display, phagemid encodes for pIII proteins which are fused 
to the displaying peptide, whereas helper phage M13K07 or VCSM13 encode for 
wild type pIII sustaining the infection function. 
The phage display technique generally utilizes two main components. One 
is a phagemid or phasmid, which is a plasmid that contains an f1 origin of 
replication enabling single stranded DNA replication observed in f1 phage. In 
other words, a phagemid can replicate as a plasmid, and also can provide single 
stranded DNA that can be packaged into viral particles (Figure 5.3A). The 
second component is a helper phage M13KO7, which is an M13 phage derivative 
with the mutation Met40Ile in pII. This helper phage carries an origin of 
replication from the p15A plasmid and the kanamycin (Kan) resistance gene from 
Tn903 both inserted within the M13 origin of replication, thus disrupting the M13 
origin (Figure 5.3B) (27). M13KO7 is able to replicate in the absence of 
phagemid DNA. In the presence of a phagemid bearing a wild-type M13 or f1 
origin, single-stranded phagemid is packaged preferentially over helper phage 
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DNA and secreted into the culture medium. This strategy allows easy production 
of single-stranded phagemid DNA for mutagenesis or sequencing. 
 
 
Figure 5.3 Components of phage display. A) Phagemid is engineered to encode for a fusion 
protein to pIII (encoded by gIII). It consists of an origin of replication in E. coli (dsDNA ori; double 
stranded DNA origin) and the f1 origin that is used for propagation of phage. (B) Helper phage 
consists of a single stranded DNA encoding for phage proteins including pIII, which was used for 
display of the lantibiotic nisin in this study.  M13 K07 helper phage genome is shown in red. Other 
genes on the genome are not shown. In this study, phagemid pSEX81 was used for N-terminal 
display. 
 
*Amp
R
: Ampicillin resistance gene, gIII: gene III, pIII: protein III, Kan
R
: Kanamycin resistance 
gene.  
 
 
 
In phage display, a desired peptide is presented on a phage surface 
protein by infection of the bacteria (for example E. coli cells), which are harboring 
a phagemid containing a fusion gene encoding of the display peptide fused to a 
phage surface protein, by the helper phage (Figure 5.4). This approach allows 
expression of phage proteins and peptide-phage protein fusion in E. coli, which 
results in the assembly of phage displaying peptide-phage protein on their 
surfaces. In addition, preferential packaging of the phagemid over helper phage 
DNA is favored as packaging of wild-type M13 or f1 origin on the phagemid is 
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more efficient than packaging using the origin of replication from P15A on the 
helper phage genome (Figure 5.4).  
 
 
Figure 5.4 Phage propagation in M13 phage display via helper phage.  
 
Peptides can be displayed either at the N-terminus or C-terminus of a 
phage coat protein (16). In this project, C-terminal display was chosen by using 
pJF3H phagemid, because C-terminal display exposes the modified-core region 
for direct interaction with a ligand of interest without interference of the leader 
peptide. The pJF3H phagemid enables peptide display at the C-terminus of a 
small peptide called Fos (Fos peptide: ~6.2 kDa), which dimerizes with the Jun 
peptide fused to the N-terminus of truncated pIII on the phage surface (22, 28). 
Therefore, this method allows for fusion of the peptide of interest with a small 
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protein rather than fusion with a big protein such as pIII (~42.5 Da), which can be 
important in substrate recognition of the modifying enzymes. Previous studies 
showed that addition of N-terminal tags such as histidine tags to the lanthipeptide 
precursor peptides did not prevent the activity of lanthipeptide synthetases (29). 
Therefore, the modifying enzymes were expected to accept their substrates 
fused to the Fos peptide.   
Phage propagates at 30 ºC instead of 18 ºC, which is the temperature 
used for the E. coli coexpression system described for the lantibiotics employed 
in this study (12, 26). Therefore, one potential concern was incomplete 
modification of the peptides displayed on phage due to non-functioning enzymes 
at 30 ºC. In order to test whether the enzymes can work at 30 ºC, nisA was 
coexpressed with nisB and nisC at 30 ºC. Analysis of the isolated NisA peptide 
by MALDI-ToF MS showed that the NisA was completely modified demonstrating 
that this temperature can be successfully employed for nisin production. 
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Figure 5.5 Phage display using pJF3H phagemid. The phagemid pJF3H allows for display 
through the dimerization of Jun and Fos peptides. Jun peptide displayed on pIII protein dimerizes 
with fos-peptide fusion through two disulfide bonds. 
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5.2.2 C-terminal display of nisin via pJF3H phagemid 
The gene encoding the precursor peptide NisA was successfully cloned 
into phagemid pJF3H. Also, a flag-tag was added to the N-terminus of the 
peptide to observe the peptide display with western blotting or enzyme-linked 
immunosorbent assay (ELISA). Nisin was displayed on phage by first 
coexpression of nisB and nisC from pACYCDuet-1, and the fos-nisA fusion from 
the pJF3H phagemid by induction with 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 3 hours, followed by infection of cells with 
helper phage M13KO7. Then, the cells were collected by centrifugation and 
transferred to new media lacking IPTG but containing the appropriate antibiotic, 
and cells were grown overnight at 30 ºC for phage to be produced. Then, phage 
was isolated from the culture medium by PEG precipitation and analyzed with 
different techniques.  
Western blot analysis with anti-flag antibody successfully detected the 
Fos-Flag-NisA (~13.5 kDa) fusion peptide that was detached from Jun-pIII 
protein by disrupting the disulfide bond between Jun and Fos by addition of the 
reducing agent DTT (Figure 5.6A). In addition, western blot analysis with anti-pIII 
antibody identified two bands, Jun-pIII and wild type pIII, which are required for 
display and infection respectively (Figure 5.6B). These results show that phage 
can proliferate under coexpression conditions, and that it can display the NisA 
precursor peptide effectively.  
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Figure 5.6 Analysis of phage produced from E. coli coexpressing nisA, nisB, and nisC. (A) 
Western blot analysis with anti-flag tag antibody, (B) Western blot analysis with anti-pIII antibody. 
 
 In order to test whether post-translational modifications were incorporated 
on the NisA precursor peptide, a custom-made commercial antibody was raised 
in a rabbit towards nisin, followed by purification with immobilized nisin and 
removal of antibodies recognizing immobilized unmodified NisA precursor 
peptide. Therefore, the antibody was expected to only bind to mature nisin but 
not unmodified NisA.  
 The core region of NisA can be cleaved by trypsin at positions 12 and 22 
as shown in red in Figure 5.7A. However, when post-translational modifications 
are introduced, trypsin does not readily cleave the core peptide (30). Should NisB 
and NisC modified peptide be incorporated into the phage, trypsin protease 
digestion of the phage obtained by the coexpression studies was expected to 
release the modified nisin into the solution where it could be recognized by the 
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anti-nisin antibody. On the other hand, if the precursor peptide NisA is not 
processed by NisB and NisC, treatment with trypsin would cause the core region 
to be digested into three pieces not recognized by the antibody. In addition, anti -
nisin antibody was able to recognize NisA modified by NisB and NisC, even 
though leader peptide was attached, providing another avenue to test for 
successful modification by NisB and NisC.  
 
 
 
 Figure 5.7 Western blot analysis with anti-nisin antibody. (A) Structure of nisin. Trypsin 
cleavage sites within nisin are shown in red. When modifications are introduced trypsin does not 
readily cleave after these two lysines. (B) Western blot analysis, lane 1: NisA peptide digested 
with trypsin, lane 2: Peptide obtained from coexpression of nisA with nisB digested with trypsin; 
lane 3: Peptide obtained from coexpression of nisA with nisB and nisC and digested with trypsin; 
lane 4: Authentic nisin. A 12%, tris-glycine gel blotted onto a PVDF membrane was used.    
 
 
 The selective binding of the anti-nisin antibody to post-translationally 
modified NisA and nisin was tested by western blot analysis with trypsin digested 
peptides, including unmodified NisA, NisB-modified NisA, NisA modified by NisB 
and NisC, and authentic nisin (Figure 5.7B). The results showed that anti -nisin 
antibody successfully detects NisA modified by NisB and NisC and treated with 
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trypsin, as well as authentic nisin but neither unmodified NisA nor NisB-modified 
NisA. This observation clearly shows that the anti-nisin antibody can be used for 
detection of nisin displayed on phage. Thus, phage displaying unmodified NisA 
and phage obtained from coexpression studies were prepared in parallel, 
digested by trypsin, and analyzed by anti-nisin antibody. Western blot analysis 
detected nisin from the phage obtained by coexpression but not in NisA-
displaying phage (Figure 5.8).  
 
 
Figure 5.8 Analysis of phage. Western blot analysis of lane 1: NisA-displaying phage, lane 2; 
NisA-displaying phage treated with trypsin, lane 3: Phage obtained from the coexpression of nisA 
with nisB and nisC; lane 4: Phage obtained from the coexpression of nisA with nisB and nisC and 
subsequent digestion with trypsin. 
 
Characterization of post-translational modifications on phage is also 
possible by mass spectrometry analysis as recently described (31). Purification 
of phage from PEG, which is used to precipitate phage from the growth medium, 
is needed for identification of the peptides by mass spectrometry. Here, the 
purification process of phage was simplified to one step, which involved C18 
solid phase extraction (SPE) purification after trypsin digest of the phage, rather 
than using a size exclusion column to separate the phage from PEG, which was 
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followed by filtration to separate the protease digested peptide (31). MALDI-ToF 
mass spectrometry was used to analyze trypsin-digested phage peptides eluted 
from the SPE column. The MS data are consistent with the mass of nisin (1-32) 
(3154 Da), which does not have the two C-terminal amino acids, in the samples 
obtained from the coexpression system but not from NisA-displaying phage 
(Figure 5.9 A, B). This degradation product of nisin is commonly observed as a 
consequence of hydrolysis of dehydrated serine at position 33 (32).  
 
 
Figure 5.9 Mass spectrometry analysis of trypsin-digested phage followed by C18 SPE 
purification. (A) Phage obtained from coexpression studies with nisA, nisB, and nisC is shown in 
red, whereas phage displaying unmodified NisA is shown in black; (B) Zoom in of the sample 
shown in red in (A). (C) Iodoacetamide (IAA) assay of trypsin-digested phage obtained from 
coexpression studies with nisA, nisB, and nisC.  
+
Calculation of the mass for NisA (1-32) + 2 * IAA; 3154 + 2 * 57 = 3268 Da, Obsrvd: 3268 Da.  
 
 
To investigate whether the displayed NisA peptide was fully-cyclized by 
NisC, iodoacetamide (IAA), a thiol alkylating agent that induces a mass increase 
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upon reaction with cysteine thiols, was reacted with this peptide in the presence 
of a reducing agent. The mass spectrometry analysis demonstrated two IAA 
additions to the peptide suggesting that two cysteines were not cyclized in 
nisin(1-32) (Figure 5.9C). Evaluation of antimicrobial activity of this product 
resulted in a faint zone of inhibition in an agar diffusion assay with B. subtilis 
6633, whereas no zone of inhibition was observed for peptide obtained from 
trypsin digestion of NisA-displaying phage, which was purified and concentrated 
with a SPE column.  
The pJF3H phagemid uses the sec-pathway to direct both Fos-NisA and 
Jun-pIII fusions into the periplasmic space. The sec-pathway transports unfolded 
proteins either post- or co-translationally through use of different mediators SecB 
and SRP, respectively (33). SecA accepts the unfolded proteins and threads 
them through the transmembrane channel at SecY that is known to not accept 
molecules larger than 2.8 nm in diameter (34). On the other hand the twin-
arginine transport (tat) pathway, another major export pathway in E. coli, is 
known to transport large molecules such as proteins, which are fully-folded in the 
cytoplasm (35) allowing more time in the cytoplasm before the export (36). 
Therefore, in order to display fully-modified nisin on phage, I aimed to transport 
nisin via the twin arginine transport (tat)-pathway. This strategy would increase 
the contact time between NisA and the enzymes NisB and NisC before the 
export into the periplasm, and help the formation of fully-modified nisin before the 
export.  
187 
 
For this purpose, a previously described system using the tat-pathway for 
display of peptides on phage was employed (37). In this experimental design, the 
pJF3H plasmid was modified to export the Fos-NisA fusion through the tat-
pathway by placing a TorA signal sequence in the place of the OmpA signal 
sequence, while the gene encoding for the Jun-pIII fusion was kept the same 
such that it was transported via the sec-pathway by employing the PelB signal 
sequence as in the case of the original pJF3H.  
Nisin was displayed on phage through the tat-pathway by first 
coexpression of nisB and nisC from pACYCDuet-1 and nisC in pCDFDuet-1, and 
the torA-fos-nisA fusion from the pJF3H phagemid by induction with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3-4 hours, followed by infection 
of cells with helper phage M13KO7. Then, the cells were collected by 
centrifugation and transferred to new media lacking IPTG but containing the 
appropriate antibiotics, and cells were grown overnight at 30 ºC for phage to be 
produced. Then, phage was isolated from the culture medium by PEG 
precipitation and analyzed with different techniques. Mass spectrometry analysis, 
which was performed after trypsin digestion followed by C18 SPE column 
purification as described above, showed the mass corresponding to nisin(1-32), 
suggesting that modified NisA can be displayed on phage through export by the 
tat-pathway. Furthermore, an IAA assay confirmed that the thioether crosslinks 
on nisin(1-32) were successfully introduced on the peptide displayed on the 
phage (Figure 5.10A). Finally, bioassay analysis of the peptide towards B. subtilis 
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6633 revealed a zone of growth inhibition, further verifying the formation of the 
lanthionine rings on nisin(1-32) (Figure 5.10B). Further experiments will be 
performed where Ser33 is mutated into an alanine to display the full lenght 
sequence of nisin on the M13 phage.  
 
 
 
Figure 5.10. Analysis of trypsin-digested phage produced using tat-pathway. (A) Mass 
spectrometry analysis of iodoacetamide-treated, trypsin-digested and SPE-purified (C18) phage 
obtained from coexpression studies with tat-fos-nisA, nisB, and nisC; (B) Growth inhibition zone 
formation assay with peptide obtained by trypsin-digested and SPE-purified (C18) phage 
obtained from coexpression studies with tat-fos-nisA, nisB, and nisC at 30 ºC (spot 2). Spot 3 is 
trypsin-digested and SPE-purified (C18) phage obtained from coexpression studies with tat-fos-
nisA, nisB, and nisC at 18 ºC (negative control). Spot 1 is authentic nisin.  
+
Calculation of the mass for NisA (1-32) + Na
+
 + H ; 3154 + 23 + 1 = 3178 Da, Obsrvd: 3177 
Da.  
 
5.2.3 Phage display of other lanthipeptides 
As mentioned above, phage propagates at 30 ºC instead of 18 ºC which is 
the temperature used for the E. coli coexpression systems described for 
cinnamycin, lacticin 481, haloduracin, and prochlorosins (12, 26). Therefore, one 
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possible concern was the incomplete modification of the peptides displayed on 
phage due to non-functioning enzymes at this temperature (e.g. because of 
solubility problems). In order to test whether the biosynthetic enzymes of these 
lanthipeptides could work at 30 ºC, several previously reported coexpression 
systems were evaluated:  lctA and lctM; cinA(A–1K) with cinM, cinX and cinorf7; 
halα with halM; and procA2.8 with procM. Analysis of the purified peptides by 
MALDI-ToF MS showed that the LctA, CinA, Halα and ProcA2.8 peptides were 
all completely modified at 30 ºC demonstrating that this temperature can be 
successfully employed for these enzymes.  
In phage display the peptide/protein to be displayed is directed to the 
periplasmic space of E. coli by a signal sequence such as PelB or OmpA at the 
N-terminus. Once the peptide/protein is translocated into the periplasmic space, 
this signal sequence is removed by periplasmic proteases and phage assembly 
takes place. Therefore, another issue to address for the display of lantibiotics on 
phage was the possible incomplete modification of the precursor peptide, which 
might arise if the transport of the precursor peptide to the periplasmic space does 
not allow enough time for enzyme substrate interaction in the cytoplasm. To test 
whether CinM, CinX and Cinorf7 function is impaired by periplasmic 
translocation, pelB-his6-cinA(A–1K) was cloned into the first multiple cloning site 
(MCSI) of pRSFDuet-1 containing the cinM gene in the MCSII. Furthermore, cinX 
and cinorf7 were inserted into pACYCDuet-1 as described in chapter II. Then, 
pelB-cinA(A–1K) together with cinM, and cinX, and cinorf7 in pACYCDuet-1 were 
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heterologously expressed in E. coli. The periplasmic fraction was separated from 
the cytosolic fraction by disrupting only cell membrane by osmotic pressure, and 
the CinA peptide was purified by IMAC followed by C18 SPE purification. The 
MALDI-ToF MS analysis of the peptide from the periplasmic fraction after LysC 
treatment showed four dehydrations and a hydroxylation of the core region. 
Cyclization by the IAA assay could not be performed due to low amount of 
peptide. In comparison, no peptide was identified in the cytoplasmic fraction of 
the cells.  
 After eliminating our concerns about this approach with at least one 
system, phage designed to display lacticin 481 and cinnamycin were prepared as 
follows. The genes encoding for the precursor peptide CinA (A–1K) of 
cinnamycin or LctA of lacticin 481 were cloned into pJF3H with a flag tag fused to 
the N-terminus of the peptides to observe the displayed peptide with western 
blotting analysis or ELISA using anti-flag tag antibody. E. coli SS320 cells were 
transformed with pCDFDuet-1 containing the cinM gene, pACYCDuet-1 
containing the cinX and cinorf7 genes, and the pJF3H phagemid containing the 
fos-cinA fusion gene for cinnamycin phage preparation. Similarly, E. coli SS320 
was transformed with lctM-containing pACYCDuet-1, and fos-lctA containing 
pJF3H phagemid for lacticin 481 phage preparation. After phage production was 
induced with 0.1 mM IPTG, western blot analysis of the phage produced did not 
display the corresponding peptides as no bands were detected by anti-flag 
antibody. Surprisingly, western blot analysis with anti-pIII antibody also did not 
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detect the display of Jun-pIII on the phage. To investigate whether selected IPTG 
levels were causing problem or not, the cells were inducted at different IPTG 
levels after infection with M13K07 helper phage and cultures were grown 
overnight at 30 ºC. Then, the phage were analyzed by sandwich ELISA where 
anti-flag antibody was immobilized on the surface of a 97-well plate and binding 
of phage onto the plate was analyzed by a secondary antibody recognizing M13 
phage. Unfortunately, the ELISA analysis of the cinnamycin and lacticin 481 
phage prepared as described at different IPTG concentrations yielded no or low 
display levels, compared to the high signal per phage arising from the nisin 
phage coexpression system as described above (Figure 5.11).  
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Figure 5.11. ELISA to determine display levels of CinA, LctA, and NisA on phage produced 
by coexpression. Anti-flag antibody-coated ELISA plate was treated with phage produced by 
cinnamycin, lacticin 481, and nisin coexpression systems. Phage employed in this study was 
prepared by 0 mM (samples 1 and 5), 0.1 mM (samples 2 and 6), 0.5 mM (samples 3 and 7), and 
1 mM (samples 4 and 8) IPTG induction of the helper phage infected E. coli SS320 cells, which 
were transformed with pJF3H phagemid containing fos-CinA(A–1K), pCDFDuet-1 containing the 
cinM gene, and pACYCDuet-1 containing the cinX and cinorf7 genes (samples 1-5). IPTG was 
added to helper phage infected E. coli SS320 cells, which were transformed with pJF3H 
phagemid containing fos-LctA, and pACYCDuet-1 containing LctM gene (samples 5-8). Sample 9 
is E. coli SS320 cells, which were transformed with pJF3H phagemid containing fos-nisA, and 
pACYCDuet-1 containing nisB and nisC genes. Sample 10 is a negative control where phage 
was prepared by 0.1 mM IPTG induction of helper phage infected or E. coli SS320 cells which 
were transformed with pJF3H phagemid containing fos-HalA with no flag tag.  
 
5.2.4 Construction of cyclic peptide libraries using ProcM  
  Initially, we aimed to design phage display libraries by use of the highly 
promiscuous enzyme ProcM. This enzyme has 29 natural substrates composed 
of a highly conserved leader domain attached to highly diverse core regions 
containing serines/threonines and cysteines at different positions (38). Therefore, 
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ProcM was considered a good candidate for constructing a library of peptides 
containing two lanthionine crosslinks (Figure 5.12).  
 
 
 
 
Figure 5.12 Peptide design for cyclic peptides containing a double ring structure. ProcA2.8 
leader peptide was attached to a core region which could lead to the formation of two rings.  
 
  The peptides in the library consisted of the ProcA2.8 wild type leader 
sequence attached to a core region coding for C(X)5S MPP S(X)5 C, where X is 
an amino acid encoded by the NWY degenerate codon. The peptides were 
encoded in a pRSFDuet-1 vector containing the gene encoding for ProcM 
(prepared by PhD student Xiao Yang). The NWY codon was selected for the 
library because it does not encode for Cys or Ser/Thr, and therefore would not 
complicate lanthionine formation at the designed positions. Twelve clones were 
investigated as shown in Table 5.1, and peptides 2.8-5, 2.8-9, and 2.8-10 were 
coexpressed with ProcM and purified by IMAC followed by RP-HPLC. The 
analysis of the peptides by MALDI-ToF tandem mass spectrometry after GluC 
endoproteinase cleavage showed that ProcM dehydrated and cycl ized all three 
peptides (Figure 5.13A, B, and C).  
ProcA 2.8 
leader 
AACXXXXSMPPSXX
XXC 
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Figure 5.13 Analysis of peptide (A) 2.8-5, (B) 2.8-9, and (C) 2.8-10 modified by ProcM in 
vivo. Left: Mass spectrometry analysis of the peptides modified by ProcM in E. coli and treated 
with GluC, Right: Tandem mass spectrometry analysis of the peptides.  
   
+ 
Calculated mass for M – 2 H2O + H for (A) 2460.6 – 2 * 18 + 1 = 2425.6 Da, (B) 2438 – 2 * 18 
+ 1 = 2403 Da, (C) 2468.8– 2 * 18 + 1 = 2432.8 Da, Obsrvd (A) 2424.1 Da, (B) 2402 Da, (C) 2432 
Da.  
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5.2.5 ProcM Promiscuity Test  
  We initially started our phage display studies by use of the pSEX81 
phagemid. In phage display using this phagemid, the peptides are displayed on 
the phage surface while they are attached to the N-terminus of the pIII protein. 
This fusion protein contains a signal sequence PelB at the N-terminus to direct it 
to the periplasmic space, where the phage assembly takes place. One concern in 
this system is that the pIII protein (~45 kDa) at the C-terminal of the precursor 
peptide might affect the dehydration and cyclization activities of lanthionine 
synthetase used.  
  Previously, I was able to show that ProcM could successfully modify 
peptide 2.8-1 and introduce two lanthionine rings.  To test the ability of ProcM to 
process a fusion protein of 2.8-1 and pIII, a gene encoding for the fusion of 2.8-1 
peptide-pIII, with an N-terminal flag tag and a factor Xa cleavage site separating 
the precursor peptide and the pIII protein, was cloned into the first cloning site of 
a pRFSDuet-1 vector containing procM in MSC II (Figure 5.14A). After 
heterologous coexpression of the genes encoding the fusion of 2.8-1 peptide-pIII 
and ProcM using this vector in E. coli, the peptide-pIII fusion was purified by 
IMAC column followed by PD10 desalting.  MALDI-ToF MS analysis of the 
peptide after Factor Xa and GluC endoproteinase cleavage showed that two 
dehydrations were introduced into the peptide (Figure 5.14B). Tandem mass 
spectrometry analysis (MALDI-ToF) of the peptide also confirmed that the rings 
were successfully formed (Figure 5.14D).  However, IAA treatment of the 
196 
 
peptide-protein fusion followed by Factor Xa and GluC cleavage also showed 1 
and 2 IAA additions to the core region showing that cyclization was not complete 
(Figure 5.14C). To conclude, ProcM was able to process precursor peptide 2.8-1 
when it was attached to the N-terminus of the pIII protein but with low efficiency 
in cyclization.  
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Figure 5.14 Analysis of 2.8-1-pIII modified by ProcM in vivo. (A) Schematic representation of 
peptide 2.8-1 attached to pIII, (B) Mass spectrometry analysis of the 2.8-1-pIII fusion after GluC 
and Factor Xa cleavage; (C) Iodoacetamide analysis of the peptide; (D) Tandem mass 
spectrometry analysis of GluC- and Factor Xa-cleaved peptide.  
+
Calculated mass for M – 2 H2O + H: 2861 – 2* 18 + 1 = 2825 Da, Obsrvd; 2826 Da; M – 2 
H2O + IAA + H; 2825 + 57 = 2882 Da, Obsrvd; 2882 Da; M – 2 H2O + 2 * IAA + H; 2882 + 57 = 
2939 Da, Obsrvd; 2939 Da.  
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5.3 DISCUSSION 
  In this chapter, the lantibiotic biosynthesis machinery of nisin, cinnamycin, 
and lacticin 481 were employed to attempt display of these peptides on the M13 
phage. It was shown that nisin(1-32) can be displayed on phage by the export of 
a Fos-NisA fusion through the tat-pathway while the Jun-pIII fusion was 
transported via the sec-pathway. In addition, it was demonstrated that fully-
dehydrated NisA(1-32) peptide containing three thioether rings instead of the five 
observed in wild-type nisin structure can be displayed on phage using the sec-
pathway.  
 This observation can be the result of several reasons. Firstly, it is possible 
that the sec-pathway is incapable of transporting fully modified peptide with large 
rings to the periplasmic space. Previous studies, which attempted nisin 
production using export via the sec-pathway in its producing strain Lactococcus 
lactis, and in B. subtilis, failed to isolate any bioactive material although fully-
dehydrated NisA peptide was obtained from this system (39). In another study 
however, the sec-pathway in E. coli was shown to export post-translationally 
biotinylated and phosphopantetheinylated recombinant proteins successfully, 
suggesting that sec-transport mechanism can carry post-translationally modified 
molecules across the membrane (40). In an experiment performed by Kenton 
Hetrick, a PhD student in our laboratory, a large amount of modified NisA was 
encountered inside cells coexpressing the genes fos-nisA and jun-pIII in pJF3H 
together with nisB and nisC in pACYCDuet-1. This experimental set up 
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resembles that of nisin displaying phage, and thus indicates that modified NisA 
accumulates in the cell because it is not able to efficiently pass through the pores 
provided by the sec-pathway components. The dimensions of the solvent-
accessible surface of nisin are about 2.2 nm by 2.7 nm by 4.7 nm (41). 
Furthermore, the A and B rings of nisin form a horseshoe-like structure at the N-
terminus causing an arrangement of a large segment that is 2.2 nm by 2.7 nm 
wide. On the other hand, the sizes of individual lanthionines on nisin range 
between 0.5-1.0 nm as observed from the NMR structure of nisin bound to lipid II 
(15). The SecY pore involved in the sec-pathway can accommodate structures of 
at least 2.2-2.4 nm (34). These findings suggest that the sec-pathway is able to 
incorporate and export each lanthionine crosslink on NisA when linear peptide is 
considered. However, the three-dimensional folding of A and B rings would 
prevent the passage of the modified peptide. Secondly, the fast translocation of 
the peptide to the periplasmic space by the sec-pathway might not allow 
sufficient time for full modification by NisC.  
  In order to increase the interaction time with NisA and NisC, a previous 
study which showed that post-translationally modified recombinant proteins can 
be exported via the sec-pathway in E. coli (40) was used. In this study, sodium 
azide was added to the culture medium that increases the modification efficiency, 
as sodium azide specifically inhibits the ATPase activity of the motor protein 
SecA which drives the translocation of preproteins across the cytoplasmic 
membrane (42). Therefore, it could be possible that the incomplete modification 
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observed in the nisin coexpression system can be overcome by use of sodium 
azide in the growth medium. However, in the experiments carried out with 
sodium azide, the cells died, thus this attempt also failed. Our previous 
experiments showed that phage can be formed at 18 ºC even though the 
optimum temperature for multiplication is 30 ºC. Thus, decreasing the 
temperature of coexpression to 18 ºC might also be helpful to slow down the 
translocation of the peptide across the inner membrane, giving more time for 
substrate-enzyme interaction. However, no improvements in the formation of 
rings were observed in phage prepared at 18 ºC. Alternatively, addition of 
multiple copies of the genes for lantibiotic biosynthesis was previously shown to 
increase the efficiency of modification simply due to a higher amount of enzyme 
being expressed in E. coli (43). Therefore, addition of more copies of nisC into 
the coexpression system was attempted; however this approach also did not 
result in the display of fully-cyclized nisin on phage. Overall, the fact that three of 
the five rings were formed on NisA suggests that the sec-pathway can be used to 
export peptides with smaller solvent exposed surfaces.  
  Both tat- and sec- transport approaches employed to display nisin on 
phage resulted in a degradation product of nisin at dehydrated Ser33, which is a 
common degradation pathway for nisin that is usually observed at higher pH (32). 
However, this breakdown product has not been observed in the coexpression 
studies described before (26). The pH of the periplasmic space directly depends 
on the pH of the exterior medium/solution (44). In our experiments we observed 
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that the growth media is becoming more alkaline after the coexpression, which 
might be the reason for the formation of the degradation product. However, our 
attempts to grow phage in phosphate buffered media failed to display nisin.  
   Phage display of lanthipeptides will enable the preparation of thioether-
containing cyclic peptide libraries to advance or alter current properties of 
lantibiotics and/or to select for binders to new targets. Phage display of nisin may 
be useful for finding binders to molecules with structures similar to the 
pyrophosphate on lipid II and/or to solve nisin`s instability problem at 
physiological conditions by forming phage libraries displaying nisin-like peptides. 
To this end our laboratory has successfully produced prochlorosins, cinnamycin, 
haloduracin, and lacticin 481 and the processing enzymes have been shown to 
have high tolerance for different substrates (12, 26). Especially ProcM, the 
lanthionine synthetase of prochlorosins, may be very valuable to prepare 
lanthionine-containing peptide libraries as it can naturally process 29 substrates 
with rings that vary in size and topology (45-46). Therefore, this technique can be 
expanded for phage display of other lanthipeptides, which would enable 
preparation of cyclic peptide libraries with thioether crosslinks providing different 
scaffolds.  
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5.4 MATERIALS 
  Oligonucleotide primers for mutagenesis were synthesized by Operon 
Technologies. Taq and Platinum Pfx DNA polymerases, DpnI, restriction 
endonucleases, and bacteriophage T4 DNA ligase were purchased from 
Invitrogen. Fusion DNA polymerase was purchased from New England Biolabs 
(NEB). Cloning vectors (pET and pDuet) were obtained from Novagen. The 
phagemids pSEX81 and pJF3H were kindly provided by Prof. Jun Yin`s 
laboratory at the University of Chicago. Gel extraction, plasmid mini-prep, and 
PCR purification kits were purchased from Qiagen. M13K07 helper phage 
(NO315S), and anti-M13 pIII monoclonal antibody (E8033S) were obtained from 
NEB. Monoclonal anti-flag M2 antibody produced in mouse was purchased from 
Sigma (F3165). Anti-nisin antibody was ordered from Thermo Fisher Scientific by 
submitting 10 mg of purified nisin and purified fully modified NisA. ELISA plates 
(Nunc), and substrate for enzyme horseradish peroxidase (HRP) in ELISA 
studies, 1-step ultra TMB-ELISA (34028), was obtained from Thermo Fisher 
Scientific. Substrate for the HRP for western blot analysis was clarity western 
ECL substrate from Bio-rad (170-5060). All strains were grown in media acquired 
from Difco laboratories. Other items procured include isopropyl-1-thio-D-
galactopyranoside (IPTG, CalBiochem), iodoacetamide (IAA, Acros Organics), 
tris(2-carboxyethyl) phosphine hydrochloride (TCEP, Aldrich), and dithiothreitol 
(DTT, Sigma). Endoproteinases LysC, GluC, and Factor Xa were purchased from 
Roche Applied Science.  
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5.5 GENERAL METHODS  
 Molecular biological manipulations were carried out using standard 
techniques (47). PCR was performed using an automatic thermocycler (PTC 150, 
MJ Research) and DNA sequencing was performed at the Biotechnology Center 
of the University of Illinois at Urbana-Champaign (UIUC). E. coli DH5α cells 
(UIUC Cell Media Facility) and E. coli BL21 (DE3) cells (Stratagene) were used 
for plasmid preparation and protein expression, respectively. MALDI-ToF MS 
analyses were conducted at the Mass Spectrometry Facility (UIUC) using an 
UltrafleXtreme TOF/TOF (Bruker Daltonics). Liquid chromatography electrospray 
ionization tandem mass spectrometry (LC/ESI-MS/MS) was carried out and 
processed using a Synapt ESI quadrupole ToF Mass Spectrometry System 
(Waters) equipped with an Acquity Ultra Performance Liquid Chromatography 
(UPLC) system (Waters).  ELISA readings were performed with  a Synergy H4 
reader.  
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5.6 EXPERIMENTAL METHODS 
5.6.1 Cloning  
5.6.1.1 Cloning of the nisin coexpression system (NB6, 34-35) 
  A gene encoding for NisA attached to a flag tag at its N-terminus was not 
available as template, therefore a two step PCR was performed to clone the 
gene into pJF3H. The primers Flag_NisA pJF3H_FP-1 and 
NisA_pJF3H_NotI_RP (see Table 5.2) were used to amplify nisA from 
nisA/pRSFDuet-1 (obtained from previous PhD student Dr. Neha Garg). The size 
of the final PCR product was confirmed by 2% agarose gel electrophoresis, and 
the product was purified using a QIAquick gel purification kit (QIAGEN). Then, a 
second PCR was conducted using Flag CinA-K/ NisAFP2 pJF3H_BssHII _FP 
and NisA_pJF3H_NotI_RP as primers and the previous PCR product as a 
template (Table 5.2). The PCRs (50 μL) included 1x HF buffer (Finnzymes), 
DMSO (4%), Fusion DNA Polymerase (Finnzymes) (0.02 unit/μL), dNTPs (1 
mM), template DNA, and primers (1 μM each). The amplification was conducted 
via 30 cycles of denaturing (98 οC for 10 s), annealing (60 οC for 30 s), and 
extending (72 οC for 15 s). The final PCR product was confirmed by 2% agarose 
gel electrophoresis, and the products were purified using QIAquick PCR 
purification kits (QIAGEN). The resulting DNA fragment and the pJF3H vector 
were digested in 1 x NEBuffer 4 (New England Biolabs) with BssHII and NotI-HF 
at 37 ºC (for 15 h). The digested products were purified by agarose gel 
electrophoresis followed by use of a QIAquick gel extraction kit (QIAGEN). The 
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resulting DNA insert was ligated with the digested pJF3H vector at 16 ºC for 15 h 
using T4 DNA ligase. The ligation reaction mixture was diluted 5 times with water 
prior to transformation. E. coli DH5α cells were transformed with the ligation 
product via heat shock, plated on LB-ampicilin/0.2 % glucose agar plates, and 
grown at 37 ºC for 15 h. Colonies were picked and incubated in 5 mL of LB-
ampicilin medium at 37 ºC for 15 h, followed by isolation of the plasmids using a 
QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmids 
were confirmed by DNA sequencing. The pACYCDuet-1 vector containing nisB 
and nisC in MCSI and MCSII, respectively, was obtained from Noah Bindman in 
the van der Donk laboratory.   
5.6.1.2 Cloning of cinA(A–1K) into pSEX81 and pJF3H, cloning of nisA into 
pSEX81, and factor Xa cleavage site insertion (NB6, p48-65) 
 Cloning of cinA(A–1K)  into pSEX81 was performed by use of the primers 
Flag_CinA-K/NisA_FP2_NcoI pSEX81 FP and CinA-K_NotI pSEX81_RP (Table 
5.1), whereas cloning into pJF3H was performed by use of Flag CinA-
K/NisA_FP2_pJF3H_ BssHII _FP and CinA-K_pJF3H_NotI_RP as forward and 
reverse primers. The PCRs (50 μL) included 1x HF buffer (Finnzymes), DMSO 
(4%), Fusion DNA Polymerase (Finnzymes) (0.02 unit/μL), dNTPs (1 mM), 
template DNA, and primers (1 μM each). As a template, flag-tag-
cinAK/pRSFDuet-1, whose construction was described in chapter II, was used. 
The amplification was conducted via 30 cycles of denaturing (98 οC for 10 s), 
annealing (60 οC for 30 s), and extending (72 οC for 15 s). The final PCR product 
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was analyzed by 2% agarose gel electrophoresis, and the products were purified 
using QIAquick PCR purification kits (QIAGEN). The resulting DNA fragment and 
the corresponding vector were digested in NEBuffer 4 at 37 ºC for 15 h (New 
England Biolabs) with NcoI-HF and NotI-HF (for pSEX81) and, BssHI and NotI-
HF (for pJF3H), respectively. The digested products were purified by agarose gel 
electrophoresis followed by use of a QIAquick gel extraction kit (QIAGEN). The 
resulting DNA insert was ligated with the digested vector at 16 ºC for 15 h using 
T4 DNA ligase. The ligation reaction mixture was diluted 5 times with water prior 
to transformation. E. coli DH5α cells were transformed with the ligation product 
via heat shock, plated on LB-ampicilin (for the plasmids pSEX81 and 
pJF3H)/0.2% glucose agar plates, and grown at 37 ºC for 15 h. Colonies were 
picked and incubated in 5 mL of LB-ampicilin medium at 37 ºC for 15 h, followed 
by isolation of the plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The 
sequences of the resulting plasmids were confirmed by DNA sequencing. 
  Since nisA encoding NisA with a flag tag at the N-terminus was not 
available for template, a two step PCR was performed to clone the gene 
encoding into pSEX81. For cloning into pSEX81, the primers 
Flag_NisA_pJF3H_FP-1 and NisA_NotI_pSEX81_RP were used to amplify nisA 
from nisA/pRSFDuet-1 (provided by PhD student Noah Bindman). The size of the 
final PCR product was confirmed by 2% agarose gel electrophoresis, and the 
product was purified using a QIAquick gel purification kit (QIAGEN). Then, a 
second PCR was conducted using Flag_CinA-K/NisA_FP2_NcoI_pSEX81_FP 
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and NisA_NotI_ pSEX81_RP as primers and the previous PCR product as a 
template. The digestion and ligation procedures were performed as explained 
above.  
  The factor Xa protease cleavage sequence was inserted between the 
leader and core regions of cinA(A–1K)  and nisA to form cinA-K-Xa and nisA-Xa 
by  Quikchange PCR. Briefly, the amplification from cinA(A–1K)-containing 
pSEX81 and nisA-containing pSEX81 was conducted via 30 cycles of denaturing 
(98 οC for 10 s), annealing (60 οC for 30 s), and extending (72 οC for 100 s) using 
appropriate mutant forward and reverse primers (see Table 5.2 for 
oligonucleotide sequences). The size of the PCRs (50 μL) included 1x HF buffer 
(Finnzymes), DMSO (4%), Fusion Hot Start High-Fidelity DNA Polymerase 
(Finnzymes) (0.04 unit/μL), dNTPs (2 mM), corresponding template (20 ng), and 
primers (1 μM each). The PCR product was checked on a 1% agarose gel and 
purified using a QIAquick PCR purification kit (QIAGEN). The resulting DNA was 
treated with DpnI at 37 οC for 15 h to digest the methylated template, and E. coli 
DH5α cells were transformed. The desired mutations were confirmed by DNA 
sequencing. 
5.6.1.3 Cloning of pelB-cinA(A–1K)-Xa, and pelB-cinA(A–1K) into 
pRSFDuet-1 
  The genes encoding for PelB-CinA(A–1K)-Xa and PelB-CinA(A–1K)  were 
cloned into the first MCS of pRSFDuet-1 containing a cinM in MCSII. For this 
purpose, PelB_CinAK/Xa_FP_Asc_I for_pRSFDuet_from_pSEX81 and CinA-
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K_pRSFDuet-1_HindIII_RP were used as forward and reverse primers (Table 
5.2). The PCRs (50 μL) included 1x HF buffer (Finnzymes), DMSO (4%), Fusion 
DNA Polymerase (Finnzymes) (0.02 unit/μL), dNTPs (1 mM), cinA(A–1K)-
containing pSEX81 or cinA(A–1K)-Xa-containing pSEX81 as template DNA (20 
ng), and primers (1 μM each). The amplification was conducted via 30 cycles of 
denaturing (98 οC for 10 s), annealing (60 οC for 30 s), and extending (72 οC for 
15 s). The size of the final PCR product was confirmed by 2% agarose gel 
electrophoresis, and the products were purified using a QIAquick PCR 
purification kit (QIAGEN). The resulting DNA fragment and pRSFDuet-1 
containing the gene encoding for CinM were digested in 1xNEBuffer 4 (New 
England Biolabs) with AscI and HindIII-HF at 37 ºC (for 15 h) respectively. The 
digested products were purified by agarose gel electrophoresis followed by use 
of a QIAquick gel extraction kit (QIAGEN). The resulting DNA insert was ligated 
with the digested vector at 16 ºC for 15 h using T4 DNA ligase. The ligation 
reaction mixture was diluted 5 times with water prior to transformation. E. coli 
DH5α cells were transformed with the ligation product via heat shock, plated on 
LB-kanamycin (kan) agar plates, and grown at 37 ºC for 15 h. Colonies were 
picked and incubated in 5 mL of LB-kan medium at 37 ºC for 15 h, followed by 
isolation of the plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The 
sequences of the resulting plasmids were confirmed by DNA sequencing. 
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5.6.1.4 Preparation of the constracts for peptides attached to the ProcA 
leader 2.8  
 Cloning of the genes encoding the library of peptides attached to the 
ProcA 2.8 leader peptide (Table 5.1) into pSEX81 was performed by using NcoI 
and NotI cut sites using the primers in Table 5.2, 
Flag_2.8_ProcA_ldr_pSEX81_NcoI_FP and 2.8_ProcA_ldr_Xiao_library_ 
pept._1_pSEX81_NotI_RP (or 2.8_ProcA_ldr_Xiao_ library_pept._1/Factor 
Xa/pSEX81_NotI RP) primers were used as forward and reverse primers to 
amplify the ProcA 2.8 leader peptide library 1 sequence from template 2.8-
peptide_1/pRSFDuet-1 provided by PhD student Xiao Yang in our group (see 
Table 5.2 for oligonucleotide sequences). The PCRs (50 μL) included 1x HF 
buffer (Finnzymes), DMSO (4%), Fusion DNA Polymerase (Finnzymes) (0.02 
unit/μL), dNTPs (1 mM), template DNA, and primers (1 μM each). The 
amplification was conducted via 30 cycles of denaturing (98 οC for 10 s), 
annealing (60 οC for 30 s), and extending (72 οC for 15 s). The final PCR product 
was confirmed by 2% agarose gel electrophoresis, and the products were 
purified using QIAquick PCR purification kits (QIAGEN). The resulting DNA 
fragment and the pSEX81 vector were digested in 1 x NEBuffer 4 (New England 
Biolabs) with NcoI-HF and NotI-HF at 37 ºC (for 15 h). The digested products 
were purified by agarose gel electrophoresis followed by use of a QIAquick gel 
extraction kit (QIAGEN). The resulting DNA insert was ligated with the digested 
pSEX81 vector at 16 ºC for 15 h using T4 DNA ligase. The ligation reaction 
210 
 
mixture was diluted 5 times with water prior to transformation. E. coli DH5α cells 
were transformed with the ligation product via heat shock, plated on LB-
ampicilin/0.2 % glucose agar plates, and grown at 37 ºC for 15 h. Colonies were 
picked and incubated in 5 mL of LB-ampicilin medium at 37 ºC for 15 h, followed 
by isolation of the plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The 
correct sequences of the resulting plasmids were confirmed by DNA sequencing.  
  Similarly, the genes encoding for peptide library 1 attached to pIII were 
cloned into pRSFDuet-1 containing procM between the NdeI and KpnI restriction 
sites. Flag 2.8_ldr_EcoRI_pRSFDuet-1_FP and pIII_pRSFDuet-1_AscI_RP were 
used as forward and reverse primers to amplify the DNA with 1-FactorXa-
pIII/pSEX81 as a template. The PCR conditions used were as indicated above. 
The resulting DNA fragment and the pRSFDuet-1 vector were digested in 1 x 
NEBuffer 4 (New England Biolabs) with EcoRI-HF and AscI at 37 ºC for 15 h. 
The digestion and ligation steps were performed as indicated above. E. coli 
DH5α cells were transformed with the ligation product via heat shock, plated on 
LB-kanamycin agar plates, and grown at 37 ºC for 15 h. Colonies were picked 
and incubated in 5 mL of LB-kanamycin medium at 37 ºC for 15 h, followed by 
isolation of the plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The 
sequences of the resulting plasmids were confirmed by DNA sequencing.  
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5.6.2 Preparation of phagemids for display of NisA, CinA, and LctA (NB10, 
p27, 29) 
  Electro-competent E. coli SS320 cells (50 μL) were transformed with 20 
ng of phagemid (pJF3H) containing the desired gene, and plated on a Amp (100 
mg/ml), Tet (5 mg/ml), 2% glucose LB plate. In this step, Amp is required for the 
phagemid, Tet is required for the F+ plasmid coding for the pili, which is needed 
for helper phage infection, and glucose is to prevent the expression of pIII since it 
slows down the cell growth overnight at 37 ºC. After the plates were incubated 
overnight at 37 οC, a colony was picked and grown in 5 mL of 2xYT media  (1.6% 
tryptone, 1.0% yeast extract, 0.5% NaCl, pH: 7, autoclaved) supplemented with 
Amp (100 mg/ml), Tet (5 mg/ml) and 2% glucose  with shaking. Then, 20 mL 
2xYT media was inoculated with 200 μL of the cells and the cells were grown 
until an O.D. of 0.5-0.6. Approximately 1x109 bacteria per mL and 1010 helper 
phage M13K07 (NEB, 10 μL for 1 ml) were added at a phage/cell ratio of ~10-20. 
Then, the culture was incubated at 30 οC for 20 min without shaking, followed by 
20 min with shaking at 30 οC. Infected cells were pelleted by centrifugation and 
resuspended in 2xYT medium (100 mL) supplemented with kanamycin (helper 
phage resistance) (50 mg/mL), ampicillin (100 mg/mL) and IPTG (0.1 mM) and 
grown for 15-18 h at 30 οC with shaking. The next day, cells were pelleted by 
centrifugation at 5000×g, and the phage particles in the supernatant were 
precipitated by adding poly(ethylene glycol) 8000 (PEG; 25 mL, 20%, w/v) and 
NaCl (2.5 M) followed by overnight incubation on ice. The next morning, the 
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precipitated phage was centrifuged for 30 min at 16,060 g. The supernatant was 
discarded, and the phage pellet at the bottom of the tubes was resuspended in 
phosphate buffered saline (PBS) buffer. Then, the phage was precipitated again 
with the PEG/NaCl addition and centrifuged for 30 min at 16 060g (13 000 rpm). 
The supernatant was discarded and, the purified phage was resuspended in PBS 
(2 mL). The phage was stored at 4 οC. Phage concentration measurement was 
roughly estimated by using this conversion formula:  O.D.268 = 1 for a solution 
containing 5x 1012 phage/mL.  
5.6.3 Phage preparation for nisin display (NB11, p84) 
  For coexpression studies to display nisin, electro-competent E. coli SS320 
cells (50 μL) were transformed with nisA-containing pJF3H, and pACYCDuet-1 
containing nisB and nisC, and plated on an Amp (50 mg/ml), Chl (25 mg/mL), Tet 
(5 mg/mL), and 2% glucose LB plate. After the plates were incubated overnight 
at 37 οC, a colony was picked and grown overnight at 37 ºC in 5 mL of 2xYT 
media (1.6% Tryptone, 1.0% yeast extract, 0.5% NaCl, pH: 7, autoclaved) 
supplemented with Amp (50 mg/mL), Chl (25 mg/mL), Tet (5 mg/mL), and 2% 
glucose. Then, 5 mL of 2xYT media was inoculated with 50 μL of the overnight 
culture and the cells were grown until the O.D. was 0.7, and gene expression 
was induced by addition of 1 mM final concentration of IPTG to the 5 mL of cell 
culture, which was then incubated at 30 οC for 3 h with shaking. Afterwards, the 
cell culture was infected with 20 μL of helper phage M13K07 (1011 per mL, NEB) 
by incubation at 30 οC for 20 min followed by shaking at 30 οC for another 20 
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min. Infected cells were centrifuged at 5000×g, and the supernatant was 
removed. The cells were resuspended in 2xYT medium (200 mL) supplemented 
with Kan (50 mg/mL), Amp (50 mg/mL), and Chl (25 mg/mL) and grown for 15-18 
h at 30 οC. After overnight shaking, cells were pelleted by centrifugation at 
5000×g, and the phage particles in the supernatant were isolated by PEG 
purification as described above. 
5.6.4 Phage preparation for cinnamycin display (NB11, p59-60) 
  For coexpression studies to display cinnamycin, electro-competent E. coli 
SS320 cells (50 μL) were transformed with cinA-K-containing pJF3H, cinM-
containing pCDFDuet-1, and pACYCDuet-1 containing cinX and cinorf7, and 
plated on an Amp (50 mg/ml), Spec (15 mg/ml), Chl (25 mg/mL), Tet (5 mg/mL), 
and 2% glucose LB plate. After the plates were incubated overnight at 37 οC, a 
colony was picked and grown overnight at 37 οC in 5 mL of 2xYT media  (1.6% 
Tryptone, 1.0% yeast extract, 0.5% NaCl, pH: 7, autoclaved) supplemented with 
Amp (50 mg/mL), Spec (15 mg/mL), Chl (25 mg/mL), Tet (5 mg/mL), and 2% 
glucose. After 12 h, 5 mL 2xYT media was inoculated with 50 μL of the overnight 
culture and the cells were grown until the O.D. was 0.7. The gene expression 
was induced by addition of 1 mM IPTG to the cell culture, which was then 
incubated at 30 οC for 3 h with shaking. Afterwards, the cell culture was infected 
with 20 μL of helper phage M13K07 (1011 per mL, NEB) by incubation at 30 οC 
for 20 min followed by shaking at 30 οC for another 20 min. Infected cells were 
centrifuged at 5000×g, and the supernatant was removed. The cells were 
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resuspended in 2xYT medium (200 mL) supplemented with Kan (helper phage 
resistance) (50 mg/mL), Amp (50 mg/mL), Spec (15 mg/ml), and Chl (25 mg/mL), 
and grown for 15-18 h at 30 οC. After overnight shaking, cells were pelleted by 
centrifugation at 5000×g, and the phage particles in the supernatant were 
isolated by PEG purification as described above. 
5.6.5 Phage preparation for lacticin 481 display (NB12, p45) 
  For coexpression studies to display lacticin 481, electro-competent E. coli 
SS320 cells (50 μL) were transformed with lctA-containing pJF3H, lctM-
containing pCDFDuet-1, and, lctM-containing pACYCDuet-1, plated on an Amp 
(50 mg/ml), Spec (15 mg/ml), Chl (25 mg/mL), Tet (5 mg/mL), 2% glucose LB 
plate. After the plates were incubated overnight at 37 οC, a colony was picked 
and grown overnight at 37 ºC in 5 mL of 2xYT media  (1.6% tryptone, 1.0% yeast 
extract, 0.5% NaCl, pH: 7, autoclaved) supplemented with Amp (50 mg/mL), 
Spec (15 mg/mL), Chl (25 mg/mL), Tet (5 mg/mL), and 2% glucose. Then, 5 mL 
of 2xYT media was inoculated with 50 μL of the overnight culture and the cells 
were grown until the O.D. was 0.7. The gene expression was induced by addition 
of 1 mM IPTG to the cell culture, which was then incubated at 30 οC for 3 h with 
shaking. Afterwards, the cell culture was infected with 20 μL of helper phage 
M13K07 (1011 per mL, NEB) by incubation at 30 οC for 20 min followed by 
shaking at 30 οC for another 20 min. Infected cells were centrifuged at 5000×g, 
and the supernatant was removed. The cells were resuspended in 2xYT medium 
(200 mL) supplemented with Kan (helper phage resistance) (50 mg/mL), Amp 
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(50 mg/mL), Spec (15 mg/ml), Chl (25 mg/mL), and grown for 15-18 h at 30 οC by 
shaking. After overnight shaking, cells were pelleted by centrifugation at 5000×g, 
and the phage particles in the supernatant were isolated by PEG purification as 
described above. 
5.6.6 Determination of phage titer (NB9 p 30, 36, 84; NB10 p73) 
  Serial dilutions of phage particles (2 x1012) were prepared by mixing 20 μL 
of the previous diluted phage stock with 180 μL of PBS. Then, 500 μL of E. coli 
SS320 or XL1blue (tetR) at exponential phase was mixed with 200 μL of each 
phage mixture and 4 mL of 2YT top agar (microwaved and cooled to 42 οC before 
adding phage). Before the mixture solidified, it was poured onto LB/tet (5 mg/mL) 
plates resulted in double layers of agar. The phage particles were incubated for 
8-15 h at 37 οC, and the plaques were counted. Then, phage particles per mL 
were calculated by dividing the number of plaques per plate per plated volume 
times the dilution factor. For example, if 347 plaques were counted when 0.1 mL 
of a 106 diluted phage suspension was plated, the titer was 3.47 x 109 phage 
particles per mL.  
5.6.7 Western blot analysis (NB9, p85) 
  Phage (20 μL, 2x1012 phage/mL) was mixed with protein loading dye 
containing 25 mM DTT. After 30 min incubation, 15 μL of this solution was loaded 
on a 12% SDS-PAGE gel (Bio-Rad). After electrophoresis, the protein bands 
were electroblotted onto a piece of polyvinylidene fluoride (PVDF) membrane 
(Bio-Rad) at 250 mAmp for 50 min in 10 mM CAPS buffer pH 10.5. The 
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membrane was then blocked with 5% non-fat dry milk in PBS-T (137 mM NaCl, 
2.7 mM KCl, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate 
monobasic, 0.1% Tween-20, pH 7.4) for 1 h, followed by incubation for 1 h (RT) 
or overnight at 4 οC with an appropriate antibody (1 μg/mL; Sigma–Aldrich) in 5% 
milk/PBS-T solution The membrane was then washed six times with PBS-T. An 
anti-mouse antibody–HRP conjugate (0.1 mg/mL antibody in 5% milk/PBS-T; 
Thermo Fisher Scientific) was incubated with the membrane for 1 h. Finally, the 
membrane was washed six times with PBS-T and twice with PBS followed by 
detection with the clarity ECL substrate (Bio-Rad, 170-5060). 
5.6.8 Enzyme-linked immunosorbent assay (ELISA) analysis (NB12, p24) 
The wells of a Nunc MaxiSorp® flat-bottom 96 well plate (Thermo 
Scientific) were coated with an anti-flag antibody at a concentration of 10 μg/mL 
in carbonate/bicarbonate buffer (pH 9.6, 100 μL) and the plate was incubated 
overnight at 4 °C. The next morning, the plate was washed twice with 20 μL of 
PBS buffer. The solutions or washes were removed. The remaining drops were 
removed by patting the plate on a paper towel. Then, the coated wells were 
blocked by addition of 300 μL of 5% non fat dry milk/PBS per well and the plate 
was incubated for 2 h at room temperature. Then, 100 μL of 10x dilution of phage 
samples (~ 1012) was added to each well and the plate was incubated for 90 min 
at 37 °C. The samples are removed and the plate was washed 6 times by filling 
the wells with 300 μL of PBS. Then, 100 μL of anti-M13 antibody-HRP in 5% milk 
solution was added to each well. The plate was incubated for another 1 h at room 
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temperature, followed by washing the plate for 6 times with PBS. The plate was 
developed with 1-Step Ultra TMB-ELISA (34028, Thermo scientific) and 
measurements were performed using a plate reader.   
5.6.9 Mass spectrometry analysis of phage displayed peptides (NB15, p80)  
 Phage solutions in PBS buffer (1 mL, ~1012 phage/mL) were digested with 
30 μL of appropriate proteases (stock solutions used: LysC = 3 U/100 μL, GluC = 
2 mg/mL, trypsin = 40 μM) for 3 h at room temperature (GluC, trypsin) or 37 ºC 
(LysC) followed by purification with a C18 solid phase extraction (SPE) column (1 
mL, Discovery DSC-18). The C18 column was first washed with 2 mL of 80% 
acetonitrile (ACN)/water and equilibrated with 2 mL of water and then the sample 
was applied. The column was washed with 8 mL of water and the sample was 
eluted with 1 mL of 80% ACN/water solution. The eluent was dried on a centrivap 
concentrator, and the products were resuspended in 50 μL of miliQ water. The 
product (1 μL) was spotted on the MALDI plate together with sinapinic acid (1 μL) 
and analyzed by MALDI-ToF MS.  
5.6.10 Purification of modified CinA from the periplasmic space (NB1, p61, 
p63, p69) 
 In order to coexpress PelB-CinA(A–1K), CinM and CinX, E. coli BL21 
(DE3) cells were transformed with a pRSFDuet-1 vector containing pelb-cinA(A–
1K) and cinM and a pACYCDuet-1 vector containing cinX and cinorf7. Single 
colony transformants were grown in a 37 ºC shaker for 12-15 h in 50 mL of Luria-
Bertani (LB) medium supplemented with 25 μg/mL kanamycin/12.5 μg/mL 
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chloramphenicol. A 20 mL aliquot was centrifuged at 5000×g for 10 min, the 
spent LB medium was discarded, and the cell pellet was resuspended in fresh LB 
medium. The resuspended cells (20 mL) were added to 2 L of LB supplemented 
with the appropriate antibiotics for maintaining the vectors, and the culture was 
grown aerobically at 37 ºC until the A600 was ~ 0.6 to 0.8. IPTG was added to a 
final concentration of 0.5 mM and the culture was transferred to 18 ºC for aerobic 
growth for an additional 20 h. Cells were harvested by centrifugation at 5000×g 
for 20 min at 4 ºC. The cell paste (~ 3-4 g) was stored at –80 ºC until use. 
 Bacterial cells (8 g) were harvested by centrifugation at 5,000 × g for 20 
min at 4 °C. The supernatant was discarded and the pellet was gently 
resuspended in ice-cold 30 mM Tris-Cl, 20% sucrose (pH 8.0) at 80 mL per gram 
wet weight. Keeping the cells on ice, 500 mM EDTA was added dropwise to 1 
mM and the cells were incubated for 5-10 min on ice with gentle agitation. The 
cells were centrifuged at 8000 x g for 20 minutes at 4 °C, the supernatant was 
discarded, and the pellet was resuspended in the same volume of ice-cold 5 mM 
MgSO4. The sample was stirred for 10 min on an ice bath and centrifuged at 
8000 x g for 20 min at 4 °C.  The pellet has the intracellular components whereas 
the supernatant contains the periplasmic fraction. Peptides inside the cell and in 
the periplasmic region were purified as described for other His6-LanA peptides 
(48) by use of a 5 mL HiTrap chelating HP nickel affinity column (GE Healthcare).  
A solid phase extraction column (SPE, 1 mL, Discovery DSC-18) was used to 
desalt the peptide. The C18 column was first washed with 2 mL of 80% 
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acetonitrile (ACN)/water and equilibrated with 2 mL of water and then the sample 
was applied. The column was washed with 4 mL of water and the sample was 
eluted with 1 mL of 80% ACN/water solution. The sample was dried on a 
centrivap concentrator and the peptide was dissolved in 100 μL of 100 mM Tris 
pH 7.5. The sample (20 μL) was mixed with 2 μL of LysC (0.4 μg/mL in 100 mM 
Tris, pH 8.3) and the protease cleavage reaction was incubated at 37 ºC for 3 h 
and then desalted using a ZipTip (Millipore). The product was eluted in 5 μL of 
sinapinic acid and analyzed by MALDI-ToF MS. 
5.6.11 Coexpression studies for nisin, lacticin 481, haloduracin, and 
prochlorosins  
   Production of lanthipeptides nisin, lacticin 481, haloduracin, and 
prochlorosins and their derivatives such as ProcA2.8-pIII in E. coli was performed 
as described before (26); however, instead of using 18 ºC, the cells were grown 
at 30 ºC overnight.  
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Table 5.1. List of the randomized peptides possessing the ProcA 2.8 wild type leader 
peptide attached to a core region with the sequence C(XXX)5S MPP S(XXX)5 C. The peptides 
shown in red were tested for dehydration and cyclization in this work.  
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Table 5.2 List of primers 
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